 | Roger F Butterworth∗Department of Medicine, University of Montreal, 45143 Cabot Trail, Englishtown, NS B0C 1H0 Canada | Department of Medicine, University of Montreal, Montreal, Canada | ... |
KOL Resume for Roger F Butterworth∗ (congenital viral hepatitis, coinfection, hepatic coma, coma, coinfection, acute, deltaagent, hepatitis, agent, hepatitis delta agent, hepatic, delta)
| Year | |
|---|---|
| 2021 | Department of Medicine, University of Montreal, 45143 Cabot Trail, Englishtown, NS B0C 1H0 Canada |
| 2020 | Department of Medicine, University of Montreal, Montreal, Canada |
| 2019 | Department of Medicine, University of Montreal, 45143 Cabot Trail, B0C 1H0, Englishtown, NS, Canada University of Montreal (St-Luc Hospital), Montreal, QC |
| 2018 | CHUM St-Luc Hospital and Department of Medicine, University of Montreal, Canada. University of Montreal (St-Luc Hospital), Montreal, Québec, Canada |
| 2015 | Department of Medicine, University of Montreal, Montreal, Quebec, Canada |
| 2014 | Neuroscience Research Unit, Hopital St-Luc (CHUM) and Department of Medicine, University of Montreal, Montreal, QC H2W 3J4, Canada |
| 2013 | Neuroscience Research Unit, Hôpital St-Luc (CHUM), 1058 Rue St-Denis, H2X 3J4, Montreal, QC, Canada |
| 2012 | Neuroscience Research Unit, Saint-Luc Hospital (CHUM), University of Montreal, Montreal, Quebec, Canada |
| 2011 | Department of Medicine, University of Montreal, Neuroscience Research Unit, Montreal, Quebec, Canada |
| 2010 | Neuroscience Research Unit, Hôpital Saint-Luc (CHUM), University of Montreal, 1058 St. Denis Street, Montreal, Quebec, Canada |
| 2009 | Neuroscience Research Unit, Hôpital Saint‐Luc, CHUM, Montreal, QC, Canada |
| 2008 | Neuroscience Research Unit, Université de Montréal, Montreal, QC, Canada |
| 2007 | Neuroscience Research Unit, CHUM (Campus Saint-Luc), University of Montreal, 1058, Saint-Denis Street, H2X 3J4, Montreal, Quebec, Canada |
| 2006 | Neuroscience Research Unit, University of Montreal (CHUM), Hôpital Saint-Luc, 1058 St-Denis Street, Montreal, Que., Canada H2X 3J4 |
| 2005 | Neuroscience Research Unit, Hôpital Saint-Luc (CHUM), Montréal, Quebec, Canada |
| 2004 | Neuroscience Research Unit, Montreal, Quebec, Canada |
Prominent publications by Roger F Butterworth∗
Region selective alterations of soluble guanylate cyclase content and modulation in brain of cirrhotic patients
[ PUBLICATION ]
Modulation of soluble guanylate cyclase (sGC) by nitric oxide (NO) is altered in brain from experimental animals with hyperammonemia with or without liver failure. The aim of this work was to assess the content and modulation of sGC in brain in chronic liver failure in humans. Expression of the alpha-1, alpha-2, and beta-1 subunits of sGC was measured by immunoblotting in autopsied frontal cortex and cerebellum from cirrhotic patients and controls. The contents of alpha-1 and alpha-2 ...
| Known for Guanylate Cyclase | Cirrhotic Patients | Modulation Sgc | Nitric Oxide Brain | Cerebellum Activation |
Hypothermia attenuates oxidative/nitrosative stress, encephalopathy and brain edema in acute (ischemic) liver failure
[ PUBLICATION ]
Encephalopathy and brain edema are serious complications of acute liver failure (ALF). The precise pathophysiologic mechanisms responsible have not been fully elucidated but it has been suggested that oxidative/nitrosative stress is involved. In the present study we evaluated the role of oxidative/nitrosative stress in the pathogenesis of hepatic encephalopathy and brain edema in rats with ALF resulting from hepatic devascularization. We also studied the effect of hypothermia, a ...
| Known for Brain Edema | Alf Rats | Nitrosative Stress | Liver Failure | Coma Stages |
KOL Index score: 13463
Acute liver failure (ALF) results in alterations of energy metabolites and of glucose-derived amino acid neurotransmitters in brain. However, the dynamics of changes in glucose metabolism remain unclear. The present study was undertaken using (1)H and (13)C nuclear magnetic resonance (NMR) spectroscopy to determine the rates of incorporation of glucose into amino acids and lactate via cell-specific pathways in relation to the severity of encephalopathy and brain edema in rats with ALF ...
| Known for Brain Lactate | Acute Liver | Magnetic Resonance | Coma Stages | Amino Acids |
Effects of hypothermia on brain glucose metabolism in acute liver failure: a 1H/13C-nuclear magnetic resonance study
[ PUBLICATION ]
BACKGROUND & AIMS: Mild hypothermia has a protective effect on brain edema and encephalopathy in both experimental and human acute liver failure. The goals of the present study were to examine the effects of mild hypothermia (35 degrees C) on brain metabolic pathways using combined (1)H and (13)C-Nuclear Magnetic Resonance (NMR) spectroscopy, a technique which allows the study not only of metabolite concentrations but also their de novo synthesis via cell-specific pathways in the ...
| Known for Acute Liver | Mild Hypothermia | Brain Glucose Metabolism | Magnetic Resonance | Frontal Cortex |
Neuroactive amino acids and glutamate (NMDA) receptors in frontal cortex of rats with experimental acute liver failure
[ PUBLICATION ]
It has been proposed that alterations of excitatory and inhibitory amino acids play a role in the pathogenesis of hepatic encephalopathy in acute liver failure. To evaluate this possibility, in vivo cerebral microdialysis was used to sample extracellular concentrations of amino acids in the frontal cortex of unanesthetized rats at various times during the progression of encephalopathy resulting from acute liver failure. Liver failure was induced by portacaval anastomosis followed 24 ...
| Known for Amino Acids | Frontal Cortex | Acute Liver Failure | Extracellular Concentrations | Hepatic Encephalopathy |
KOL Index score: 12801
Mild hypothermia is effective in the prevention of brain edema associated with cerebral ischemia and traumatic brain injury. Brain edema is also a serious complication of acute liver failure (ALF). To assess the effectiveness of hypothermia in ALF, groups of rats were subjected to hepatic devascularization (portacaval anastomosis, followed 48 hours later by hepatic artery ligation), and body temperatures were maintained at either 35 degrees C (hypothermic) or 37 degrees C (normothermic). ...
| Known for Mild Hypothermia | Brain Edema | Acute Liver | Rats Alf | Hepatic Encephalopathy |
Ammonia‐induced brain edema and intracranial hypertension in rats after portacaval anastomosis
[ PUBLICATION ]
Brain edema, leading to intracranial hypertension and brain herniation, is a major cause of death in fulminant liver failure. Astrocyte swelling is a prominent neuropathological feature in experimental fulminant liver failure. It has been postulated that the osmotic effects of glutamine, generated in astrocytes from ammonia and glutamate in a reaction catalyzed by glutamine synthetase, could mediate brain swelling. Normal rats and rats that received a portacaval anastomosis were infused ...
| Known for Intracranial Hypertension | Brain Edema | Portacaval Anastomosis | Ammonium Acetate | Osmotic Effects |
Effect of Portacaval Anastomosis on Glutamine Synthetase Protein and Gene Expression in Brain, Liver and Skeletal Muscle
[ PUBLICATION ]
The effects of chronic liver insufficiency resulting from end-to-side portacaval anastomosis (PCA) on glutamine synthetase (GS) activities, protein and gene expression were studied in brain, liver and skeletal muscle of male adult rats. Four weeks following PCA, activities of GS in cerebral cortex and cerebellum were reduced by 32% and 37% (p<0.05) respectively whereas GS activities in muscle were increased by 52% (p<0.05). GS activities in liver were decreased by up to 90% (p<0.01), a ...
| Known for Skeletal Muscle | Portacaval Anastomosis | Gene Expression | Surgical Rna | Pca Rats |
Cerebral inflammation contributes to encephalopathy and brain edema in acute liver failure: protective effect of minocycline
[ PUBLICATION ]
Encephalopathy and brain edema are serious complications of acute liver failure (ALF). The precise pathophysiologic mechanisms responsible have not been fully elucidated but it has been recently proposed that microglia-derived proinflammatory cytokines are involved. In the present study we evaluated the role of microglial activation and the protective effect of the anti-inflammatory drug minocycline in the pathogenesis of hepatic encephalopathy and brain edema in rats with ALF resulting ...
| Known for Brain Edema | Liver Failure | Rats Alf | Microglial Activation | Pathogenesis Hepatic Encephalopathy |
KOL Index score: 11822
There is evidence to suggest that, in acute liver failure (ALF), brain ammonia and proinflammatory cytokines may act synergistically to cause brain edema and its complications (intracranial hypertension, brain herniation). However, the molecular mechanisms involved remain to be established. In order to address this issue, semi-quantitative RT-PCR was used to measure the expression of genes coding for astrocytic proteins with an established role in cell volume regulation in cerebral ...
| Known for Brain Edema | Liver Failure | Proinflammatory Cytokines | Astrocytic Proteins | Cultured Astrocytes |
KOL Index score: 11726
Although earlier studies on thiamine deficiency have reported increases in extracellular glutamate concentration in the thalamus, a vulnerable region of the brain in this disorder, the mechanism by which this occurs has remained unresolved. Treatment with pyrithiamine, a central thiamine antagonist, resulted in a 71 and 55% decrease in protein levels of the astrocyte glutamate transporters GLT-1 and GLAST, respectively, by immunoblotting in the medial thalamus of day 14 symptomatic rats ...
| Known for Medial Thalamus | Glutamate Transporter | Glt1 Glast | Spraguedawley Statistics | Protein Levels |
KOL Index score: 11620
N-acetylcysteine (NAC) is an effective antidote to treat acetaminophen (APAP)-induced acute liver failure (ALF). NAC is hepatoprotective and prevents the neurological complications of ALF, namely hepatic encephalopathy and brain edema. The protective effect of NAC and its mechanisms of action in ALF due to other toxins, however, are still controversial. In the present study, we investigated the effects of NAC in relation to liver pathology, hepatic and cerebral glutathione, plasma ...
| Known for Liver Failure | Nac Alf | Induced Acute | Aom Mice | Brain Edema |
Ammonia and related amino acids in the pathogenesis of brain edema in acute ischemic liver failure in rats
[ PUBLICATION ]
The pathogenesis of brain edema in acute liver failure is poorly understood. We have previously shown that rats with ischemic acute liver failure (portacaval anastomosis followed by hepatic artery ligation) exhibit brain edema and intracranial hypertension, with swelling of cortical astrocytes as the most prominent neuropathological abnormality. Because ammonia has been shown to induce swelling of astrocytes in vivo and in vitro, we examined the relationship between brain ammonia, amino ...
| Known for Amino Acids | Brain Edema | Portacaval Anastomosis | Liver Failure | Glutamine Alanine |
Ammonia induces MK‐801‐sensitive nitration and phosphorylation of protein tyrosine residues in rat astrocytes
[ PUBLICATION ]
Astrocytes play a key role in the pathogenesis of ammonia-induced neurotoxicity and hepatic encephalopathy. As shown here, ammonia induces protein tyrosine nitration in cultured rat astrocytes, which is sensitive to the N-methyl-D-aspartate (NMDA) receptor antagonist MK-801. A similar pattern of nitrated proteins is produced by NMDA. Ammonia-induced tyrosine nitration depends on a rise in [Ca2+]i, IkB degradation, and NO synthase (iNOS) induction, which are prevented by MK-801 and the ...
| Known for Rat Astrocytes | Glutamine Synthetase | Protein Tyrosine | Ammonia Induces | Oxide Nitric |
Pathogenesis of hepatic encephalopathy and brain edema in acute liver failure: Role of glutamine redefined
[ PUBLICATION ]
Acute liver failure (ALF) is characterized neuropathologically by cytotoxic brain edema and biochemically by increased brain ammonia and its detoxification product, glutamine. The osmotic actions of increased glutamine synthesis in astrocytes are considered to be causally related to brain edema and its complications (intracranial hypertension, brain herniation) in ALF. However studies using multinuclear (1)H- and (13)C-NMR spectroscopy demonstrate that neither brain glutamine ...
| Known for Brain Edema | Acute Liver Failure | Hepatic Encephalopathy | Intracranial Hypertension | Glutamine Synthesis |
Roger F Butterworth∗: Influence Statistics
Open the FULL List in Excel
| Concept | World rank |
|---|---|
| polyclonal antibody glt1 | #1 |
| decreased expression glt1 | #1 |
| dawley ammonia | #1 |
| increased csf lactate | #1 |
| 213caspartate | #1 |
| loss righting reflexes | #1 |
| encephalopathy brain | #1 |
| gabaaassociated receptors | #1 |
| precipitation severe stages | #1 |
| ammonia proinflammatory | #1 |
| brain gaba uptake | #1 |
| therapeutic efficacy prevention | #1 |
| 062 009 liter | #1 |
| deficiency transketolase | #1 |
| brain astrocytes alterations | #1 |
| alf37 alf37 degrees | #1 |
| regionselective alterations | #1 |
| alpha1 isoform ec50 | #1 |
| astrocytes ammonia levels | #1 |
| encephalopathy pse | #1 |
| albumin dialysis systems | #1 |
| 3hpk11195 binding sites | #1 |
| pharmaceutical benzodiazepines | #1 |
| 3hpk11195 binding | #1 |
| glt1 transporter proteins | #1 |
| congenital acquired hyperammonemia | #1 |
| thiamine monophosphatetmp | #1 |
| cytokines mild | #1 |
| glast spraguedawley statistics | #1 |
| portacaval shunting hyperammonemia | #1 |
| increased gabaergic | #1 |
| alf hepatic | #1 |
| glut1 alf | #1 |
| ammonia liver failure | #1 |
| encephalopathy | #1 |
| rats varying degrees | #1 |
| nh4 neurons | #1 |
| plasma alf rats | #1 |
| glutamine synthetase activities | #1 |
| deficiency binding | #1 |
| pca beta endorphin | #1 |
| alf effects | #1 |
| abnormal pyruvate oxidation | #1 |
| azoxymethane brain | #1 |
| pca brainstem | #1 |
| 2 7fold increases | #1 |
| reactive gliosis contrast | #1 |
| brain prominent neurotoxin | #1 |
| precise nature | #1 |
| activities thalamus | #1 |
| ammonia glutamate uptake | #1 |
| thiamine deficiency appearance | #1 |
| activation ptbr | #1 |
| experimental pse | #1 |
| brain edema complications | #1 |
| neuropsychiatric disorder evidence | #1 |
| subclass sites | #1 |
| hypothermia delay | #1 |
| administration novo synthesis | #1 |
| model human disorder | #1 |
| widespread alterations | #1 |
| cerebrospinal fluid ammonia | #1 |
| fastigial interpositus | #1 |
| thiamine deficiency encephalopathy | #1 |
| pca increased densities | #1 |
| pons gaba content | #1 |
| encephalopathy prevention | #1 |
| hypothesis hepatic encephalopathy | #1 |
| ptbr nnos | #1 |
| lcarnitine doses | #1 |
| cirrhosis nature | #1 |
| edema encephalopathy | #1 |
| cns pca | #1 |
| encephalopathy increased | #1 |
| taurine medium | #1 |
| region‐selective alterations | #1 |
| hippocampal sclerosis induction | #1 |
| alzheimer type astrocytosis | #1 |
| astrocyte morphology alterations | #1 |
| brain edema encephalopathy | #1 |
| cox2 ca1 subfield | #1 |
| findings therapeutic efficacy | #1 |
| deficiency tritium | #1 |
| thiamine interactions | #1 |
| akgdh | #1 |
| pons thiamine treatment | #1 |
| proinflammatory cytokines strategies | #1 |
| liver failure ucds | #1 |
| finding loss | #1 |
| disorder portalsystemic encephalopathy | #1 |
| hypothermia brain | #1 |
| pathogenesis cerebral complications | #1 |
| activation brain ptbr | #1 |
| reversal neurological symptoms | #1 |
| taurines role | #1 |
| hepatocerebral disorders | #1 |
| altered thiamine neurochemistry | #1 |
| acquired hyperammonemia | #1 |
| transverese friedreich ataxia | #1 |
| brain levels dheas | #1 |
| reduced thiamine intake | #1 |
| csf lactate accumulation | #1 |
| brain levels tmp | #1 |
| glutamine synthetase capacity | #1 |
| neurological complications alf | #1 |
| loss tdpase activities | #1 |
| portacaval shunted | #1 |
| pathogenesis pse | #1 |
| monoamines hplc | #1 |
| mmt manganese phosphate | #1 |
| primary energy failure | #1 |
| ro15 10 microm | #1 |
| lola mental state | #1 |
| serum lad friedreich | #1 |
| cerebellum 22 | #1 |
| nh4ac rats | #1 |
| iii flumazenil | #1 |
| encephalopathy central | #1 |
| methylspiperone pet | #1 |
| rat sustained hyperammonemia | #1 |
| acute male pregnenolone | #1 |
| local brain production | #1 |
| cerebral hepatic levels | #1 |
| alterations brain dopamine | #1 |
| portacavalshunted rats protective | #1 |
| evidence otc deficiency | #1 |
| phenols fig 1structure | #1 |
| encephalopathy brain edema | #1 |
| metabolites term fluorescence | #1 |
| compounds pyrithiamine | #1 |
| efficacy lola | #1 |
| alf nmda receptor | #1 |
| benzodiazepine site contrast | #1 |
| alf relation | #1 |
| pallidal signal hyperintensity | #1 |
| pregnenolone brain tissue | #1 |
| specific l3hnoarg binding | #1 |
| receptors pca | #1 |
| “peripheraltype | #1 |
| frontal cortex exp | #1 |
| radioenzymatic assays activities | #1 |
| major role mechanisms | #1 |
| ammonium acetate challenge | #1 |
| binding sites cerebellum | #1 |
| rats fpc | #1 |
| tdpase activities loss | #1 |
| nacl taurine | #1 |
| nakatpase activities striatum | #1 |
| human hepatic encephalopathy | #1 |
| maoa activities cerebellum | #1 |
| weeks portacaval | #1 |
| αkgdh | #1 |
| minocyclinetreated alf rats | #1 |
| chat loss | #1 |
| gabaa ammonia animals | #1 |
| inherited ataxias characteristics | #1 |
| ” benzodiazepine receptors | #1 |
| dissected brain tissue | #1 |
| dehydrogenase αkgdh | #1 |
| alf35 | #1 |
| etanercepttreated alf mice | #1 |
| encephalopathy activities | #1 |
| pca increased | #1 |
| brain edema rats | #1 |
| taurine hepatic encephalopathy | #1 |
| brain ammonia concentrations | #1 |
| increase brain extracts | #1 |
| hepatic abnormality characteristics | #1 |
| 3hmuscimol binding studies | #1 |
| agents metabolic potential | #1 |
| decreased detoxification ammonia | #1 |
| wistar receptors pca | #1 |
| cns wernickekorsakoff | #1 |
| pca rat | #1 |
| selective ptbr ligand | #1 |
| pfco brain tissue | #1 |
| alcohol‐thiamine interactions | #1 |
| ptbrs portacaval anastomosis | #1 |
| prevents brain | #1 |
| liver failure muscle | #1 |
| neuroinflammatory response alf | #1 |
| hepatic coma bbb | #1 |
| pse csf lactate | #1 |
| hepatic encephalopathy cirrhosis | #1 |
| sgc activation brain | #1 |
| hypokinesia et495 | #1 |
| gaba 11 | #1 |
| additional bloodborne ammonia | #1 |
| coma edema stages | #1 |
| thdoc brain tissue | #1 |
| experimental wernicke | #1 |
| pbgd rat model | #1 |
| symptoms wernicke | #1 |
| 3hpk11195 ligands | #1 |
| αkgdh onset | #1 |
| devascularized rat | #1 |
| congenital otc deficiencies | #1 |
| hyperammonemic spf | #1 |
| disorder isomorphic model | #1 |
| ammonia brain | #1 |
| hippocampus cirrhotic patients | #1 |
| transketolase enzyme activities | #1 |
| caudate putamen sum | #1 |
| failure alanine | #1 |
| leigh disease forms | #1 |
| focal lactic acidosis | #1 |
| increased glutamine synthesis | #1 |
| brain ptbr | #1 |
| ouabain pyrimethamine rats | #1 |
| increased binding sites | #1 |
| brain altered expression | #1 |
| selectively decreased | #1 |
| neurobiology hepatic encephalopathy | #1 |
| csf concentrations ammonia | #1 |
| pyrithiamine rats | #1 |
| investigator predictions | #1 |
| concentrations serotonin precursor | #1 |
| brain regions pyrithiamine | #1 |
| hyperammonemic pathologies | #1 |
| glutamate exposure ammonia | #1 |
| alf restricted transfer | #1 |
| manganese pathogenesis | #1 |
| portacaval pcs rats | #1 |
| postshunt myelopathy | #1 |
| ptbr mrna thalamus | #1 |
| azoxymethane mouse model | #1 |
| propanolamines putamen rats | #1 |
| ptbribp frontal cortex | #1 |
| term fluorescence phenomenon | #1 |
| etanercept il6 levels | #1 |
| cirrhotic patients benzodiazepines | #1 |
| neuromodulatory site | #1 |
| acquired hyperammonemic | #1 |
| thiamine‐deficient | #1 |
| normal conditions kidney | #1 |
| portalsystemic encephalopathy | #1 |
| ohe cirrhosis | #1 |
| neurosteroids pregnenolone allopregnanolone | #1 |
| pca loss | #1 |
| ammonialowering strategies | #1 |
| rats thiamine deficiency | #1 |
| reflex selective decreases | #1 |
| components brain glutamate | #1 |
| muscle ammonia removal | #1 |
| increased brain | #1 |
| cirrhosis brain dysfunction | #1 |
| lipoamide dehydrogenase lad | #1 |
| cirrhotic patients densities | #1 |
| pathophysiology hepatic | #1 |
| lactate medial thalamus | #1 |
| diabetes ataxia humans | #1 |
| ammonia mrna | #1 |
| manganese distribution brain | #1 |
| noradrenaline transporter sites | #1 |
| autopsy brain choline | #1 |
| increased activities maoa | #1 |
| thalamus pyrithiamine treatment | #1 |
| 32°c–35°c | #1 |
| concomitantly increased | #1 |
| cox2 cuznsod mrna | #1 |
| nimesulide thiamine deficiency | #1 |
| glt1 encephalopathy humans | #1 |
| csf portacaval anastomosis | #1 |
| blood ammonia improvement | #1 |
| cerebral cortex hypokinesia | #1 |
| astrocytic integrity | #1 |
| failure brain | #1 |
| inhibitory ammonium ions | #1 |
| loss nmda | #1 |
| liver dysfunction findings | #1 |
| fco cirrhotic patients | #1 |
| 90 fmol protein | #1 |
| dose dependent swelling | #1 |
| brain edema increases | #1 |
| comatose rats | #1 |
| encephalopathy animals | #1 |
| preference pca | #1 |
| pse altered expression | #1 |
| 15–1788 | #1 |
| ammonia normal conditions | #1 |
| result toxins | #1 |
| hepatic devascularization | #1 |
| bbb animal hepatic | #1 |
| atp free coenzyme | #1 |
| 3hcitalopram sites rats | #1 |
| seesection | #1 |
| that11cpk11195 | #1 |
| ptbr ligand 3hpk11195 | #1 |
| combined metabolic stresses | #1 |
| encephalopathy new | #1 |
| hepatic coma patients | #1 |
| veratramines action parachlorophenylalanine | #1 |
| portacavalshunting | #1 |
| rtpcr experiments betaactin | #1 |
| psychometric testing risk | #1 |
| hyperammonemic spf mice | #1 |
| pglycoprotein willebrand factor | #1 |
| nmda receptor alf | #1 |
| ligand3hpirenzepine | #1 |
| measured homogenates | #1 |
| reversal antiparkinson drugs | #1 |
| markedly impaired | #1 |
| pca ethanol | #1 |
| neurosteroid modulatory | #1 |
| stages encephalopathy | #1 |
| vulnerable medial thalamus | #1 |
| tk activity onset | #1 |
| pca rats pca | #1 |
| matkowskyj | #1 |
| control alf37 | #1 |
| failure amino | #1 |
| veratramines action | #1 |
| increased activities tdpase | #1 |
| additional thiamine | #1 |
| grc integrity | #1 |
| 3htryptamine receptors | #1 |
| acute symptomatic animals | #1 |
| metabolism ammonia | #1 |
| neuroinhibitory steroid | #1 |
| distribution l3hnoarg | #1 |
| lcarnitine energy metabolites | #1 |
| brain portacaval anastomosis | #1 |
| fumazenil | #1 |
| regional lactate levels | #1 |
| progressive volume increase | #1 |
| 3acetyl pyridine rats | #1 |
| expression ptbrs | #1 |
| integrity gabaa receptors | #1 |
| congenitally hyperammonemic | #1 |
| acute male muscle | #1 |
| pathogenesis clinic | #1 |
| reflex pdhc activities | #1 |
| cirrhotic brain tissue | #1 |
| cirrhosis extrapyramidal symptoms | #1 |
| brain pca rats | #1 |
| acute male microglia | #1 |
| portalsystemic encephalopathy pse | #1 |
| portacaval anastomosis brain | #1 |
| malnutrition hepatic failure | #1 |
| brains pcs rats | #1 |
| portacaval shunting activities | #1 |
| spectrum neuropsychiatric abnormalities | #1 |
| thiamine deficiency decreases | #1 |
| loss transporter sites | #1 |
| increased brain ammonia | #1 |
| friedreichs ataxia dehydrogenase | #1 |
| l3hnoarg | #1 |
| glast medial thalamus | #1 |
| development nutritional recommendations | #1 |
| encephalopathy zidovudine | #1 |
| hypoglycaemic convulsions | #1 |
| astrocyticneuronal cross | #1 |
| encephalopathy vivo | #1 |
| alf precise role | #1 |
| edema energy | #1 |
| accumulate brain | #1 |
| cirrhotic patients cau | #1 |
| brain major | #1 |
| ammonia mechanisms | #1 |
| deficiency wernicke | #1 |
| alf increases | #1 |
| dha administration mnsod | #1 |
| αkgdh activities | #1 |
| 3htryptamine receptor | #1 |
| alterations receptor sites | #1 |
| interferongamma brains | #1 |
| ammoniainduced decrease | #1 |
| ammonium acetate administration | #1 |
| ammoniainduced inhibition | #1 |
| genes brain edema | #1 |
| 3hcitalopram sites | #1 |
| indwelling cisterna | #1 |
| pdhc activities | #1 |
| cerebral aminoacids | #1 |
| experimental thiamine deficiency | #1 |
| neuronal crosstalk | #1 |
| electroencephalogram tracings | #1 |
| age time interval | #1 |
| poor nutrition vitamin | #1 |
| 3hpk11195 | #1 |
| pse findings | #1 |
| cox2 tle | #1 |
| caudate nucleus cau | #1 |
| alcoholic peripheral neuropathy | #1 |
| hepatic encephalopathies | #1 |
| lipopolysaccharide precipitates | #1 |
| pyrithiaminetreated rats | #1 |
| receptor ptbr | #1 |
| abstract5fluoromethylornithine | #1 |
| mechanisms wemickes encephalopathy | #1 |
| precise role glutamine | #1 |
| platelet taurine uptake | #1 |
| ammonia pca | #1 |
| pse increased densities | #1 |
| pca rats patients | #1 |
| surgical portacaval anastomosis | #1 |
| liver pathology increases | #1 |
| mice encephalopathy | #1 |
| severe encephalopathy coma | #1 |
| alcoholrelated brain dysfunction | #1 |
| novo synthesis gaba | #1 |
| capacity ammonia removal | #1 |
| cns relation | #1 |
| ethanol nutritional deficit | #1 |
| plasma clearance halflife | #1 |
| liver failure neuroinflammation | #1 |
| presence brain extracts | #1 |
| pbgd mrna expression | #1 |
| diencephalic cerebellar | #1 |
| thiamine phosphatases | #1 |
| hypothermia ammonia | #1 |
| mhe life | #1 |
| glyt1 mrna | #1 |
| ptbr mrna levels | #1 |
| increased levels allopregnanolone | #1 |
| brain ammonia measurement | #1 |
| coma stages encephalopathy | #1 |
| ptbrs | #1 |
| distribution 3htryptamine | #1 |
| shunted rat | #1 |
| wernicke′s encephalopathy | #1 |
| decreased detoxification | #1 |
| restricted transfer glutamine | #1 |
| reduction mild hypothermia | #1 |
| neurosteroids hepatic encephalopathy | #1 |
| parkinsonism cirrhosis | #1 |
| enzyme perivenous hepatocytes | #1 |
| thiaminedeficient medium 7 | #1 |
| ammonia central nervous | #1 |
| role endogenous benzodiazepines | #1 |
| dehydrogenase complex transketolase | #1 |
| liver failure alterations | #1 |
| experimental thiamine | #1 |
| alterations pse | #1 |
| opca messenger receptors | #1 |
| liver failure modulation | #1 |
| 24 hours pca | #1 |
| ucds liver failure | #1 |
| thiamine‐deficient rats | #1 |
| flunitrazepam modulation | #1 |
| nnos expression result | #1 |
| rats metallic | #1 |
| dehydrogenase complex friedreichs | #1 |
| edema formation mnsod | #1 |
| induction astrocytic cox2 | #1 |
| selective damage pdhc | #1 |
| pfco fco | #1 |
| continues rely | #1 |
| in3hpk11195 binding sites | #1 |
| encephalopathy cerebral edema | #1 |
| decarboxylase hepatic | #1 |
| ptbr alterations | #1 |
| brain hepatic | #1 |
| tissues spf mice | #1 |
| encephalopathy male | #1 |
| surgical probenecid rats | #1 |
| disorder thiamine deficiency | #1 |
| glutamine resonance | #1 |
| neuroinflammation cns complications | #1 |
| 3h8ohdpat frontal cortex | #1 |
| encephalopathy humans pallidus | #1 |
| nonsclerotic tle patients | #1 |
| cerebellar concentration aspartate | #1 |
| modulation nitric oxide | #1 |
| reduction circulating neurotoxins | #1 |
| subjects transport defect | #1 |
| alf mild hypothermia | #1 |
| brain herniation alf | #1 |
| thiamine deficiency 23 | #1 |
| expression astrocytic | #1 |
| glutamine astrocyte | #1 |
| serum lad patients | #1 |
| 15–1788 plasma levels | #1 |
| alf37 degrees | #1 |
| pca operation | #1 |
| neuroinflammation alf | #1 |
| normothermic alf rats | #1 |
| shunting hyperammonemia rats | #1 |
| tdpase tdpase activities | #1 |
| oxygenase1 hepatic | #1 |
| assessment locomotor activities | #1 |
| alterations 3h8ohdpat | #1 |
| thiamine deficiency expression | #1 |
| previous portacaval anastomoses | #1 |
| autopsy cirrhotic | #1 |
| atp acetyl coa | #1 |
| ω3 receptor 3hpk11195 | #1 |
| azoxymethane mouse | #1 |
| lola prevention | #1 |
| onset neurological symptoms | #1 |
| 3hkainate sites | #1 |
| 071−084 | #1 |
| experimental portacaval shunt | #1 |
| thiamine daily administration | #1 |
| hyperammonemic syndromes | #1 |
| thiamine deficiency neurons | #1 |
| 2 mm ammonia | #1 |
| s‐3h5‐fluorowillardiine | #1 |
| ammonia increased production | #1 |
| thiaminedeficient brain | #1 |
| humans gabaa steroids | #1 |
| brain cirrhotic patients | #1 |
| isoquinolinebinding moiety | #1 |
| binding sites 3hpk11195 | #1 |
| glutamate originating | #1 |
| 3hnisoxetine sites | #1 |
| lactate brain regions | #1 |
| acute chronic hyperammonemia | #1 |
| normal limits findings | #1 |
| increased blood manganese | #1 |
| thalamus cirrhotic patients | #1 |
| liver pca | #1 |
| encephalopathy il1beta | #1 |
| alf alterations | #1 |
| enzyme activities loss | #1 |
| thiamine deficiency activities | #1 |
| pdhc step | #1 |
| brains alf rats | #1 |
| aom animal hypothermia | #1 |
| superoxide dismutase rat | #1 |
| hereferences | #1 |
| brain liver failure | #1 |
| pss dopamine hepatic | #1 |
| brain ammonia reduction | #1 |
| friedreich gilbert | #1 |
| hyperammonemia aaas | #1 |
| deficiency prior | #1 |
| mbr astrocytes | #1 |
| thalamus vulnerable region | #1 |
| astrocytic cox2 | #1 |
| microglia neuroinflammatory response | #1 |
| treatment mild encephalopathy | #1 |
| complications alf | #1 |
| initial reports pathogenesis | #1 |
| selective alterations | #1 |
| nh4cl glutamate release | #1 |
| manganese etiology | #1 |
| daily pyrithiamine treatment | #1 |
| severe liver atrophy | #1 |
| increased brain concentrations | #1 |
| ouabain doses | #1 |
| metabolic scavengers | #1 |
| overt encephalopathy alterations | #1 |
| molecular standpoint | #1 |
| glutamateper | #1 |
| dismutase hyperglycemic | #1 |
| manganese extrapyramidal symptoms | #1 |
| enos gene deletion | #1 |
| ammonia cns function | #1 |
| mitochondrial enzyme αkgdh | #1 |
| dansyl chloride microassay | #1 |
| deterioration neurological status | #1 |
| l‐deprenyl treatment | #1 |
| 202 55 nm | #1 |
| blood ammonia concentrations | #1 |
| clinicallydefined entities | #1 |
| histamine receptor sites | #1 |
| encephalopathy humans opioid | #1 |
| sustained hyperammonemia pca | #1 |
| alterations brain glutamate | #1 |
| oatreated rats alf | #1 |
| alf animals expression | #1 |
| rats hepatic devascularization | #1 |
| alcoholic manganese | #1 |
| pca activities | #1 |
| regional variation bckdh | #1 |
| progression prevention | #1 |
| densities ptbr sites | #1 |
| human brain ammonia | #1 |
| hepatic devascularized rats | #1 |
| nacl mm nacl | #1 |
| bloodborne ammonia | #1 |
| familial hyperbilirubinemia | #1 |
| pregnanolone brain chemistry | #1 |
| blood manganese etiology | #1 |
| ammonialowering agents | #1 |
| locomotor activities difference | #1 |
| 70 tk | #1 |
| cerebellar amino acids | #1 |
| mild hypothermia delay | #1 |
| exposure azoxymethane | #1 |
| pathogenetic defect | #1 |
| pca astrocytic | #1 |
| thiaminedeficient animals | #1 |
| heneuropathology | #1 |
| 15–1788 kinetics | #1 |
| nac normalization | #1 |
| congenital hyperammonemia lcarnitine | #1 |
| portacaval anastomosis tips | #1 |
| findings neuroinflammatory response | #1 |
| spontaneous release glutamate | #1 |
| 3hpk binding | #1 |
| ptbr increased expression | #1 |
| pathophysiology cirrhosis | #1 |
| coma pathophysiologic basis | #1 |
| astrocytic glycine transporter | #1 |
| maternal thiamine | #1 |
| fluid taurine | #1 |
| thalamus thiamine deficiency | #1 |
| microglial activation protective | #1 |
| unchanged brain | #1 |
| free coa atp | #1 |
| aom treatment alf | #1 |
| precoma coma stages | #1 |
| symptomatic stages encephalopathy | #1 |
| neurotransmitter function | #1 |
| cell increased synthesis | #1 |
| ldeprenyl thiamine deficiency | #1 |
| tdwt mice | #1 |
| congenital otc | #1 |
| humans wernickes encephalopathy | #1 |
| ammonia increased expression | #1 |
| precoma | #1 |
| glial filament network | #1 |
| alf rats expression | #1 |
| nacl calcium | #1 |
| receptor cirrhotic patients | #1 |
| spraguedawley statistics immunohistochemistry | #1 |
| isomorphic model predictions | #1 |
| caudate putamen concentrations | #1 |
| ptbr expression | #1 |
| 5mm nh4cl p0001 | #1 |
| 1 lola | #1 |
| died hepatic | #1 |
| pyrithiamine treatment | #1 |
| genes astrocytic proteins | #1 |
| h1 receptor density | #1 |
| 10 microm flumazenil | #1 |
| rats antisense elements | #1 |
| findings reported increase | #1 |
| blood ammonia md | #1 |
| neurological symptoms encephalopathy | #1 |
| caudate putamen 57 | #1 |
| liver failure upregulation | #1 |
| mm nacl nacl | #1 |
| severe pse | #1 |
| hepatic microcirculation patients | #1 |
| alf include | #1 |
| mg2dependentatpase | #1 |
| aspartate pons | #1 |
| increased expression ptbribp | #1 |
| alf rats precoma | #1 |
| hypothermia prevents | #1 |
| ethanol preference ratio | #1 |
| etanercept aom | #1 |
| effects ammonia | #1 |
| key astrocytic | #1 |
| brain osmolytes | #1 |
| vulnerable medial | #1 |
| brain dysfunction pse | #1 |
| taurine electrolyte balance | #1 |
| ligand3h | #1 |
| csf concentrations bzrls | #1 |
| animal model encephalopathy | #1 |
| medial thalamus day | #1 |
| alf37 | #1 |
| early astrocytic response | #1 |
| offspring animal pyruvate | #1 |
| ptbr complex | #1 |
| cell damage mechanisms | #1 |
| failure hepatic | #1 |
| autopsied brain tissue | #1 |
| shunted rats presence | #1 |
| thiaminedeficient encephalopathy implications | #1 |
| pathogenesis brain | #1 |
| l3hnoarg binding | #1 |
| 5mm nh4cl | #1 |
| mbr decreased expression | #1 |
| frontal cortex fco | #1 |
| astrocytic proteins | #1 |
| wks spraguedawley receptors | #1 |
| appearance neurological symptoms | #1 |
| “ peripheral | #1 |
| alf studies | #1 |
| manganese deposition | #1 |
| mutant spf | #1 |
| pbg pbgd | #1 |
| electroencephalogram tracings patients | #1 |
| betaactin housekeeping gene | #1 |
| pugh score iii | #1 |
| neurological symptoms normalisation | #1 |
| portacavalshunted pcs rats | #1 |
| fur spf | #1 |
| encephalopathy adult | #1 |
| ptbr brain | #1 |
| manifest altered expression | #1 |
| perivascular endothelial cells | #1 |
| homogenates cirrhotic patients | #1 |
| kgdh decreased | #1 |
| pharmaceutical benzodiazepine | #1 |
| ldopa octopamine | #1 |
| glucose loading precipitates | #1 |
| hepatic encephalopathy activities | #1 |
| alf animal hypothermia | #1 |
| daily injections thiamine | #1 |
| alf brain edema | #1 |
| acute hyperammonemic syndromes | #1 |
| taurine microsomes | #1 |
| alcoholthiamine interactions | #1 |
| alterations neurological alterations | #1 |
| concentrations olfactory bulb | #1 |
| lola treatment | #1 |
| ptbr mrna | #1 |
| lumbar gray matter | #1 |
| elucidation neurotransmitter | #1 |
| microsomes medium | #1 |
| hepatic encephalopathy neurobiology | #1 |
| free neurological | #1 |
| disorders ammonia metabolism | #1 |
| microglia evidence | #1 |
| hepatic microcirculation addition | #1 |
| acids aaas | #1 |
| opioid encephalopathy humans | #1 |
| 25mm nh4cl | #1 |
| 8 cirrhotic patients | #1 |
| nakatpase activity thalamus | #1 |
| wernickes encephalopathy humans | #1 |
| nac aom | #1 |
| astrocytic accumulation | #1 |
| dawley thiamine | #1 |
| testis densities | #1 |
| ammonia removal brain | #1 |
| coma stages | #1 |
| congenital ornithine | #1 |
| cns complications alf | #1 |
| csf benzodiazepine | #1 |
| proinflammatory mechanisms | #1 |
| brain glutamine | #1 |
| osmotic actions | #1 |
| lornithinelaspartate prevention | #1 |
| hepatic encephalopathy authors | #1 |
| manganese phosphate mmt | #1 |
| brains spf mice | #1 |
| pglycoprotein mild hypothermia | #1 |
| brains increased concentrations | #1 |
| predictive model investigator | #1 |
| nh4oac administration | #1 |
| acute hyperammonemia activation | #1 |
| thiamine deficiency bckdh | #1 |
| increased densities | #1 |
| nuclei fastigial interpositus | #1 |
| patient olivopontocerebellar atrophy | #1 |
| measurement aqp4 levels | #1 |
| reduction bbb breakdown | #1 |
| encephalopathy alanine | #1 |
| exp assessment | #1 |
| glast protein day | #1 |
| alf evidence | #1 |
| encephalopathy neuropsychiatric | #1 |
| pca rats phosphate | #1 |
| encephalopathy cau | #1 |
| circulating neurotoxins | #1 |
| rats coma | #1 |
| removal bloodborne ammonia | #1 |
| rendered ataxic | #1 |
| alf therapeutic | #1 |
| dying hepatic | #1 |
| pss rats | #1 |
| tnfα delayed progression | #1 |
| thiamine deficiency humans | #1 |
| spf mice | #1 |
| normalisation enzyme activities | #1 |
| induction epileptic patients | #1 |
| neuroinflammation liver failure | #1 |
| regionselective reductions | #1 |
| iotal6 | #1 |
| azoxymethane toxicity | #1 |
| brain distribution rats | #1 |
| selective loss | #1 |
| disproportionately levels | #1 |
| spf mouse | #1 |
| muscarinic thiamine | #1 |
| decreased pdhc | #1 |
| pathogenesis hyperammonemic syndromes | #1 |
| prevention ohe | #1 |
| flumazenil cirrhotic patients | #1 |
| ligase hepatic | #1 |
| edema cytokines | #1 |
| regionselective increases | #1 |
| region selective alterations | #1 |
| aqp4 proinflammatory mediators | #1 |
| loss 3hnisoxetine sites | #1 |
| thiaminedeficient rats | #1 |
| circulating ammonia | #1 |
| tmpase tdpase | #1 |
| rats alf | #1 |
| central thiamine antagonist | #1 |
| pca portacaval anastomosis | #1 |
| astrocyte undergoes | #1 |
| region selective | #1 |
| brain glutamate synthesis | #1 |
| ptbribp | #1 |
| cerebellar concentration | #1 |
| 11 thiamine deficiency | #1 |
| failure thiamine | #1 |
| liver diseases range | #1 |
| therapeutic efficacy lcarnitine | #1 |
| portacaval anastomosis | #1 |
| onset brain edema | #1 |
| doses lcarnitine | #1 |
| bzrls | #1 |
| receptors thiamine | #1 |
| cerebral disorder | #1 |
| friedreichs ataxia thiaminedeficient | #1 |
| etanercept biological plausibility | #1 |
| propanolamines putamen | #1 |
| astrocytic accumulation glutamine | #1 |
| surgical rna | #1 |
| pathogenesis wernicke | #1 |
| mrnas ampa receptor | #1 |
| perivenous hepatocytes brain | #1 |
| cell swelling major | #1 |
| effective approach onset | #1 |
| akinesia rats | #1 |
| reduction brain ammonia | #1 |
| vicious cycle sarcopenia | #1 |
| varying degrees pss | #1 |
| inhibition bloodbrain transfer | #1 |
| ammoniainduced reduction | #1 |
| aom nac | #1 |
| action acute hyperammonemia | #1 |
| restricted transfer cell | #1 |
| animals thiamine deficiency | #1 |
| portocaval shunting activities | #1 |
| borne ammonia | #1 |
| increased extracellular brain | #1 |
| mild hypothermia onset | #1 |
| alterations increased expression | #1 |
| normal cd1 | #1 |
| pathogenesis brain edema | #1 |
| liver normal cd1 | #1 |
| clf alf | #1 |
| jadad cochrane ohe | #1 |
| oxotremorine particle size | #1 |
| etanercept treatment reduction | #1 |
| maternal thiamine deficiency | #1 |
| selectively increased | #1 |
| cirrhosis ammonia hepatic | #1 |
| oatreated rats | #1 |
| tissue cirrhotic | #1 |
| glutaminecycle | #1 |
| rats acute | #1 |
| autopsied frontal cortex | #1 |
| nh4 forms neurons | #1 |
| medium kcl | #1 |
| neurotransmitter alterations prevention | #1 |
| transketolase tk activities | #1 |
| alcoholic peripheral | #1 |
| prevention brain edema | #1 |
| mild hypothermia prevention | #1 |
| encephalopathy nitrogen | #1 |
| etanercept decreased plasma | #1 |
| brain human experimental | #1 |
| 6hydroxydopamine anterolateral hypothalamus | #1 |
| pathogenesis portalsystemic encephalopathy | #1 |
| immunohistochemistry spraguedawley statistics | #1 |
| expression ptbr | #1 |
| excess bloodborne ammonia | #1 |
| hyperglycemic focal | #1 |
| cerebral cortex pca | #1 |
| histamine caudate putamen | #1 |
| endogenous opioid brain | #1 |
| direct hepatoprotective effects | #1 |
| pallidal binding sites | #1 |
| selective reversible decreases | #1 |
| neuroinflammatory mechanisms pathogenesis | #1 |
| experimental alf increases | #1 |
| protective pathogenesis | #1 |
| isoquinoline benzodiazepine ligands | #1 |
| ammonia exposure brain | #1 |
| glut1 expression alf | #1 |
| brain portacaval | #1 |
| cau cirrhotic patients | #1 |
| ohe mhe patients | #1 |
| portacaval‐shunted rat | #1 |
| stress encephalopathy | #1 |
| pse lornithinelaspartate | #1 |
| coa levels brain | #1 |
| brain thiamine metabolism | #1 |
| pfco cirrhotic patients | #1 |
| ohe prevention prophylaxis | #1 |
| alterations expression result | #1 |
| neurological syndrome nature | #1 |
| findings ammonia | #1 |
| liver spleen ratios | #1 |
| pca encephalopathy humans | #1 |
| establishment adult activities | #1 |
| portacaval | #1 |
| 3hpk11195 human brain | #1 |
| bbb permeability alf | #1 |
| pathogenesis hepatic | #1 |
| chronic hyperammonemic syndromes | #1 |
| stroke forms | #1 |
| prophylaxis reductions | #1 |
| encephalopathy cirrhosis | #1 |
| xlinked inherited defect | #1 |
| congenital otc deficiency | #1 |
| densities 3hpk11195 | #1 |
| dipeptides hepatic | #1 |
| expression hyperglycemic | #1 |
| glur3 subunits opca | #1 |
| hypoglycaemia cerebral cortex | #1 |
| raphe serotonin serotonin | #1 |
| synthesis intercellular transport | #1 |
| ligand 3hpk11195 | #1 |
| degree shunting hyperammonemia | #1 |
| alf mice deletion | #1 |
| glucose loading decreases | #1 |
| pca penicillamine | #1 |
| bzrls cirrhotic patients | #1 |
| rats portacaval | #1 |
| progression thiamine deficiency | #1 |
| ammonia metabolism disorders | #1 |
| r071–084 | #1 |
| vivo cerebral microdialysis | #1 |
| experimental model metabolic | #1 |
| hypermmonemia | #1 |
| ammonia toxins | #1 |
| ammonia increased | #1 |
| bioaccumulation neuropathology | #1 |
| tissue distribution neuropathology | #1 |
| protective portacavalshunted rats | #1 |
| ammoniaprecipitated coma | #1 |
| alanine cerebral cortex | #1 |
| encephalopathy sham | #1 |
| 15–1788 pharmacokinetics cirrhosis | #1 |
| thalamus thiaminedeficient rats | #1 |
| pca portacaval shunt | #1 |
| pyrithiamine | #1 |
| thiamine deficiency alcoholics | #1 |
| anastomosis ammonia | #1 |
| mental state grade | #1 |
| csf ammonia control | #1 |
| azoxymethane bloodbrain barrier | #1 |
| ligand3hpk11195 | #1 |
| ammonia major roles | #1 |
| exposure proinflammatory | #1 |
| encephalopathy binding | #1 |
| evidence thiamine deprivation | #1 |
| induced stereotyped behavior | #1 |
| hepatic glt1 | #1 |
| encephalopathy alf rats | #1 |
| antagonist pyrithiamine | #1 |
| rats ouabain pyrimethamine | #1 |
| densities 3hpk11195 sites | #1 |
| rats probenecid treatment | #1 |
| sites ptbr | #1 |
| cox2 cuznsod | #1 |
| maximal binding absence | #1 |
| reduction cognitive dysfunction | #1 |
| glutamine synthetase protein | #1 |
| nonvulnerable fpc | #1 |
| type astrocytosis | #1 |
| psychometric testing falls | #1 |
| protein coma stages | #1 |
| thalamus symptomatic rats | #1 |
| ouabain pyrimethamine | #1 |
| cyclase content | #1 |
| cerebellum sustained hyperammonemia | #1 |
| encephalopathy thiamine | #1 |
| nac animal hepatic | #1 |
| previous exposure benzodiazepines | #1 |
| occludin medial thalamus | #1 |
| chronic hyperammonemia syndromes | #1 |
| inflammation thiamine deficiency | #1 |
| daily injections ldeprenyl | #1 |
| p005 5mm nh4cl | #1 |
| chronic thiamine deprivation | #1 |
| brain consequent increases | #1 |
| alf rats | #1 |
| experimental portal | #1 |
| surgical rats rats | #1 |
| proinflammatory mechanisms pathogenesis | #1 |
| muscarinic m1 sites | #1 |
| activities alpha kgdh | #1 |
| l‐3hnitroarginine | #1 |
| investigator neurological disorders | #1 |
| alf hypothermia | #1 |
| thiamine‐dependent enzymes | #1 |
| increases glutamine | #1 |
| aom mice nac | #1 |
| olivopontocerebellar atrophy expression | #1 |
| ptbrs binding | #1 |
| encephalopathy alcoholic | #1 |
| reduced astrocytic uptake | #1 |
| pse surgical probenecid | #1 |
| direct evidence rats | #1 |
| amines hepatic | #1 |
| 3hpk11195 rats | #1 |
| ” benzodiazepine | #1 |
| catecholaminelike trace amines | #1 |
| deficiency encephalopathy | #1 |
| male pyrithiamine | #1 |
| l‐3harginine | #1 |
| mild hypothermia alf | #1 |
| thiamine deficiency implications | #1 |
| liver spf mice | #1 |
| hepatic encephalopathy activation | #1 |
| dopamine thiamine deficiency | #1 |
| material equal | #1 |
| death wernicke | #1 |
| predilection neuropathologic damage | #1 |
| lornithine laspartate lola | #1 |
| edema complications | #1 |
| freechoice drinking paradigm | #1 |
| alf neuroinflammation | #1 |
| pyrithiamine quinuclidinyl | #1 |
| acute neurons mechanisms | #1 |
| thiamine deficiency synthesis | #1 |
| absence wernickes encephalopathy | #1 |
| shunted dogs | #1 |
| 25mm nh4cl p005 | #1 |
| cerebral γ‐aminobutyric acid | #1 |
| benzoate spf | #1 |
| ptbr | #1 |
| activities thiamine | #1 |
| prevention brain | #1 |
| neuroinflammationinflammation | #1 |
| key astroglial proteins | #1 |
| modulatory sites | #1 |
| lola effective | #1 |
| lcarnitinetreated | #1 |
| hepatic encephalopathy relationship | #1 |
| thalamus thiamine | #1 |
| lad platelets | #1 |
| result manganese deposition | #1 |
| serotonin transporter deficit | #1 |
| fasting intravenous injection | #1 |
| cultured cells mrna | #1 |
| pathogenesis neuronal loss | #1 |
| spf mutant | #1 |
| stages igg immunohistochemistry | #1 |
| routine neurological evaluation | #1 |
| cox2 il1beta mrna | #1 |
| alf messenger | #1 |
| key astrocytic proteins | #1 |
| lornithine laspartate ammonia | #1 |
| nac neurological complications | #1 |
| pfco frontal cortex | #1 |
| ampa sites | #1 |
| brain ammonia removal | #1 |
| encephalopathy expression | #1 |
| peripheral inflammation etanercept | #1 |
| fco cau | #1 |
| loss 3hcitalopram sites | #1 |
| pathogenesis wernickekorsakoff syndrome | #1 |
| 3865 258 nm | #1 |
| edema glutamine | #1 |
| 15–1788 pharmacokinetics | #1 |
| edema acute | #1 |
| exclusion brain diseases | #1 |
| cirrhosis psychometric testing | #1 |
| modulators hepatic | #1 |
| pyrithiamine pyruvate | #1 |
| seasonal ataxia | #1 |
| brain pregnant rats | #1 |
| pbz receptor densities | #1 |
| lola reductions | #1 |
| disease outcome prevention | #1 |
| sparsefur spf mice | #1 |
| pathogenesis hepatic encephalopathy | #1 |
| protective findings | #1 |
| gut ammonia | #1 |
| failure ammonia | #1 |
| cau lobe hepatic | #1 |
| tdpase activities | #1 |
| loss gfap expression | #1 |
| alf azoxymethane | #1 |
| 100 microm manganese | #1 |
| 3hpk cultured astrocytes | #1 |
| hyperammonemic disorders | #1 |
| inhibitory nh4cl | #1 |
| encephalopathy hypothermia | #1 |
| focal lactic | #1 |
| increased activity katpase | #1 |
| csf lactate pse | #1 |
| betaep brain | #1 |
| response alf | #1 |
| content pallidum | #1 |
| ldopa trace amines | #1 |
| lola efficacy | #1 |
| improvements hepatic microcirculation | #1 |
| therapy ornithine transcarbamylase | #1 |
| 57 caudate putamen | #1 |
| brain glutamine severity | #1 |
| selective increases | #1 |
| ptbr densities | #1 |
| normal conditions gut | #1 |
| hepatic encephalopathy integrity | #1 |
| downregulation glutamate transporter | #1 |
| atrophy brain glutamate | #1 |
| wernickes encephalopathy aids | #1 |
| igg extravasation reduction | #1 |
| bilirubin ataxics | #1 |
| otc deficiency activities | #1 |
| pse portalsystemic shunting | #1 |
| animal hepatectomy hepatitis | #1 |
| rats pca | #1 |
| thalamus symptomatic | #1 |
| genetic xlinked deficiency | #1 |
| dawley amino | #1 |
| spf mice activities | #1 |
| pse neurotransmitter agents | #1 |
| 7 thiaminedeficient medium | #1 |
| decreased tdp concentrations | #1 |
| pfco | #1 |
| pbz binding site | #1 |
| update hepatic encephalopathy | #1 |
| alf glucose | #1 |
| encephalopathy alf | #1 |
| surgical probenecid | #1 |
| ptbr ligand | #1 |
| stress alf | #1 |
| pse probenecid | #1 |
| hypokinesia stereotaxic microinjection | #1 |
| anastomosis pca | #1 |
| lornithinelaspartate therapeutic efficacy | #1 |
| copper pallidum | #1 |
| peripheral‐type benzodiazepine receptors | #1 |
| severity brain edema | #1 |
| thiaminedeficient encephalopathy | #1 |
| pse complication | #1 |
| brain ammonia pca | #1 |
| coding key | #1 |
| peripheral steroidal sources | #1 |
| brain congenital | #1 |
| regions pyrithiamine | #1 |
| pcs rats protective | #1 |
| pss degree | #1 |
| findings manganese | #1 |
| etanercept hepatic | #1 |
| older cirrhotic patients | #1 |
| degree pss | #1 |
| pathogenesis wernicke encephalopathy | #1 |
| sodium benzoate atp | #1 |
| muscle portacaval shunting | #1 |
| hepatic encephalopathy | #1 |
| neuronal thalamus | #1 |
| viral hepatitis alf | #1 |
| alzheimertype astrocytosis | #1 |
| neuropathologic damage | #1 |
| pharmacological manipulation ptbr | #1 |
| animal liver failure | #1 |
| rate thiamine turnover | #1 |
| loss thiamine | #1 |
| astrocytic glycine | #1 |
| hyperammonemia accounts | #1 |
| progression encephalopathy | #1 |
| increased synthesis cell | #1 |
| thiaminedeficient ataxic gait | #1 |
| relationship blood manganese | #1 |
| sites thiamine | #1 |
| nonvulnerable frontal cortex | #1 |
| antiparkinson drugs hypokinesia | #1 |
| ω3 receptor | #1 |
| animal pyridinium | #1 |
| fig dansyl | #1 |
| effective approach prevention | #1 |
| serotonin precursor metabolite | #1 |
| pathogenesis reversible symptoms | #1 |
| pca portacaval | #1 |
| congenital hyperammonemia nakatpase | #1 |
| sgc cerebral cortex | #1 |
| neuronastrocytic trafficking | #1 |
| prevention ammoniaprecipitated coma | #1 |
| encephalopathy histamine humans | #1 |
| rats surgical probenecid | #1 |
| spine neurochemical | #1 |
| brain pse | #1 |
| novo synthesis aspartate | #1 |
| wernickekorsakoff syndrome disturbances | #1 |
| affinity ptbr | #1 |
| caveolin1 pathway | #1 |
| haloperidol humans haloperiodol | #1 |
| cloned rat ptbr | #1 |
| ptbr sites | #1 |
| prior detoxification liver | #1 |
| magna catheter | #1 |
| ammonia central | #1 |
| thiamine deficiency brains | #1 |
| capacity cerebral cortex | #1 |
| thiamine neurochemistry | #1 |
| thiamine deficiency result | #1 |
| inhibitors acute hyperammonemia | #1 |
| omega 3 receptor | #1 |
| central thiamine | #1 |
| activities neuronal | #1 |
| hyperammonemic sparse | #1 |
| mild hypothermia reduction | #1 |
| novo lactate synthesis | #1 |
| ammonia intoxication rats | #1 |
| thiaminedeficient medium | #1 |
| deficiency densities | #1 |
| therapy refractive tle | #1 |
| nh4cl glutamates hippocampus | #1 |
| primary astrocytopathy | #1 |
| neuroprotection onset | #1 |
| 3h 11195 | #1 |
| rat wernickes encephalopathy | #1 |
| rtpcr experiments messenger | #1 |
| ammonia acute | #1 |
| rats insulin hypoglycaemia | #1 |
| thiaminedeficient mothers | #1 |
| action ro15 | #1 |
| sparsefur spf mouse | #1 |
| thiamine deficiency | #1 |
| thiaminedependent enzymes establishment | #1 |
| mechanisms brain edema | #1 |
| pca rats | #1 |
| tdpase encephalopathy humans | #1 |
| aom mice | #1 |
| lola nash | #1 |
| severity akinesia | #1 |
| shunting hyperammonemia | #1 |
| thalamus wernicke encephalopathy | #1 |
| ptbr expression pathogenesis | #1 |
| liver failure increases | #1 |
| gabaa neurosteroids | #1 |
| symptomatic pyrithiamine | #1 |
| flunitrazepam hepatic | #1 |
| rats direct evidence | #1 |
| neurological disorders selection | #1 |
| maob encephalopathy humans | #1 |
| specific energy metabolism | #1 |
| wellestablished actions | #1 |
| liver pca rats | #1 |
| 001 cerebral | #1 |
| kidney portacaval anastomosis | #1 |
| hypoglycaemia onset | #1 |
| pfco cau | #1 |
| effective urea cycle | #1 |
| relation sustained hyperammonemia | #1 |
| hereditary familial hyperbilirubinemia | #1 |
| sgc activation lymphocytes | #1 |
| alf amino | #1 |
| activities maob | #1 |
| autopsied brain samples | #1 |
| increased gabaergic tone | #1 |
| hyperammonaemia brain function | #1 |
| pca cns | #1 |
| cuznsod cox2 | #1 |
| igg extravasation expression | #1 |
| monoaminergic synaptic function | #1 |
| kgdh activities | #1 |
| cerebral levels glutamine | #1 |
| alf aom | #1 |
| relation deterioration | #1 |
| encephalopathy selective loss | #1 |
| maob cerebellum | #1 |
| region‐selective | #1 |
| reversible symptoms | #1 |
| mhe clinical practice | #1 |
| 44433a | #1 |
| treatment lola | #1 |
| cerebral energy deficit | #1 |
| increased brain content | #1 |
| atp free coa | #1 |
| alf proinflammatory | #1 |
| expression glyt1 transporter | #1 |
| surgical rna messenger | #1 |
| immunohistochemistry cox2 immunoreactivity | #1 |
| deficiency selective | #1 |
| relation energy metabolism | #1 |
| ngnitrol3harginine | #1 |
| cirrhosis vicious cycle | #1 |
| onset hypoglycaemic convulsions | #1 |
| nacetylcysteine cerebral complications | #1 |
| osmotic disturbance | #1 |
| encephalopathy onset | #2 |
| liver spf | #2 |
| failure alf | #2 |
| swelling cortical astrocytes | #2 |
| development ethanol preference | #2 |
| male portacaval shunt | #2 |
| implicated pathogenesis | #2 |
| rat brain relation | #2 |
| cerebral complications alf | #2 |
| hepatic cerebral | #2 |
| shunted | #2 |
| taurine platelets | #2 |
| kinetics taurine | #2 |
| lactate coma stages | #2 |
| 3000 microg m3 | #2 |
| brain shunted rats | #2 |
| isomorphic models | #2 |
| millimolar concentrations brain | #2 |
| disorder loss | #2 |
| brain dehydroepiandrosterone dhea | #2 |
| thiaminedependent enzymes | #2 |
| defect membrane transport | #2 |
| thiamine bloodbrain barrier | #2 |
| kidney ammonia | #2 |
| neuropsychiatric complication | #2 |
| 2 flumazenil | #2 |
| alf control | #2 |
| edematous cerebral cortex | #2 |
| novo synthesis lactate | #2 |
| thiaminedeficient mice | #2 |
| brain levels neurosteroids | #2 |
| computerized autotrack | #2 |
| brain lactate increase | #2 |
| wks decreased activities | #2 |
| controls 3alpha5alphathp | #2 |
| activities muscle | #2 |
| astrocytic benzodiazepine | #2 |
| brain lactate synthesis | #2 |
| pathophysiologic mechanisms | #2 |
| vesicular dysfunction | #2 |
| concentrations dheas | #2 |
| protein levels glast | #2 |
| liver failure gfap | #2 |
| failure altered | #2 |
| loss eaat2 protein | #2 |
| congenital hyperammonemias | #2 |
| liver failure studies | #2 |
| tyrosine tyr levels | #2 |
| pdh activity platelets | #2 |
| increased novo synthesis | #2 |
| thiamine phosphorylation | #2 |
| brain glutamine synthesis | #2 |
| ammoniainduced alterations | #2 |
| gfap immunoreactivity degree | #2 |
| sites increased | #2 |
| thiamine turnover | #2 |
| spf mutant mice | #2 |
| lower levels arginine | #2 |
| rats cortex male | #2 |
| nmda receptor pca | #2 |
| shunted pcs | #2 |
| alpha1 sites | #2 |
| model wernicke | #2 |
| mice acetaminophen toxicity | #2 |
| alanine frontal cortex | #2 |
| thiamine deficiency wks | #2 |
| concentrations gammaguanidinobutyric acid | #2 |
| moderate grade iii | #2 |
| chronic thiamine | #2 |
| modulation brain | #2 |
| 3alpha5alphathp 3alpha5betathp | #2 |
| animal hepatic encephalopathy | #2 |
| hypokinesia produced | #2 |
| densities binding | #2 |
| body fatigue rats | #2 |
| ohe encephalopathy humans | #2 |
| 3acetyl pyridine | #2 |
| activities maoa | #2 |
| thiamine deficiency patients | #2 |
| sustained hyperammonemia | #2 |
| mice congenital | #2 |
| ligand 3hpk | #2 |
| serum lad | #2 |
| edema alf | #2 |
| rats thiamine | #2 |
| immunohistochemistry liver failure | #2 |
| liver thiamine | #2 |
| precoma stages p001 | #2 |
| symptoms thiamine | #2 |
| 2 brain samples | #2 |
| thiamine dependent | #2 |
| treatment cns complications | #2 |
| cerebellum output | #2 |
| mouse astrocytes effects | #2 |
| fold allopregnanolone | #2 |
| increase coma | #2 |
| impaired gaba function | #2 |
| deficiency include | #2 |
| indomethacin locomotor deficit | #2 |
| inbred strains glutamine | #2 |
| phosphate sulfate mixture | #2 |
| wernickes encephalopathy patients | #2 |
| animals hepatic | #2 |
| wks enzyme activities | #2 |
| ouabain upregulation | #2 |
| pca brain regions | #2 |
| gammagba | #2 |
| cisterna magna catheters | #2 |
| membranes tomography | #2 |
| glutamate syndrome | #2 |
| brain taurine concentrations | #2 |
| alf drug | #2 |
| 5ht turnover brain | #2 |
| haloperiodol | #2 |
| l‐ornithine‐l‐aspartate | #2 |
| csf ammonia | #2 |
| neuroinhibitory steroids | #2 |
| nash addition | #2 |
| dheas hepatic | #2 |
| reduction dopamine turnover | #2 |
| coma stages p001 | #2 |
| encephalopathy wernicke | #2 |
| brain organic myoinositol | #2 |
| concentrations ammonium chloride | #2 |
| mice alf | #2 |
| bergmann glial pathology | #2 |
| precoma coma | #2 |
| liver cirrhosis activation | #2 |
| increased activities | #2 |
| hyperammonaemia hepatic encephalopathy | #2 |
| densities binding sites | #2 |
| gammagba nalphaacetylarginine nalphaaa | #2 |
| autopsy delay intervals | #2 |
| pyrithiamine induced | #2 |
| thiamine deprivation | #2 |
| diseases manganese | #2 |
| computed wernicke encephalopathy | #2 |
| pallidal manganese | #2 |
| ammonia detoxification glutamine | #2 |
| improvement mental state | #2 |
| neurons glutamine synthesis | #2 |
| densities bmax | #2 |
| hyperammonemic brain | #2 |
| intracranial hypertension alf | #2 |
| alf mrna expression | #2 |
| fold thdoc | #2 |
| ataxia animals | #2 |
| carboxamide binding | #2 |
| pathogenesis friedreichs ataxia | #2 |
| 3alpha5betathp patients | #2 |
| hydrolases aged | #2 |
| nitric oxide brain | #2 |
| human brain contrast | #2 |
| reduced brain dheas | #2 |
| neuropathic pain etanercept | #2 |
| plasma proinflammatory cytokines | #2 |
| aged muscimol | #2 |
| 3hpk11195 brain regions | #2 |
| mental state trials | #2 |
| ammonia central role | #2 |
| wernickes encephalopathy | #2 |
| systemic encephalopathy | #2 |
| brain samples alcoholics | #2 |
| increase coma stages | #2 |
| responsible neurological | #2 |
| binding 3hpk11195 | #2 |
| death thiamine | #2 |
| gaba ammonia | #2 |
| mrna expression gfap | #2 |
| brains 36 patients | #2 |
| cortical astrocytes ammonia | #2 |
| pallidum cirrhotic patients | #2 |
| plasma levels 3alpha5alphathp | #2 |
| ammonia octanoic acid | #2 |
| thirtytwo cirrhotic patients | #2 |
| deficient encephalopathy | #2 |
| encephalopathy portacaval | #2 |
| 26 153 | #2 |
| thiamine‐dependent enzyme | #2 |
| thiamine‐dependent | #2 |
| symptomatic rats | #2 |
| sgc brain | #2 |
| cns consequences | #2 |
| pca rats allopregnanolone | #2 |
| reflex stage | #2 |
| electrified grid | #2 |
| increased levels pregnenolone | #2 |
| loss eaat2 expression | #2 |
| hepatic encephalopathy complication | #2 |
| activities choline acetyltransferase | #2 |
| reduced concentrations dheas | #2 |
| encephalopathy glutamine concentrations | #2 |
| bath concentration ammonia | #2 |
| degree gfap immunoreactivity | #2 |
| iggimmunoreactivity | #2 |
| dheas body fatigue | #2 |
| edema hepatic | #2 |
| osmotic effects glutamine | #2 |
| encephalopathy acute | #2 |
| hyperammonemia increased | #2 |
| cholinergic neuronal loss | #2 |
| decreased reuptake | #2 |
| increased manganese | #2 |
| 67 coma stages | #2 |
| isomorphic model | #2 |
| thiamine deprivation loss | #2 |
| thdoc fold | #2 |
| neurosteroid pregnenolone fold | #2 |
| dheas reduced | #2 |
| allopregnanolone fold | #2 |
| progression ohe | #2 |
| 3beta5alphathp | #2 |
| precoma stages increase | #2 |
| rats portacaval anastomosis | #2 |
| alpha kgdh | #2 |
| 150 dose increase | #2 |
| decreased gfap immunoreactivity | #2 |
| ammoniainduced neurotoxicity | #2 |
| glutamate glur2 | #2 |
| enzyme deficits | #2 |
| cirrhotic patients modulation | #2 |
| encephalopathy major | #2 |
| methyhistamine | #2 |
| cerebellum cirrhotic patients | #2 |
| ornithine aminotransferase administration | #2 |
| tdp dependent enzymes | #2 |
| portacaval anastomosis pca | #2 |
| alcoholics absence | #2 |
| brain edema concentrations | #2 |
| portacaval shunting | #2 |
| experimental alf | #2 |
| cuznsod mrna cuznsod | #2 |
| pyrithiamine rats rats | #2 |
| ataxic animals | #2 |
| 4week portacaval | #2 |
| reduced brain levels | #2 |
| glt1 increased | #2 |
| encephalopathy aids | #2 |
| gabaa receptor indomethacin | #2 |
| neurons nmr | #2 |
| early precoma stages | #2 |
| cerebral edema loss | #2 |
| treatment asparagine | #2 |
| ammonia gabaergic neurotransmission | #2 |
| aqp4 cerebral cortex | #2 |
| hepatic encephalopathy ohe | #2 |
| modulation sgc | #2 |
| increased brain turnover | #2 |
| neuronal loss alterations | #2 |
| disorder mystery | #2 |
| thiaminedeficiency | #2 |
| glutamine intracranial | #2 |
| hyperammonemia synaptosomes | #2 |
| central neuroinflammatory | #2 |
| mri neurological evaluation | #2 |
| pyrithiamine treated | #2 |
| vulnerable brain structures | #2 |
| glutamine hepatic | #2 |
| cirrhotic patients pathology | #2 |
| thp metabolites fatigue | #2 |
| increasing dheas currents | #2 |
| induced liver failure | #2 |
| 970±079 | #2 |
| dheas bdl rats | #2 |
| lornithinelaspartate | #2 |
| bckdh bckdh activity | #2 |
| form ataxia | #2 |
| gabaa encephalopathy humans | #2 |
| ammonia animal hepatic | #2 |
| cisterna magna catheter | #2 |
| ammonia metabolism astrocytes | #2 |
| sustained deficiency arginine | #2 |
| encephalopathy histamine | #2 |
| extracellular brain | #2 |
| hepatic encephalopathy controls | #2 |
| selective increase | #2 |
| brain portacaval shunting | #2 |
| pathogenesis portal | #2 |
| restricted transfer | #2 |
| hepatic encephalopathy gabaa | #2 |
| activities brains | #3 |
| neurobiological characterization | #3 |
| increased ptbr | #3 |
| bckdh activity rats | #3 |
| decreased aspartate | #3 |
| acrylamide pyrithiamine | #3 |
| doubt25 ammonia | #3 |
| cerebellum activities | #3 |
| midbrain turnover study | #3 |
| nmda subclass | #3 |
| glutamates hippocampus rats | #3 |
| central cholinergic deficit | #3 |
| homogenates frontal cortex | #3 |
| encephalopathy hepatic | #3 |
| liver–brain axis | #3 |
| 13 consecutive weeks | #3 |
| administration ammonium | #3 |
| lobe hepatic | #3 |
| animals profiles | #3 |
| neuroglial proteins | #3 |
| acids relation | #3 |
| basal ganglia βendorphin | #3 |
| intraneuronal release | #3 |
| βendorphin akinesia | #3 |
| protein hepatic | #3 |
| singlesite model | #3 |
| skeletal portacaval shunt | #3 |
| gfap mrna gfap | #3 |
| synthesis aspartate | #3 |
| il6 levels brain | #3 |
| decreased concentrations striatum | #3 |
| pdh friedreich | #3 |
| hyperammonemia acute | #3 |
| doubt25 | #3 |
| cerebral cortex pons | #3 |
| adequate substrates | #3 |
| effects ldeprenyl | #3 |
| congenital hyperammonemia | #3 |
| amphetamine amphetamine animals | #3 |
| turnover study rats | #3 |
| rats pse | #3 |
| 5fmorn | #3 |
| increases il1beta | #3 |
| models thiamine | #3 |
| 3hdaspartate uptake | #3 |
| deficiency thiamine | #3 |
| severity reviews see1–4 | #3 |
| decreased concentrations αmt | #3 |
| rats pyrithiamine | #3 |
| coma equal | #3 |
| encephalopathy inflammation | #3 |
| pallidal signals | #3 |
| ishen guidelines | #3 |
| thiamine deficient | #3 |
| platelets 10 patients | #3 |
| drug situ nickend | #3 |
| coma stage | #3 |
| mk‐801‐sensitive nitration | #3 |
| cirrhosis iii | #3 |
| repetitive removal | #3 |
| selective brain lesions | #3 |
| medium 5 mm | #3 |
| portacavalshunted rats | #3 |
| pathogenesis central | #3 |
| ammoniainduced impairment | #3 |
| major neurotransmitter systems | #3 |
| rats glutamates hippocampus | #3 |
| akinesia βendorphin | #3 |
| cerebellar amino | #3 |
| 5fmorn treatment | #3 |
| pallidus hepatic | #3 |
| activities reduced | #3 |
| glutamine brain edema | #3 |
| endogenous agonists role | #3 |
| brain portocaval anastomosis | #3 |
| brain densities | #3 |
| ammonia energy metabolism | #3 |
| βendorphin apomorphine basal | #3 |
| prevents cerebral | #3 |
| alf animals | #3 |
| akinesia corneal reflex | #3 |
| acute ammonia exposure | #3 |
| increase brain lactate | #3 |
| ammonia‐induced brain edema | #3 |
| signs mild personality | #3 |
| tetrahydrodesoxycorticosterone | #3 |
| thiamine deficiency wernicke | #3 |
| αmt midbrain | #3 |
| cholestasis‐associated fatigue | #3 |
| hypothermia brain edema | #3 |
| globus pallidus putamen | #3 |
| controls emax | #3 |
| ganglia structures | #3 |
| statistical significance regions | #3 |
| protective glutamine | #3 |
| encephalopathy aged | #3 |
| addition astrocyte morphology | #3 |
| transporter snat5 | #3 |
| brain improvement | #3 |
| selective down‐regulation | #3 |
| pbgd study | #3 |
| abstract hepatic encephalopathy | #3 |
| late symptomatic stages | #3 |
| mrna ammonia | #3 |
| autotrack | #3 |
| lcarnitine atp | #3 |
| neurotransmission failure | #3 |
| peripheral‐type | #3 |
| genial expression | #3 |
| strains thiamine | #3 |
| type ” | #3 |
| predictions disorder | #3 |
| brain concentrations rats | #3 |
| βendorphin decreased concentrations | #3 |
| hepatic neurological | #3 |
| portacaval anastomosis rats | #3 |
| male portacaval | #3 |
| astrocytic cell swelling | #3 |
| muscle glutamine synthetase | #3 |
| mhe lola | #3 |
| reflex serotonin βendorphin | #3 |
| alcoholics wks | #3 |
| decreased densities | #3 |
| carnitine ammonia | #3 |
| ammonia brain edema | #3 |
| cogent explanation | #3 |
| total brain glutamine | #3 |
| corneal reflex apomorphine | #3 |
| altered glial | #3 |
| vitro binding technique | #3 |
| thiamine phosphate | #3 |
| ammoniatreated cells | #3 |
| hepatic devascularized rat | #3 |
| deletion delays | #3 |
| homologous models | #3 |
| effects ro15 | #3 |
| tissue ornithine concentrations | #3 |
| rats αmt | #3 |
| blood transketolase | #3 |
| portocaval anastomosis pca | #3 |
| hepatobiliary route | #3 |
| glial cells ammonia | #3 |
| abstract mild hypothermia | #3 |
| electrically stimulated release | #3 |
| operated controls | #3 |
| pdhc acetyl coa | #3 |
| testis preparations | #3 |
| pca odn immunolabeling | #3 |
| precoma stages | #3 |
| pcs rat brain | #3 |
| rats pathogenesis | #3 |
| humans neurotransmitter | #3 |
| treatment portalsystemic encephalopathy | #3 |
| onset neurological signs | #3 |
| binding sites heart | #3 |
| ammonia swelling | #3 |
| glutamate transporter cells | #3 |
| αketoglutarate dehydrogenase | #3 |
| edema intracranial | #3 |
| animals coma | #3 |
| cholinergic m1 | #3 |
| 38 alcoholic patients | #3 |
| potent neuroactive properties | #3 |
| transketolase activities | #3 |
| 320350 degrees | #3 |
| brain edema alf | #3 |
| hepatic encephalopathy humans | #3 |
| cirrhosis agents | #3 |
| ammonia glutamate | #3 |
| cellspecific pathways | #3 |
| acids cerebrospinal | #3 |
| kornetsky | #3 |
| αmt βendorphin | #3 |
| concentrations αmt | #3 |
| astrocyte glutamine | #3 |
| ammonia hepatic | #3 |
| odn immunolabeling | #3 |
| deficiency acidosis | #3 |
| regions cns | #3 |
| increased uptake capacity | #3 |
| mmars brain water | #4 |
| brain hepatic encephalopathy | #4 |
| alf expression | #4 |
| liver brain | #4 |
| otcdeficient mice | #4 |
| histaminergic histamine | #4 |
| edema gene | #4 |
| rats asparagine | #4 |
| arterial ammonia alf | #4 |
| maoa isoform | #4 |
| newly synthesized glutamine | #4 |
| thiamine antagonist | #4 |
| condition development | #4 |
| cerebral amino acids | #4 |
| benzodiazepines increase | #4 |
| cerebral cortex kidney | #4 |
| animals liver failure | #4 |
| subclinical seizure activity | #4 |
| brain thiamine | #4 |
| activities brain | #4 |
| rats βendorphin | #4 |
| sham mmars | #4 |
| activities prefrontal cortex | #4 |
| ammonia levels blood | #4 |
| xlinked deficiency | #4 |
| expression alf | #4 |
| taurine friedreichs ataxia | #4 |
| brain dopamine receptor | #4 |
| mhe mildest form | #4 |
| vitro techniques ketoglutarate | #4 |
| inbred strains ammonia | #4 |
| thiochrome derivatives | #4 |
| degree alzheimer type | #4 |
| protein expression brain | #4 |
| inos mnsod | #4 |
| effects mild hypothermia | #4 |
| patients wernicke | #4 |
| izuru matsumoto | #4 |
| treatment hepatic encephalopathy | #4 |
| acute ammonia treatment | #4 |
| ischemic liver failure | #4 |
| regional amino | #4 |
| cbf inflammatory mediators | #4 |
| postsynaptic action | #4 |
| early microglial response | #4 |
| p001 hypothermia | #4 |
| ouabainlike compounds | #4 |
| wernickekorsakoff syndrome | #4 |
| thiamine deficiency rats | #4 |
| rats portacaval shunting | #4 |
| elevated ammonia levels | #4 |
| glt1 transcript | #4 |
| aged pyruvate | #4 |
| tdinduced cell death | #4 |
| pse increased | #4 |
| astrocytic metabolic | #4 |
| extrapyramidal symptoms patients | #4 |
| gaba friedreich | #4 |
| lornithine laspartate | #4 |
| astrocytic genes | #4 |
| hepatocytes ascorbate | #4 |
| 5 mm nh4cl | #4 |
| ions synaptic | #4 |
| postmortem delay interval | #4 |
| locomotor deficit | #4 |
| increased brain glutamine | #4 |
| cases alcohol abuse | #4 |
| encephalopathy coma | #4 |
| brain glutamic | #4 |
| normal coupling | #4 |
| locomotor evaluation | #4 |
| liver central | #4 |
| tdpase | #4 |
| thiamine deficient animals | #4 |
| alcohol thiamine deficiency | #4 |
| guanylate cyclase patients | #4 |
| ouabain ec50 | #4 |
| neurotransmitter dysfunction | #4 |
| rat brain pca | #4 |
| time mmars | #4 |
| severe neuronal dysfunction | #4 |
| transketolase wernicke | #4 |
| thp metabolites | #4 |
| plasma clearance groups | #4 |
| arterial ammonia mmars | #4 |
| brain energy failure | #4 |
| decreased activities | #4 |
| deoxyglucose endothelium | #4 |
| loss glt1 | #4 |
| increased icp alf | #4 |
| amino acids regions | #4 |
| shamoperated controls | #4 |
| surgical rna rats | #4 |
| mmars time | #4 |
| thiamine diphosphatase | #4 |
| amino acids areas | #4 |
| increased concentrations prostaglandins | #4 |
| mmars increased icp | #4 |
| total shunting | #4 |
| albumin dialysis alf | #4 |
| synaptic membrane preparations | #4 |
| peripheral‐type benzodiazepine | #4 |
| 13 moles | #4 |
| administration central | #4 |
| activities glutamine synthetase | #4 |
| carnitine energy | #4 |
| tspo sites | #4 |
| ornithine aspartate | #4 |
| shunted rats | #4 |
| onset severe encephalopathy | #4 |
| anastomosis rat | #4 |
| inflammation mediators icp | #4 |
| calcium microsomes | #4 |
| alcoholism thiamine | #4 |
| affinities densities | #4 |
| 6 hrs alf | #4 |
| alf | #4 |
| brain 5ht release | #4 |
| thiamine thiamine pyrophosphate | #4 |
| alf brain | #4 |
| brain pregnenolone content | #4 |
| thiamine‐deficient rat brain | #4 |
| brain edema increase | #4 |
| brain neuroinflammation | #4 |
| icp arterial ammonia | #4 |
| opioid pca | #4 |
| acute liver failure | #4 |
| pse encephalopathy humans | #5 |
| brain glutamate concentrations | #5 |
| manganese astrocytes | #5 |
| patients hepatic | #5 |
| content modulation | #5 |
| gait animals | #5 |
| 45 cirrhotic patients | #5 |
| increases ammonia | #5 |
| monoamines metabolites | #5 |
| ammonia metabolism | #5 |
| sites peripheral | #5 |
| alcoholic receptors | #5 |
| currents concentrations | #5 |
| glur2 glur3 subunits | #5 |
| activities cerebellum | #5 |
| thiaminedeficient diet | #5 |
| saturation binding isotherms | #5 |
| age matched subjects | #5 |
| hexyl1h | #5 |
| cytokines ammonia | #5 |
| studied brain | #5 |
| homologous model | #5 |
| glutamate symporters | #5 |
| exposure cultured astrocytes | #5 |
| sustained deficiency | #5 |
| anterolateral hypothalamus | #5 |
| chronic exposure manganese | #5 |
| allopregnanolone thdoc | #5 |
| spectroscopy tomography emissioncomputed | #5 |
| aspartate lola | #5 |
| liver disease rats | #5 |
| latenight snack | #5 |
| responsible brain | #5 |
| amino acids pathogenesis | #5 |
| rats fatigue | #5 |
| treatment malnutrition | #5 |
| allopregnanolone gabaa | #5 |
| neurotransmitter pool | #5 |
| maoa activities | #5 |
| publication animals rats | #5 |
| mild personality | #5 |
| tk activities | #5 |
| activities gad | #5 |
| cerebral hepatic | #5 |
| intracranial hypertension rats | #5 |
| acute rats rats | #5 |
| topic rifaximin | #5 |
| tpp cofactor | #5 |
| acetyl pyridine | #5 |
| reduction glutamate | #5 |
| kstimulated ca2dependent release | #5 |
| alf ammonia | #5 |
| genetics astrocytes blotting | #5 |
| laspartate lola | #5 |
| methioninesulfoximine | #5 |
| vulnerable brain | #5 |
| pet scan study | #5 |
| vulnerable regions | #5 |
| acute magnetic | #5 |
| pregnenolone content | #5 |
| extracellular quin | #5 |
| brain ammonia | #5 |
| reserpinelike | #5 |
| cns ammonia | #5 |
| complication acute | #5 |
| brain histamine receptors | #5 |
| ammonia muscle | #5 |
| transporter sites | #5 |
| prevention prophylaxis | #5 |
| thiamine status | #5 |
| hyperammonemia liver | #5 |
| mmars | #5 |
| liver assist devices | #5 |
| congenital urea | #5 |
| maoa function | #5 |
| neurological status | #5 |
| encephalopathy cerebral | #5 |
| amino acid regions | #5 |
| kgdh | #5 |
| adequate experimental models | #5 |
| hepatic encephalopathy gaba | #5 |
| medial thalamus | #5 |
| spf mice controls | #5 |
| onset coma | #5 |
| brain acute | #5 |
| activities choline | #5 |
| alterations glutamatergic | #5 |
| tissue autopsy | #5 |
| kinetics pharmacology | #5 |
| result altered | #5 |
| branchedchain analysis | #5 |
| convulsions onset | #5 |
| hand densities | #5 |
| wernicke | #5 |
| astrocytic | #5 |
| ammonia lowering | #5 |
| surgical receptors | #5 |
| rats portacaval shunts | #5 |
| ammonia removal | #5 |
| glutamine hypothesis | #5 |
| cerebral amino | #6 |
| inflammatory mediators groups | #6 |
| brain benzodiazepine | #6 |
| fmorn | #6 |
| deterioration neurological | #6 |
| increased expression aqp4 | #6 |
| platelets 11 patients | #6 |
| receptors hepatic | #6 |
| alphaketoglutarate dehydrogenase | #6 |
| dha administration | #6 |
| thiamine esters | #6 |
| hepatic encephalopathy effects | #6 |
| cerebral cortex activities | #6 |
| lola improvement | #6 |
| gabaergic tone | #6 |
| blood‐brain barrier integrity | #6 |
| frontal cortex rats | #6 |
| controls arginine | #6 |
| encephalopathy humans | #6 |
| induced thiamine | #6 |
| nac alf | #6 |
| fur mice | #6 |
| acetyl lcarnitine | #6 |
| thiamine phosphate esters | #6 |
| glt1 glast protein | #6 |
| righting reflexes | #6 |
| term fluorescence | #6 |
| models alf | #6 |
| disease ammonia | #6 |
| arginine brain | #6 |
| benzodiazepine intake | #6 |
| 14c taurine | #6 |
| liver failure | #6 |
| concomitant 24fold increase | #6 |
| 3nmol | #6 |
| enzymes brains | #6 |
| 3htryptamine binding | #6 |
| mice nacetylcysteine | #6 |
| 3htryptamine binding sites | #6 |
| dehydrogenase pdhc | #6 |
| relationship neurological symptoms | #6 |
| humans hyperammonemia | #6 |
| output cerebellum | #6 |
| dogs hepatic encephalopathy | #6 |
| brain cirrhotic | #6 |
| tmpase | #6 |
| activities liver | #6 |
| expression astrocytic genes | #6 |
| cerebellum caudate nucleus | #6 |
| increased glut1 expression | #6 |
| capacity removal | #6 |
| endstage liver failure | #6 |
| implications pathogenesis | #6 |
| basal ganglia structures | #6 |
| mars alf | #6 |
| plasma frontal cortex | #6 |
| hyperammonemic | #6 |
| ammonia glutamine | #6 |
| unaltered distribution | #6 |
| hypothermia alf | #6 |
| nencki | #6 |
| alf nac | #6 |
| pca sham | #6 |
| direct neurotoxic | #6 |
| glt1 brain | #6 |
| astrocyte cell volume | #6 |
| perispinal etanercept | #6 |
| enzymes pyruvate | #6 |
| glast transporter | #6 |
| ascorbate protects | #6 |
| central proinflammatory | #6 |
| inhibitor src | #7 |
| igg immunohistochemistry | #7 |
| transporter deficit | #7 |
| icp alf | #7 |
| thiamine absorption | #7 |
| flumazenil 10 microm | #7 |
| metallic phosphate | #7 |
| cyclase hepatic | #7 |
| rats ammonium acetate | #7 |
| hepatic encephalopathy studies | #7 |
| chronic deprivation | #7 |
| severe thiamine deficiency | #7 |
| fatigue severity patients | #7 |
| perineuronal astrocytes | #7 |
| surgical rats | #7 |
| neuroinhibitory | #7 |
| thiamine dependent enzymes | #7 |
| transketolase animals | #7 |
| acute minocycline | #7 |
| wernicke‐korsakoff syndrome | #7 |
| 3htryptamine | #7 |
| pca pss | #7 |
| chemistry disease | #7 |
| cerebral alterations alf | #7 |
| tppdependent enzymes | #7 |
| glutamine synthesis ammonia | #7 |
| frontal cortex controls | #7 |
| glutamine increased | #7 |
| liver hepatic encephalopathy | #7 |
| gdh activities | #7 |
| alf sham | #7 |
| edema plasma | #7 |
| skeletal muscle adapts | #7 |
| astrocytic transporters | #7 |
| typical friedreichs ataxia | #7 |
| flumazenil patients | #7 |
| alf arterial ammonia | #7 |
| mediators liver | #7 |
| central benzodiazepine receptors | #7 |
| swelling astrocytes | #7 |
| neuropsychiatric abnormalities patients | #7 |
| edema extracellular | #7 |
| l3harginine uptake | #7 |
| ischemia hyperglycemic | #7 |
| concentrations allopregnanolone | #7 |
| columbia rating scale | #7 |
| 70 mm kcl | #7 |
| glutamate acute | #7 |
| neurological symptoms | #7 |
| failure acute | #7 |
| brain glutamate | #7 |
| central neuroinflammation | #7 |
| tdp ttp | #7 |
| alcoholic brain damage | #7 |
| encephalopathy findings | #7 |
| size portacaval | #7 |
| neuronal cell loss | #7 |
| pregnant rats offspring | #7 |
| animal hepatic | #7 |
| increased cerebellum | #7 |
| hiaa increased | #7 |
| nutritional management patients | #7 |
| uremic coma | #7 |
| loss transporter | #7 |
| ammonia kidney | #7 |
| fulminant liver failure | #7 |
| notion activation | #7 |
| vpmt | #7 |
| kcl medium | #7 |
| complications liver disease | #8 |
| ammonia metabolites | #8 |
| disease gad | #8 |
| neurobehavioral damage | #8 |
| thalamus cerebellum | #8 |
| prefrontal nmda | #8 |
| antisense elements genetics | #8 |
| content frontal cortex | #8 |
| induced akinesia | #8 |
| active pyruvate dehydrogenase | #8 |
| intracranial pressure increase | #8 |
| receptors mitochondrial | #8 |
| regional alterations | #8 |
| assessment bioaccumulation | #8 |
| clive harper | #8 |
| lactate synthesis | #8 |
| neuropathologic consequences | #8 |
| cirrhotic patients | #8 |
| result decreased | #8 |
| ammonium ions | #8 |
| spraguedawley temporal lobe | #8 |
| alcohol thiamine | #8 |
| brain ammonia levels | #8 |
| alcohol brain damage | #8 |
| taurine ca2 | #8 |
| affinity glutamate uptake | #8 |
| hyperglycemic cerebral | #8 |
| measurement cell volume | #8 |
| gaba reverse | #8 |
| loss congenital | #8 |
| izuru | #8 |
| rindi | #8 |
| ultraviolet uv spectrum | #8 |
| chronic brain dysfunction | #8 |
| alterations modulation | #8 |
| cerebellum activation | #8 |
| portalsystemic shunting | #8 |
| falls cirrhosis | #8 |
| probenecid 5 | #8 |
| tests ataxia | #8 |
| dependent enzymes | #8 |
| autopsied human | #8 |
| hyperglycemic cerebral ischemia | #8 |
| strains ornithine | #8 |
| proinflammatory mediators expression | #8 |
| ammonia hyperammonemia | #8 |
| 3alpha5betathp | #8 |
| sourkes | #8 |
| nmda sites | #8 |
| direct toxic actions | #8 |
| cells ammonia | #8 |
| elfar adalsteinsson | #8 |
| portocaval anastomosis | #8 |
| concentrations thdoc | #8 |
| synthesis thiamine | #8 |
| expression glyt1 | #8 |
| voluntary ethanol consumption | #8 |
| peter dodd | #8 |
| normal metabolic balance | #8 |
| alf administration | #8 |
| activities glutamine | #8 |
| study binding sites | #8 |
| tellez | #8 |
| synthesis lactate | #8 |
| brain increased expression | #8 |
| arterial ammonia concentrations | #8 |
| central noradrenergic function | #8 |
| neuroprotective steroids | #8 |
| animals acute | #9 |
| sham alf | #9 |
| edema rats | #9 |
| ammonia binding | #9 |
| nonneuronal elements | #9 |
| taurine calcium | #9 |
| kinetics distribution | #9 |
| gaba reference | #9 |
| ammonia neurotoxicity | #9 |
| acid hepatic | #9 |
| rats phosphate | #9 |
| pcs rats | #9 |
| cerebral ammonia toxicity | #9 |
| prevention complications | #9 |
| vulnerable brain regions | #9 |
| acute hyperammonemia | #9 |
| hepatocerebral | #9 |
| thiamine monophosphatase | #9 |
| transcarbamylase otc | #9 |
| protein glut1 | #9 |
| male cirrhotic patients | #9 |
| 37 decrease | #9 |
| disease thiamine | #9 |
| mild hypothermia | #9 |
| pallidal signal | #9 |
| autopsied brain | #9 |
| brain postsynaptic | #9 |
| neuroinhibition | #9 |
| portacaval rat | #9 |
| arterial ammonia concentration | #9 |
| cerebellum medulla oblongata | #9 |
| central gabaa receptor | #9 |
| glyt1 transporter | #9 |
| observed frontal | #9 |
| binding sites brain | #9 |
| rat brain density | #9 |
| perispinal administration | #9 |
| ammonia key role | #9 |
| acute nitric oxide | #9 |
| hepatic coma | #9 |
| brain herniation | #9 |
| order address | #9 |
| activities skeletal muscle | #9 |
| hepatic encephalopathy ammonia | #9 |
| 5fluoromethylornithine | #9 |
| adolf pfefferbaum | #9 |
| manganese dust | #9 |
| edith sullivan | #9 |
| joanne lewohl | #9 |
| taurine binding | #9 |
| glutamate receptor ligands | #9 |
| neurotoxic substance | #9 |
| 11 cirrhotic patients | #9 |
| portal hypertension result | #9 |
| acute rats | #9 |
| mechanisms responsible | #9 |
| ammonia induced | #9 |
| hyperammonemia liver cirrhosis | #9 |
| glucose hypothermia | #9 |
| glial tca cycle | #9 |
| glutamate glt1 | #9 |
| binding sites nmda | #9 |
| gabaa tissue distribution | #9 |
| sites frontal | #9 |
| 3hketanserin binding sites | #10 |
| cord taurine | #10 |
| glutathione levels expression | #10 |
| rats daily injections | #10 |
| activation pathogenesis | #10 |
| neuroactive amino acids | #10 |
| anastomosis hepatic | #10 |
| swelling ammonia | #10 |
| flumazenil hepatic | #10 |
| mnsod cuznsod | #10 |
| progression hepatic encephalopathy | #10 |
| brain pca | #10 |
| identification alterations | #10 |
| nh4 forms | #10 |
| stress thiamine | #10 |
| thiamine transketolase | #10 |
| fur mouse | #10 |
| complication chronic | #10 |
| expression superoxide | #10 |
| thalamic structures | #10 |
| mechanisms free radicals | #10 |
| urea cycle enzymopathies | #10 |
| affinities binding sites | #10 |
| nh4ac | #10 |
| model alf | #10 |
| mechanisms tnfalpha | #10 |
| 200 appearance | #10 |
| encephalopathy grade | #10 |
| cerebellum pons | #10 |
| brain edema | #10 |
| neuropsychiatric disorder | #10 |
| thiamine replenishment | #10 |
| ammonia study | #10 |
| deficiency congenital | #10 |
| 3hpk | #10 |
| rats nimesulide | #10 |
| dissected material | #10 |
| subsequent gc analysis | #10 |
| disorders include | #10 |
| bdl surgery | #10 |
| labeling glutamine | #10 |
| 10 mm concentration | #10 |
| 3omethylglucose animals animals | #10 |
| glutamine synthesis astrocytes | #10 |
| selective brain regions | #10 |
| loss reflex | #10 |
| decreased glutamate | #10 |
| neurological symptomatology | #10 |
| encephalopathy cirrhotic | #10 |
| rats stereotyped behavior | #10 |
| massive brain edema | #10 |
| mechanisms include | #10 |
| rat leads | #10 |
| cerebral consequences | #10 |
| hrqol mhe | #10 |
| benzodiazepines neurosteroids | #11 |
| biosynthetic purposes | #11 |
| dehydrogenase alpha | #11 |
| amino acids rats | #11 |
| pca brain | #11 |
| experimental design limitations | #11 |
| ammonia astrocytes | #11 |
| portal systemic | #11 |
| cerebral vulnerability | #11 |
| capacity ammonia | #11 |
| 1h‐13c | #11 |
| oxidative nitrosative stress | #11 |
| benzodiazepine bdz receptors | #11 |
| pca p005 | #11 |
| glutamate gammaaminobutyric acid | #11 |
| gabaergic tonic currents | #11 |
| benzodiazepinelike compounds | #11 |
| impaired oxidation | #11 |
| manganese blood | #11 |
| brain h1 | #11 |
| reduced activities | #11 |
| time icp | #11 |
| ammonia animals rats | #11 |
| hypothermia liver | #11 |
| cirrhotic patients relationship | #11 |
| studies convincing evidence | #11 |
| ammonia pathogenesis | #11 |
| rats nh4cl | #11 |
| isoforms mrna | #11 |
| placebo benzodiazepines | #11 |
| ammonia amino acids | #11 |
| deficiency brain | #11 |
| fluoromethylornithine | #11 |
| dawley thalamus | #11 |
| impaired locomotor activity | #11 |
| hyperammonemias | #11 |
| halflife age | #11 |
| brain increased | #11 |
| brain alf | #11 |
| alterations brain | #11 |
| signal hyperintensity | #11 |
| patients gabaa | #11 |
| brain liver | #11 |
| pdh alpha | #11 |
| increased expression brain | #11 |
| cerebellar tissue | #12 |
| clinical hepatic encephalopathy | #12 |
| anaplerotic activity | #12 |
| pairfed control mice | #12 |
| subclinical encephalopathy | #12 |
| diphosphate form | #12 |
| ammonia salts | #12 |
| brains rats | #12 |
| humans ketoglutarate | #12 |
| ammonia animals | #12 |
| prevention hepatic encephalopathy | #12 |
| acetyltransferase disease | #12 |
| p005 pca | #12 |
| humans hepatic | #12 |
| thiamin triphosphate | #12 |
| mild hypothermia patients | #12 |
| patients frontal cortex | #12 |
| binding medium | #12 |
| blood manganese concentrations | #12 |
| improvement neurological symptoms | #12 |
| aqp4 brain edema | #12 |
| hyperammonemia liver failure | #12 |
| total glutamine | #12 |
| deficiency amino | #12 |
| microglial activation brain | #12 |
| rats glut1 | #12 |
| perispinal | #12 |
| thalamus cerebral cortex | #12 |
| brain slices synaptosomes | #12 |
| neuroactive amino | #12 |
| selective inactivator | #12 |
| mm nh4cl | #12 |
| brain chronic | #12 |
| loss righting | #12 |
| binding sites ligands | #12 |
| thiamine deficient diet | #12 |
| shunt surgical | #12 |
| contribute pathogenesis | #12 |
| ammonia | #12 |
| increased ammonia | #12 |
| selective radioligands | #12 |
| igg extravasation | #12 |
| selective loss expression | #12 |
| ammonia amino | #12 |
| ammonia cytokines | #13 |
| increased copper content | #13 |
| hyperammonemic conditions | #13 |
| loss gfap | #13 |
| neurosteroids gabaa | #13 |
| neurosteroids pregnenolone | #13 |
| role selective vulnerability | #13 |
| blood csf concentrations | #13 |
| butyrylglycine | #13 |
| growing body evidence | #13 |
| regions rat brain | #13 |
| brain water accumulation | #13 |
| ampa receptor glur2 | #13 |
| development severe encephalopathy | #13 |
| liver toxins | #13 |
| greatest vulnerability | #13 |
| presence hippocampal sclerosis | #13 |
| peripheral nerve conduction | #13 |
| ishen | #13 |
| patients flumazenil | #13 |
| amino acids lactate | #13 |
| complex ketone | #13 |
| increased brain lactate | #13 |
| hyperammonemia ammonia | #13 |
| gfap protein | #13 |
| endogenous neuropeptide ligands | #13 |
| expression ammonia | #13 |
| treatment liver failure | #13 |
| hyperglycemic ischemia | #13 |
| veratramine | #13 |
| hepatic encephalopathy patients | #13 |
| survival liver injury | #13 |
| thiamine intake | #13 |
| ammonia manganese | #13 |
| hand activities | #13 |
| cytokines hepatic | #13 |
| evidence central | #13 |
| increased csf concentrations | #13 |
| pallidal dopamine | #13 |
| transcarbamylase deficiency | #13 |
| tissuespecific alterations | #13 |
| body fatigue | #13 |
| frontal cortex administration | #13 |
| sites brain | #13 |
| levels octopamine | #13 |
| cerebral edema icp | #13 |
| loss chat | #13 |
| neuroprotection pretreatment | #13 |
| acute ammonia | #13 |
| postsynaptic gaba | #13 |
| pathogenesis | #14 |
| gfap aqp4 | #14 |
| cerebellum cerebellar cortex | #14 |
| models hepatic | #14 |
| ataxia neurological signs | #14 |
| αmt | #14 |
| 8024 | #14 |
| glutamine concentrations | #14 |
| aged biogenic | #14 |
| manganese distribution | #14 |
| clinical neurological signs | #14 |
| systemic shunting | #14 |
| antibiotic minocycline | #14 |
| mammillary body atrophy | #14 |
| sparse fur | #14 |
| portacaval rats | #14 |
| striatum concentrations | #14 |
| hypothermia reduction | #14 |
| brain energy metabolites | #14 |
| failure encephalopathy | #15 |
| 3hquisqualate | #15 |
| fulminant liver | #15 |
| role thiamine | #15 |
| alcoholic brain | #15 |
| manganese phosphate | #15 |
| astrocytic volume | #15 |
| apaptreated mice | #15 |
| activity pdhc | #15 |
| portocaval shunts | #15 |
| treatment measurement | #15 |
| vulnerable region | #15 |
| microglial activation neuroinflammation | #15 |
| hyperintensity patients | #15 |
| acute liver | #15 |
| thiamin metabolism | #15 |
| cirrhosis systematic review | #15 |
| moderate drinkers | #15 |
| ataxics | #15 |
| 3hpk 11195 | #15 |
| white matter cbf | #15 |
| glur3 subunits | #15 |
| purkinje cell terminals | #15 |
| cerebral complications | #15 |
| gabaa reference values | #15 |
| encephalopathy liver | #16 |
| benzodiazepine gaba | #16 |
| endothelial glucose | #16 |
| glutamine increase | #16 |
| cirrhosis ammonia | #16 |
| hypothermia 35 | #16 |
| new mechanistic basis | #16 |
| socalled type | #16 |
| taurine brain | #16 |
| encephalopathy chronic | #16 |
| benzodiazepine ligands | #16 |
| hypothesises | #16 |
| pcs sham | #16 |
| nonvulnerable | #16 |
| isoform gene | #16 |
| brain proinflammatory | #16 |
| addition degree | #16 |
| proteins implicated | #16 |
| brain modulation | #16 |
| agonal status | #16 |
| encephalopathy loss | #16 |
| distribution tritium | #16 |
| gabaa receptor complex | #16 |
| new prospects | #16 |
| wks | #16 |
| animal modelling | #16 |
| hepatic metabolic pathways | #16 |
| pathophysiologic cascade | #16 |
| 4fold increases | #17 |
| loss liver | #17 |
| vulnerable structures | #17 |
| excess ammonia | #17 |
| patient malnutrition | #17 |
| early glial | #17 |
| antibiotic rifaximin | #17 |
| cerebellum enzyme | #17 |
| cox2 expression immunohistochemistry | #17 |
| neuroinflammatory mechanisms | #17 |
| surgical construction | #17 |
| ammonia induces | #17 |
| acids ammonia | #17 |
| isoquinoline carboxamide | #17 |
| pathogenesis complications | #17 |
| absence ammonia | #17 |
| liver disease mice | #17 |
| onset convulsions | #17 |
| encephalopathy rats | #17 |
| glutamate enzyme | #17 |
| cortical astrocyte | #17 |
| platelets dopamine | #17 |
| activation sgc | #17 |
| endogenous benzodiazepines | #17 |
| benzoate therapy | #17 |
| synthetase activities | #17 |
| dependent enzyme | #17 |
| acid thiamine | #17 |
| early microglial | #17 |
| glutamine phenylalanine | #17 |
| reprint | #17 |
| upregulation aqp4 | #17 |
| day heavy drinking | #17 |
| pregnenolone allopregnanolone | #17 |
| complications malnutrition | #17 |
| 11195 binding | #18 |
| activities alpha | #18 |
| alcoholic cirrhotic patients | #18 |
| 13c isotopomer analysis | #18 |
| compared pair | #18 |
| patients therapeutic options | #18 |
| neuropathological damage | #18 |
| active pyruvate | #18 |
| astrocytic glutamine synthetase | #18 |
| doserelated reduction | #18 |
| administration aom | #18 |
| astrocytes blotting | #18 |
| wernicke korsakoff syndrome | #18 |
| prevention progression | #18 |
| portocaval shunting | #18 |
| binding sites hippocampus | #18 |
| encephalopathy patients | #18 |
| beta endorphin betaep | #18 |
| neurological psychiatric | #18 |
| concentrations kcl | #18 |
| autopsied | #18 |
| coa levels | #18 |
| result molecules | #18 |
| type benzodiazepine | #18 |
| selective neuronal | #18 |
| reversible coma | #18 |
| condition evidence | #18 |
| neuropathologic evaluation | #18 |
| wernicke korsakoff | #18 |
| generalized reduction | #18 |
| brain regions rat | #18 |
| bbb igg | #18 |
| distribution binding | #19 |
| acids glutamate | #19 |
| brain lactate | #19 |
| 125iiodopindolol | #19 |
| rats stages | #19 |
| ornithine transcarbamylase | #19 |
| response neurodegeneration | #19 |
| complications acute | #19 |
| free coa | #19 |
| astrocytic neuronal | #19 |
| control groups animals | #19 |
| energy metabolism brain | #19 |
| glutamates glutamine | #19 |
| brain peripheral | #19 |
| exposure cultured | #19 |
| cholinergic cell loss | #19 |
| increase brain water | #19 |
| lola patients | #19 |
| equal age | #19 |
| serum ammonia levels | #19 |
| pathophysiology hepatic encephalopathy | #19 |
| treatment mhe | #19 |
| outcome prevention | #19 |
| synthetase protein | #19 |
| disease frontal | #19 |
| errors mice | #19 |
| agents hepatic | #19 |
| cirrhotic patients controls | #19 |
| endogenous benzodiazepine | #19 |
| blood manganese | #19 |
| severe encephalopathy | #19 |
| expression result | #19 |
| csf concentrations 5hiaa | #19 |
| coma brain | #20 |
| benzodiazepine medication | #20 |
| lola | #20 |
| diencephalic | #20 |
| l3harginine | #20 |
| regions rat | #20 |
| brain autopsy samples | #20 |
| syndrome wks | #20 |
| bbb alterations | #20 |
| animal frontal | #20 |
| biochemical lesion | #20 |
| expression oxidative stress | #20 |
| volume plasmapheresis | #20 |
| alf mars | #20 |
| adequate dietary protein | #20 |
| acute ammonia toxicity | #20 |
| rats patients | #20 |
| brain organic osmolytes | #20 |
| pallidal hyperintensity | #20 |
| glutamate increased | #20 |
| aids patients patients | #20 |
| effects neurosteroids | #20 |
| glutamate nmda receptors | #20 |
| animals tests | #20 |
| tetrahydrodeoxycorticosterone | #21 |
| deficiency synthesis | #21 |
| symptomatic stages | #21 |
| selective loss neurons | #21 |
| 8094 | #21 |
| plasma ammonia concentrations | #21 |
| endorphin induced | #21 |
| hyperammonemia rats | #21 |
| nakatpase activities | #21 |
| vivo cerebral | #21 |
| transport ammonia | #21 |
| blood–brain barrier permeability | #21 |
| metabolic trafficking | #21 |
| 3alpha5alphathp | #21 |
| mild hypothermia survival | #21 |
| protective hypothermia | #21 |
| direct neurotoxic effects | #21 |
| 5 p0001 | #21 |
| glast protein | #21 |
| failure skeletal | #21 |
| mhe encephalopathy humans | #21 |
| sgc nitric oxide | #21 |
| cisterna magna csf | #21 |
| alanine increased | #21 |
| normal circumstances | #22 |
| gabaa receptors humans | #22 |
| hepatic carnitine | #22 |
| sites cerebral | #22 |
| cerebral cortex brainstem | #22 |
| stereotyped behavior rats | #22 |
| 3alpha5beta | #22 |
| gaba regions | #22 |
| brain alanine | #22 |
| characterized model | #22 |
| temporal cortex cerebellum | #22 |
| alf infection | #22 |
| deficiency alterations | #22 |
| zieve | #22 |
| inbred strains cns | #22 |
| partial inverse agonists | #22 |
| antiparkinson drugs | #22 |
| brain experimental | #22 |
| 3hafdx | #22 |
| distribution amino acids | #22 |
| exposed manganese | #22 |
| sites measured | #22 |
| concentrations glycine | #22 |
| effects glutamate | #22 |
| acute hepatic encephalopathy | #22 |
| sham operation rats | #22 |
| amino acids model | #23 |
| diphosphate dependent | #23 |
| ammonia lactate | #23 |
| hippocampus thalamus | #23 |
| impaired absorption | #23 |
| neuropathological evaluation | #23 |
| oxidative stress nac | #23 |
| bckdh activity | #23 |
| glutamine taurine | #23 |
| glutamine neurons | #23 |
| increased sites | #23 |
| mm ammonia | #23 |
| cerebral gaba | #23 |
| brain neurosteroid | #23 |
| brain cell function | #23 |
| deficiency animals | #23 |
| thiamine homeostasis | #23 |
| treatment sarcopenia | #23 |
| proinflammatory cytokines mice | #23 |
| astrocytic protein | #23 |
| aspartate alanine | #23 |
| ammonia liver | #23 |
| portal systemic encephalopathy | #23 |
| cortex male rats | #23 |
| marrero | #23 |
| gabaa steroids | #23 |
| glutamine accumulation | #23 |
| dewhurst | #23 |
| activites | #24 |
| pathophysiological levels | #24 |
| brain coenzyme | #24 |
| serotonin 5ht metabolism | #24 |
| sites ligands | #24 |
| controls cirrhotic | #24 |
| ” ligands | #24 |
| encephalopathy ammonia | #24 |
| external warming | #24 |
| p005 activities | #24 |
| neuropathologic studies | #24 |
| human experimental | #25 |
| extracellular glutamine | #25 |
| cns complication | #25 |
| glutamine liver | #25 |
| transketolase tk | #25 |
| malnutrition chronic | #25 |
| synthase activities | #25 |
| nmdareceptor | #25 |
| severe muscle damage | #25 |
| katpase src | #25 |
| ammonia reduction | #25 |
| glutamine synthesis | #25 |
| deficiency regulation | #25 |
| 11195 | #25 |
| cytotoxic brain edema | #25 |
| damage dysfunction | #25 |
| chronic hepatic | #25 |
| inhalation exposure rats | #25 |
| uptake 14c | #25 |
| mousseau | #25 |
| copper zinc concentrations | #25 |
| sites glutamate | #25 |
| fluid amino | #26 |
| isoquinolines ligands | #26 |
| flumazenil placebo | #26 |
| treatment hepatic | #26 |
| anastomosis rats | #26 |
| arterial ammonia levels | #26 |
| concentrations ammonia | #26 |
| failure increased | #26 |
| synthesis amino acids | #26 |
| aqp4 levels | #26 |
| oxidative stress processes | #26 |
| adult patterns | #26 |
| ketoglutarate dehydrogenase | #26 |
| 60p | #26 |
| pathophysiological significance | #26 |
| pathogenesis cerebral | #26 |
| 17 39 | #26 |
| alanine concentrations | #26 |
| liver fasting | #27 |
| support potential | #27 |
| noradrenaline transport | #27 |
| cerebellum brain | #27 |
| regional densities | #27 |
| asparagine glutamine | #27 |
| glucose loading | #27 |
| binding site densities | #27 |
| rifaximin mhe | #27 |
| fgin1 | #27 |
| alf induced | #27 |
| deficient brain | #27 |
| accumulation glutamine | #27 |
| increased concentrations | #27 |
| beta sites | #27 |
| brain serotonin metabolism | #27 |
| manganese ammonia | #27 |
| binding 3hmuscimol | #27 |
| ornithine transcarbamylase otc | #27 |
| oxidative stress evidence | #27 |
| treatment cirrhosis | #27 |
| onset encephalopathy | #27 |
| wernicke encephalopathy | #28 |
| metabolism relation | #28 |
| chronic liver failure | #28 |
| experimental acute | #28 |
| effects thiamine | #28 |
| selective neuronal loss | #28 |
| astrocytes loss | #28 |
| baldessarini | #28 |
| astrocytic metabolism | #28 |
| glutamate transporter activity | #28 |
| allosteric modulatory | #28 |
| devascularized | #28 |
| eaat3 expression | #28 |
| type hepatic | #28 |
| activities decreased | #28 |
| ataxic gait | #28 |
| pairfed controls | #29 |
| increased glutamine | #29 |
| flumazenil flunitrazepam | #29 |
| superoxide scavenger | #29 |
| dopamine metabolism striatum | #29 |
| cerebral cortex thalamus | #29 |
| travelled distance | #29 |
| putamen frontal cortex | #29 |
| oxide brain | #29 |
| re‐evaluation | #29 |
| serotonin turnover | #29 |
| isopregnanolone | #29 |
| effective adjunct therapy | #29 |
| 3hro5 | #29 |
| subchronic inhalation exposure | #29 |
| diverse etiology | #29 |
| cytoplasmic nuclear signal | #29 |
| induction mild hypothermia | #29 |
| dust rats | #29 |
| shamoperated control animals | #29 |
| cerebral energy failure | #29 |
| frontal temporal cortex | #29 |
| striatum contrast | #29 |
| rats probenecid | #29 |
| optimal supply | #29 |
| glutamine content | #29 |
| neuronal cell counts | #30 |
| frontal cortex samples | #30 |
| nonabsorbable disaccharides | #30 |
| glutamate content | #30 |
| mediated excitotoxicity | #30 |
| hyperglycemic stroke | #30 |
| chat activities | #30 |
| quantitative receptor | #30 |
| studies experimental | #30 |
| aspartate glutamine | #30 |
| glycine glutamine | #30 |
| flumazenil gaba | #30 |
| encephalopathy portal | #30 |
| neurotransmitter amino acids | #30 |
| glutamate cgmp | #30 |
| blood ammonia concentration | #30 |
| 3dsrt | #30 |
| chronic hyperammonemia | #30 |
| increased nmda | #30 |
| west criteria | #30 |
| gaba receptor complex | #30 |
| presymptomatic animals | #30 |
| inflammatory cascades | #30 |
| stroke neurological | #30 |
| progression liver injury | #30 |
| stupor | #31 |
| peripheral type | #31 |
| brain monoamine oxidase | #31 |
| brain decreased | #31 |
| shunted animals | #31 |
| study ammonia | #31 |
| dogs hepatic | #31 |
| production microglial | #31 |
| cerebral glutamate | #31 |
| cuznsod protein | #31 |
| antisense elements | #31 |
| expression tight junction | #31 |
| leading increased | #31 |
| pannecrosis | #31 |
| glutamate nmda | #31 |
| clinical prospects | #31 |
| neuroinflammation pathogenesis | #31 |
| fixed intervals | #32 |
| minimal mhe | #32 |
| gabaa receptor ligands | #32 |
| indian national association | #32 |
| acute hyperglycemic | #32 |
| telemethylhistamine | #32 |
| intracellular osmolarity | #32 |
| hepatic symptoms | #32 |
| increased nitric | #32 |
| effects mild | #32 |
| temporal cortex patients | #32 |
| cerebral ammonia | #32 |
| uptake ammonia | #32 |
| binding sites presence | #32 |
| binding gaba | #32 |
| akinesia | #32 |
| 2 alteration | #32 |
| deficiencies vitamins | #32 |
| astrocytes ammonia | #32 |
| detoxification unit | #32 |
| hepatoprotective properties | #32 |
| friedreichs ataxia | #32 |
| species rats | #33 |
| rats ammonia | #33 |
| cns concentrations | #33 |
| selective decreases | #33 |
| reversible alterations | #33 |
| glycine aspartate | #33 |
| regions brains | #33 |
| monoamines brain | #33 |
| hand addition | #33 |
| otc deficiency | #33 |
| clinical laboratory findings | #33 |
| nash treatment | #33 |
| proinflammatory cytokines brain | #33 |
| snat5 | #33 |
| neuronal cell survival | #33 |
| ohe patients | #33 |
| cns complications | #33 |
| binding microsomes | #33 |
| gaba aspartate | #33 |
| failing liver | #33 |
| brain gaba levels | #33 |
| et495 | #33 |
| nac reduction | #34 |
| metabolite 5 | #34 |
| acetylcholinesterase activities | #34 |
| severe neurological symptoms | #34 |
| nonepileptic controls | #34 |
| severe neurological dysfunction | #34 |
| relation brain | #34 |
| encephalopathy hippocampus | #34 |
| 11 agematched controls | #34 |
| inadequate dietary intake | #34 |
| groups cirrhotic patients | #34 |
| cytotoxic brain | #34 |
| gad activities | #34 |
| nh4oac | #34 |
| ammonium tartrate | #34 |
| hepatic artery ligation | #34 |
| stupor coma | #34 |
| effects manganese | #35 |
| space glutamic | #35 |
| octadecaneuropeptide | #35 |
| activation proinflammatory | #35 |
| type gaba | #35 |
| fluid ammonia | #35 |
| chapter 29 | #35 |
| ammonia concentrations | #35 |
| neurotransmitter amino | #35 |
| overt encephalopathy | #35 |
| dawley reverse | #35 |
| free hepatic | #35 |
| chronic hepatic encephalopathy | #35 |
| manganese tricarbonyl | #35 |
| fatigue rats | #35 |
| severe compromise | #35 |
| neuropsychiatric abnormalities | #35 |
| total thiamine | #35 |
| astrocytic glutamate | #35 |
| aom treatment | #36 |
| synthesis glutamate | #36 |
| thioacetamide treatment | #36 |
| acid brain | #36 |
| arterial ammonia | #36 |
| brain regions studies | #36 |
| astrocytic glutamine | #36 |
| cerebral cortical astrocytes | #36 |
| numerous etiologies | #36 |
| detoxification product | #36 |
| cycle glucose | #36 |
| astrocyte glutamate | #36 |
| muscarinic sites | #36 |
| electricalfield stimulation | #36 |
| uptake glutamate | #36 |
| increased voluntary | #37 |
| 3beta5alpha | #37 |
| acute receptors | #37 |
| csf cisterna magna | #37 |
| alf mice | #37 |
| mice ammonia | #37 |
| excitotoxic mechanism | #37 |
| increased blood glucose | #37 |
| mild hypothermia therapy | #37 |
| perivenous hepatocytes | #37 |
| blood manganese levels | #37 |
| protein glutamate | #37 |
| brain amino acids | #38 |
| glutamatergic function | #38 |
| ammonium acetate | #38 |
| failure male | #38 |
| astrocytic marker | #38 |
| corneal reflex | #38 |
| brain rats | #38 |
| gfap immunohistochemistry | #38 |
| increase glutamine | #38 |
| hypothermia attenuates | #38 |
| glutamate ammonia | #38 |
| pdhc | #39 |
| chronic alcoholism | #39 |
| severe liver dysfunction | #39 |
| hyperammonaemic | #39 |
| glutamine formation | #39 |
| findings increased | #39 |
| loss gene expression | #39 |
| pca surgery | #39 |
| clive | #39 |
| thiamine administration | #39 |
| posterior columns | #39 |
| benzodiazepine antagonist | #39 |
| concomitant decreases | #39 |
| brain regional distribution | #39 |
| acetylcoa levels | #40 |
| glutamine glycine | #40 |
| liver inasl | #40 |
| nmdamediated excitotoxicity | #40 |
| argininic acid | #40 |
| seizures mental retardation | #40 |
| nitroarginine rats rats | #40 |
| regionally selective | #40 |
| increased density | #40 |
| regiondependent manner | #40 |
| dheas | #40 |
| etiology severity | #40 |
| arginine uptake | #40 |
| quin levels | #40 |
| concentrations catecholamines | #40 |
| concentration areas | #40 |
| ammonia homeostasis | #40 |
| neurological alterations | #40 |
| detoxification ammonia | #41 |
| brain benzodiazepine receptors | #41 |
| acid neurotransmitter | #41 |
| vulnerable area | #41 |
| regulation caveolin1 | #41 |
| deficiency disease | #41 |
| sgc activation | #41 |
| complications chronic | #41 |
| brain taurine | #41 |
| regions concentrations | #41 |
| thiamine metabolism | #41 |
| increased glutamate release | #41 |
| activation nmda receptor | #41 |
| cellcell signalling | #41 |
| lateral vestibular nucleus | #41 |
| brain extracts | #41 |
| trace amines | #42 |
| pk11195 binding | #42 |
| cerebral alterations | #42 |
| benzodiazepine sites | #42 |
| thdoc | #42 |
| illness terminology topic | #42 |
| cerebral glutamine | #42 |
| complex pdhc | #42 |
| glutamine insulin | #43 |
| gabaa tritium | #43 |
| metabolism acute | #43 |
| nonalcoholic patients | #43 |
| carbamoyltransferase deficiency | #43 |
| transcarbamylase | #43 |
| liver assist | #43 |
| acute ammonia intoxication | #43 |
| increased neuronal | #43 |
| ohe mhe | #44 |
| ammonia increases | #44 |
| treament | #44 |
| behavioral excitation | #44 |
| ataxia humans | #44 |
| sarcopenia cirrhosis | #44 |
| mechanisms disorder | #44 |
| reduction brain | #44 |
| increased serotonin | #44 |
| aged portacaval | #44 |
| western brain dna | #44 |
| severe hyperammonemia | #44 |
| toxic liver | #44 |
| cerebral levels | #44 |
| acid glutamine | #44 |
| ventral white matter | #45 |
| cholinergic neuronal | #45 |
| mild encephalopathy | #45 |
| small meals | #45 |
| welldefined areas | #45 |
| mice etanercept | #45 |
| cortex dose | #45 |
| isoquinolines kinetics | #45 |
| thiamin deficiency | #45 |
| aspartate gaba | #45 |
| glutamate transporter | #45 |
| model congenital | #45 |
| brain gamma | #46 |
| normoglycemic rats | #46 |
| 11cnmethylspiperone | #46 |
| exposed ammonia | #46 |
| brain oxidative metabolism | #46 |
| fatigue controls | #46 |
| treatment downregulation | #46 |
| cortex glutamate | #46 |
| glutamate aspartate | #47 |
| human rat brain | #47 |
| neurosteroid | #47 |
| anaplerotic flux | #47 |
| benzodiazepine receptors | #47 |
| distinctive pattern | #47 |
| alcoholic cirrhotics | #47 |
| rtpcr experiments | #47 |
| glutamate removal | #47 |
| microsomes isolated | #47 |
| pathophysiologically | #47 |
| brain amino | #47 |
| metabolism astrocytes | #47 |
| hyperammonemia | #48 |
| central nervous function | #48 |
| 3hmuscimol | #48 |
| 113cglucose | #48 |
| allopregnanolone concentrations | #48 |
| thalamus pons | #48 |
| mitochondrial benzodiazepine | #48 |
| neurotoxic agents | #48 |
| age injection | #48 |
| tnf brain | #48 |
| amino acid synthesis | #48 |
| cerebral dysfunction | #48 |
| cerebellum medulla | #48 |
| maob | #48 |
| sites nmda | #48 |
| concomitant increases | #48 |
| pallidal | #49 |
| rcts low risk | #49 |
| glycerol phenylbutyrate | #49 |
| cerebellum patients | #49 |
| ammonia detoxification | #49 |
| nmda binding | #49 |
| voluntary ethanol | #49 |
| neurotoxic actions | #49 |
| central benzodiazepine | #49 |
| brain tryptophan | #49 |
| rational explanation | #50 |
| alcoholic dementia | #50 |
| manganese middle | #50 |
| effects body temperature | #50 |
| levels brain | #50 |
| hepatic encephalopathy study | #50 |
| tyrosine ammonia | #50 |
| extracellular glycine | #50 |
| increased extracellular | #50 |
| expression glt1 | #50 |
| hepatic congestion | #50 |
| brain banks | #50 |
| false neurotransmitters | #51 |
| acids measured | #51 |
| early microglial activation | #51 |
| management hepatic | #51 |
| inflamed brain | #51 |
| glutamate receptors nmda | #51 |
| electromyographic evaluation | #51 |
| righting | #51 |
| lcarnitine treatment | #51 |
| early losses | #52 |
| complex rats | #52 |
| friedreichs ataxia patients | #52 |
| mice carnitine | #52 |
| nitroarginine rats | #52 |
| vivo microdialysis | #52 |
| brain concentrations | #52 |
| cognitive motor dysfunction | #52 |
| severe stages | #52 |
| synthesis glutamine | #52 |
| 12 rats | #52 |
| alcoholic cirrhotic | #52 |
| pse | #52 |
| altered permeability | #52 |
| neurobehavioral disturbances | #52 |
| 3hkainate | #53 |
| neurosteroid pregnenolone | #53 |
| central histaminergic | #53 |
| treatment alf | #53 |
| pathophysiologic | #53 |
| neurosteroid synthesis | #53 |
| 3hmuscimol binding | #53 |
| rats portacaval shunt | #53 |
| portacaval shunts | #54 |
| kidney testis | #54 |
| stroke penumbra | #54 |
| mildest form | #54 |
| mechanisms proposed | #54 |
| substitutive therapy | #54 |
| gene expression liver | #54 |
| ischemic liver | #54 |
| liver atrophy | #54 |
| neuropsychiatric syndrome | #54 |
| subsequent alteration | #54 |
| portacaval shunt pcs | #54 |
| activation guanylate cyclase | #54 |
| cerebral inflammation | #54 |
| encephalopathy hyperammonemia | #55 |
| neurotransmitter agents | #55 |
| glutathione plasma | #55 |
| occludin levels | #55 |
| human disorder | #55 |
| activation glutamate receptors | #55 |
| hyperglycemic | #55 |
| messenger spraguedawley receptors | #55 |
| heterogenity | #55 |
| concomitant reductions | #55 |
| delays onset | #56 |
| awaits | #56 |
| severe cognitive dysfunction | #56 |
| deficiency decreased | #56 |
| levels allopregnanolone | #56 |
| oxidative nitrosative | #56 |
| ca2dependent release | #56 |
| regions rats | #56 |
| brain glutamate levels | #57 |
| ammonia exposure | #57 |
| coma patients | #57 |
| increased intracellular ca2 | #57 |
| resonance signal | #57 |
| tetrahydroprogesterone | #57 |
| mechanisms implicated | #57 |
| type mitochondrial | #57 |
| current therapeutic options | #57 |
| rats ouabain | #57 |
| failure muscle | #57 |
| h1 receptors | #57 |
| pdhc activity | #58 |
| probenecid treatment | #58 |
| severity encephalopathy | #58 |
| levels amino acids | #58 |
| lowering strategies | #58 |
| swelling brain | #58 |
| manganese copper | #58 |
| dansyl derivatives | #58 |
| brain histamine | #58 |
| levels ammonia | #58 |
| astrocytes glutamate | #58 |
| activation glutamate | #58 |
| portacaval shunt | #58 |
| nervous complications | #58 |
| acetaminophen toxicity | #59 |
| saline treated controls | #59 |
| patients thiamine | #59 |
| mechanism protective | #59 |
| bilirubin metabolism | #59 |
| uptake arginine | #59 |
| neuropharmacological studies | #59 |
| 13c enrichments | #59 |
| gfap gfap mrna | #59 |
| hyperammonaemia | #59 |
| cirrhosis middle | #60 |
| alcoholic patients | #60 |
| energy metabolites | #60 |
| cirrhotic patients patients | #60 |
| alcoholics patients | #60 |
| brain production | #60 |
| ammonia toxicity | #60 |
| spontaneous synaptic activity | #60 |
| ammonia intoxication | #60 |
| required cofactor | #60 |
| purposing | #60 |
| lazabemide | #60 |
| comparable magnitude | #61 |
| subjects free | #61 |
| opioid penicillamine | #61 |
| threefold increase | #61 |
| ataxia friedreich | #61 |
| concentrations glutamate | #61 |
| excitotoxic brain injury | #61 |
| 015 mmol | #61 |
| stem cerebral | #61 |
| maob maoa | #61 |
| sham operated | #61 |
| affinity gaba | #61 |
| il1beta mrna expression | #61 |
| bz receptors | #61 |
| acid distribution | #61 |
| forebrain cholinergic neurons | #62 |
| elevated uptake | #62 |
| taurine synthesis | #62 |
| βendorphin | #62 |
| ultimate test | #62 |
| increased expression mrna | #62 |
| receptors pathogenesis | #62 |
| brain1 | #62 |
| suggested role | #62 |
| hypertension brain | #62 |
| manganese treatment | #63 |
| gaba glutamic acid | #63 |
| portocaval | #63 |
| metabolism glutamine | #63 |
| thiamine | #63 |
| subclinical hepatic | #63 |
| rtpcr gene expression | #63 |
| role glutamate | #63 |
| manganese intoxication | #63 |
| focal increases | #63 |
| regions contrast | #63 |
| spectroscopy tomography | #63 |
| failure evidence | #63 |
| heavy drinking day | #63 |
| parietal lobe rats | #64 |
| thalamus gamma | #64 |
| attenuates oxidative | #64 |
| transketolase activity | #64 |
| disease activities | #64 |
| neurosteroid allopregnanolone | #64 |
| neurotoxic substances | #64 |
| brain | #64 |
| sodium phenylacetate | #64 |
| fatigue pbc | #64 |
| hypokinesia | #65 |
| manganese deposits | #65 |
| brain cell death | #65 |
| kcl nacl | #65 |
| methylhistamine | #65 |
| frontal parietal cortex | #65 |
| deficiency induced | #65 |
| glutamine ammonia | #65 |
| brain chemistry | #65 |
| butyrylcholinesterases | #65 |
| 2454 | #65 |
| sodium benzoate | #65 |
| symptoms addition | #65 |
| female flumazenil | #65 |
| uptake cultured | #66 |
| putative endogenous ligands | #66 |
| isethionic | #66 |
| gaba animals | #66 |
| mice sodium | #66 |
| brain water | #66 |
| increases brain | #66 |
| ataxia patients | #66 |
| 13cnmr | #66 |
| cerebral energy metabolism | #67 |
| humans korsakoff | #67 |
| αmethylptyrosine | #67 |
| ascorbate synthesis | #67 |
| erythrocyte transketolase | #67 |
| brain 24 | #67 |
| lactate increase | #67 |
| tyrosine content | #67 |
| brain patients | #67 |
| decreased concentrations | #68 |
| benzodiazepine receptor ligands | #68 |
| reduction ammonia | #68 |
| indian national | #68 |
| serotonin transport | #68 |
| selective reductions | #68 |
| glutamate transporter glast | #68 |
| rats sham operation | #69 |
| drug repositioning humans | #69 |
| active removal | #69 |
| hepatoprotection | #69 |
| processing product | #69 |
| unleaded gasoline | #69 |
| attenuation effects | #69 |
| substance rats | #69 |
| decreased removal | #69 |
| osmotic effects | #69 |
| bergmann glial | #70 |
| electronic manual searches | #70 |
| reduces brain | #70 |
| cortex caudate | #70 |
| m1 sites | #70 |
| glutamic acid hippocampus | #70 |
| animals benzodiazepines | #71 |
| carbamoyltransferase | #71 |
| glutamates glutamic | #71 |
| alloxan diabetes | #71 |
| medium concentrations | #71 |
| failure animals | #71 |
| shunting | #71 |
| glutamine brain | #72 |
| organic aciduria | #72 |
| concentration norepinephrine | #72 |
| common inborn error | #72 |
| hyperammonemia male | #72 |
| brain allopregnanolone | #72 |
| gabaa tomography | #72 |
| agematched control subjects | #72 |
| cortex increased | #72 |
| ro15 | #73 |
| onset neurological | #73 |
| alterations mitochondrial function | #73 |
| sites observed | #73 |
| astrocyte swelling | #73 |
| pse patients | #73 |
| cerebroprotective effects | #73 |
| glutamine glutamate | #73 |
| hippocampal ca1 subfield | #73 |
| homologous structures | #73 |
| thiamine treatment | #73 |
| astrocytes brain | #74 |
| cortex chromatography | #74 |
| brain content | #74 |
| gaba steroids | #74 |
| mechanisms involving | #74 |
| bath concentration | #74 |
| decrease brain | #74 |
| glutamic | #74 |
| nature distribution | #75 |
| fully elucidated | #75 |
| normal limits | #75 |
| expression glial | #75 |
| thiamine transport | #75 |
| severe neurological impairment | #75 |
| superfused slices | #75 |
| acids hepatic | #75 |
| cerebral cortex patients | #75 |
| gaba glutamine | #76 |
| direct toxic effects | #76 |
| larginine uptake | #76 |
| receptors gaba | #76 |
| receptors studied | #76 |
| glutamate binding | #76 |
| cirrhosis brain | #76 |
| transporter eaat3 | #76 |
| metabolite acetaldehyde | #77 |
| glutamate concentration | #77 |
| glycine concentrations | #77 |
| brain skeletal muscle | #77 |
| alcoholic patients cirrhosis | #77 |
| muscle acute | #77 |
| millimolar range | #77 |
| benzodiazepines binding | #78 |
| brain glucose metabolism | #78 |
| function hepatic | #78 |
| oxide liver | #78 |
| nnos protein | #78 |
| interatomic bonds | #78 |
| lnitroarginine methyl ester | #78 |
| muscle glutamine | #78 |
| semiquantitative rtpcr | #79 |
| thiamine triphosphate | #79 |
| previous reports | #79 |
| deep coma | #79 |
| neuronally | #79 |
| l‐carnitine | #79 |
| methylcyclopentadienyl | #79 |
| cns function | #79 |
| metabolism brain | #79 |
| excited ground states | #79 |
| hepatic energy | #79 |
| taming | #79 |
| expression glutamate | #80 |
| maximal binding | #80 |
| quantitative autoradiographic | #80 |
| medullapons | #80 |
| encephalopathy treatment | #80 |
| neurosteroid biosynthesis | #80 |
| cresyl violet staining | #80 |
| gaba benzodiazepine | #80 |
| emerging therapeutic target | #80 |
| failure nitric | #80 |
| pathogenesis animals | #80 |
| astrocyte morphology | #81 |
| glutamine astrocytes | #81 |
| molecular neurobiology | #81 |
| controls increased | #81 |
| study sections | #81 |
| 85 mmol | #81 |
| muscle ammonia | #81 |
| shortchain acylcoa dehydrogenase | #82 |
| chaired | #82 |
| receptor regions | #82 |
| agents receptors | #82 |
| lcarnitine administration | #82 |
| glutamate nitric | #82 |
| brain extracellular | #82 |
| glutamate brain | #83 |
| tca cycle flux | #83 |
| ethanol preference | #83 |
| proposed explain | #83 |
| 3hro15 | #83 |
| treatment thiamine | #83 |
| aom induced | #84 |
| measured brain | #84 |
| 3hflumazenil | #84 |
| elevated ammonia | #84 |
| water channel protein | #84 |
| pbgd | #84 |
| devascularization | #84 |
| cerebral cortex striatum | #84 |
| patients decreases | #84 |
| pathophysiologic basis | #84 |
| concomitant decrease | #85 |
| urea cycle enzymes | #85 |
| ammonia patients | #85 |
| decreased ca2 | #85 |
| 3hgammaaminobutyric acid | #85 |
| 5ht turnover | #85 |
| maoa maob | #85 |
| increase brain | #85 |
| arga | #85 |
| role glutamine | #85 |
| glutamate amino | #86 |
| release synaptic | #86 |
| central muscarinic | #86 |
| wilsonian | #87 |
| spraguedawley statistics | #87 |
| rats sacrificed | #87 |
| benzodiazepines brain | #88 |
| csf lactate | #88 |
| 52 mmol | #88 |
| tissue brain | #88 |
| brain binding | #88 |
| selective vulnerability | #88 |
| concomitantly | #88 |
| complication cirrhosis | #88 |
| caudate nuclei | #89 |
| role human diseases | #89 |
| undoubtedly | #89 |
| sham operations | #89 |
| edema cerebral | #89 |
| brain regions rats | #89 |
| prior onset | #89 |
| olivopontocerebellar atrophy opca | #89 |
| exposure ammonia | #89 |
| alpha ketoglutarate | #89 |
| patients alf | #90 |
| encephalopathy ohe | #90 |
| glutamatemediated excitotoxicity | #90 |
| rats species | #90 |
| receptor ligand | #90 |
| lactate increased | #90 |
| reduced brain | #91 |
| gaba modulators | #91 |
| bcaa concentrations | #91 |
| monoamine neurotransmitters | #91 |
| neuroinflammatory response | #92 |
| bckdh | #92 |
| enzymopathies | #92 |
| leucine concentrations | #92 |
| amino acids brain | #92 |
| altered protein expression | #92 |
| acid liver | #93 |
| induced alf | #93 |
| widespread damage | #93 |
| congenital deficiencies | #93 |
| increases extracellular | #94 |
| brain compared | #94 |
| manganese poisoning | #94 |
| neuronal loss | #94 |
| mri intensity | #94 |
| thiamin diphosphate | #94 |
| brain kidney | #94 |
| benzodiazepines treatment | #95 |
| patients liver failure | #95 |
| acetate administration | #95 |
| glutamine synthetase expression | #95 |
| induced stereotyped | #95 |
| inhibitory neurotransmission | #95 |
| ammonia accumulation | #95 |
| astrocytic function | #96 |
| βlipotropin | #96 |
| discrete areas | #96 |
| ornithine phenylacetate | #96 |
| 16 mmol | #96 |
| skeletal muscle brain | #96 |
| astrocytes neurons | #97 |
| covert hepatic encephalopathy | #97 |
| molecules brain | #97 |
| ammonia release | #97 |
| brain vivo | #97 |
| brain cytokine | #97 |
| glutamate glutamine | #98 |
| dehydroascorbic acid | #98 |
| hepatocerebral degeneration | #98 |
| carbamoyltransferase ornithine | #98 |
| dorsal tegmental nucleus | #98 |
| glycine transporters | #98 |
| thiamine diphosphate | #98 |
| receptors increased | #98 |
| acrylamides animals | #98 |
| stress ammonia | #99 |
| 3045 | #99 |
| walking gait | #99 |
| examination role | #99 |
| symptomatic stage | #100 |
| fatigue impact scale | #100 |
| aspartate levels | #100 |
| commonly encountered | #100 |
| animal hypothermia | #101 |
| temporal cortex | #101 |
| pressure liver | #101 |
| proinflammatory | #101 |
| inhibitory amino acids | #101 |
| increases levels | #101 |
| synergistic mechanisms | #102 |
| treatment complications | #102 |
| levels dheas | #102 |
| brain barrier breakdown | #102 |
| neurological symptoms patients | #102 |
| cerebral cortex cerebellum | #102 |
| tk activity | #102 |
| microdialysis rats | #102 |
| lcarnitine | #102 |
| brain extracellular space | #103 |
| controls cirrhotic patients | #103 |
| benzodiazepine receptor | #103 |
| collisional deactivation | #103 |
| removal ammonia | #103 |
| brain levels | #103 |
| thiamine monophosphate | #104 |
| cerebral oxidative metabolism | #104 |
| label incorporation | #104 |
| 90 loss | #104 |
| experimental animal models | #104 |
| methylspiperone | #104 |
| regional distribution | #104 |
| transporter glt1 | #105 |
| loss cholinergic | #105 |
| receptors brain | #105 |
| olivopontocerebellar atrophy | #105 |
| m3 exposure | #105 |
| experimental models | #105 |
| fatigue severity | #105 |
| neurological consequences | #105 |
| toxic liver injury | #106 |
| complication liver | #106 |
| 3h8ohdpat | #107 |
| concentrations serotonin | #107 |
| receptors rats | #107 |
| gaba content | #108 |
| monoamines | #108 |
| sham operated controls | #108 |
| dopaminergic dysfunction | #108 |
| current theories | #108 |
| characteristic alterations | #108 |
| t1weighted magnetic resonance | #109 |
| glutamate plasma | #109 |
| ldeprenyl | #109 |
| disease hepatic | #109 |
| symptomatic animals | #109 |
| rats hepatic | #110 |
| extrapyramidal symptoms | #110 |
| azoxymethane aom | #110 |
| 3hnisoxetine | #110 |
| glutamates humans | #110 |
| deficiency humans | #110 |
| reye syndrome | #111 |
| enzymes brain | #111 |
| glt1 glast | #111 |
| evidence role | #112 |
| 3alpha5alpha | #112 |
| expression testis | #113 |
| metabolic block | #113 |
| hypertension liver | #113 |
| lymphocytes rats | #113 |
| glutamate synaptic | #113 |
| midbrain striatum | #113 |
| activities | #113 |
| ligated rats | #113 |
| brain preparations | #113 |
| 57 reduction | #114 |
| fco | #114 |
| radioenzymatic assay | #114 |
| rat astrocytes | #114 |
| nutritional management | #114 |
| experimental animals | #115 |
| nmda receptor expression | #115 |
| brain dogs | #115 |
| pallidum putamen | #116 |
| gabaa gabaergic | #116 |
| mammillary body | #116 |
| decreased synthesis | #116 |
| 3hmepyramine | #116 |
| opioid brain | #117 |
| friedreich ataxia patients | #117 |
| growing body | #117 |
| controls plasma levels | #117 |
| cholinergic deficit | #117 |
| tips procedure | #117 |
| cortex alzheimer | #117 |
| cirrhotic | #118 |
| mechanism ammonia | #118 |
| arginine deficiency | #118 |
| myelin synthesis | #118 |
| amine levels | #118 |
| brain dopamine | #118 |
| albumin dialysis | #118 |
| allopregnanolone | #118 |
| pathologic manifestations | #119 |
| apapinduced | #119 |
| cerebral energy | #119 |
| site densities | #119 |
| nervous dysfunction | #119 |
| hydroxylating | #119 |
| patients fatty liver | #119 |
| opioid beta | #119 |
| frontal cortex | #120 |
| genes coding | #120 |
| glutamates | #120 |
| ouabain induced | #120 |
| balb cbyj mice | #120 |
| monoamine oxidaseb | #121 |
| copper manganese | #121 |
| mechanisms pathogenesis | #121 |
| 3hketanserin | #121 |
| pugh score | #121 |
| unleaded | #122 |
| rat brain synaptosomes | #122 |
| brain evidence | #122 |
| brain enzyme | #122 |
| nuclear signal | #122 |
| complex activities | #122 |
| bergmann glia | #122 |
| selective damage | #123 |
| implicated | #123 |
| beneficial patients | #123 |
| normal human brains | #123 |
| asterixis | #124 |
| gene expression brain | #124 |
| newborn astrocytes cells | #124 |
| modulatory site | #124 |
| icp cbf | #125 |
| ammonia control | #125 |
| neurological signs | #125 |
| striatum cerebellum | #125 |
| ol20 | #126 |
| ala2mephe4met0ol | #126 |
| role ammonia | #126 |
| glt1 | #126 |
| synthase nitroarginine | #126 |
| ornithine aminotransferase | #126 |
| brain male | #126 |
| 11cpk11195 | #126 |
| high‐affinity | #127 |
| cytokines brain | #128 |
| proteins nitric | #128 |
| neuronal cell | #128 |
| taurine uptake | #128 |
| cox2 immunoreactivity | #129 |
| glutamate concentrations | #129 |
| neurochemical mechanisms | #129 |
| chronic alcoholic patients | #129 |
| patients friedreichs ataxia | #129 |
| spontaneous activities | #130 |
| agonist action | #130 |
| unanesthetized dogs | #130 |
| cox2 levels | #130 |
| blood ethanol levels | #130 |
| ammonia levels | #131 |
| llactate dehydrogenase | #131 |
| observed brain | #131 |
| primary deficit | #131 |
| blood ammonia | #132 |
| animals azoxymethane | #132 |
| continuous supply | #132 |
| carnitine administration | #132 |
| taurine release | #132 |
| hepatic abnormalities | #132 |
| manganese neurotoxicity | #133 |
| factor pathogenesis | #133 |
| ischemia rat | #133 |
| friedreich | #133 |
| site human | #133 |
| nacetyl cysteine | #133 |
| lipoamide dehydrogenase | #133 |
| α ketoglutarate | #133 |
| brain glial | #134 |
| lactate accumulation | #134 |
| models acute | #135 |
| kidney skeletal muscle | #135 |
| endogenous amino acids | #135 |
| concentrations gaba | #135 |
| exposure manganese | #135 |
| impact treatments | #136 |
| manganese toxicity | #137 |
| increased intracranial pressure | #137 |
| acid ammonia | #137 |
| function addition | #137 |
| pregnenolone rats | #137 |
| psychometric testing | #137 |
| 3hcitalopram | #137 |
| release glutamate | #137 |
| spinocerebellar degeneration | #138 |
| neuropsychiatric complications | #138 |
| inherited ataxias | #138 |
| cerebral herniation | #139 |
| cycle enzyme | #139 |
| disorder animals | #139 |
| lornithine | #139 |
| nanomolar affinity | #139 |
| tracer doses | #139 |
| glutamine alanine | #139 |
| chatpositive neurons | #139 |
| −70°c | #139 |
| patients friedreich | #140 |
| nutritional recommendations | #140 |
| aminobutyric acid | #141 |
| nonbenzodiazepine | #141 |
| concentrations nacl | #141 |
| cortex male | #141 |
| dehydrogenase pdh | #141 |
| gaba synaptic | #142 |
| huntingtons chorea | #142 |
| development hepatic | #142 |
| alcoholic nonalcoholic | #142 |
| cerebellar ataxias | #142 |
| humans isoquinolines | #142 |
| cbyj | #142 |
| brain glucose uptake | #143 |
| lactate alanine | #143 |
| hypothermia induced | #143 |
| alternative site | #143 |
| serotonin precursor | #143 |
| monoamine oxidasea | #143 |
| diminished activity | #143 |
| glutamateglutamine | #144 |
| insulin hypoglycaemia | #144 |
| dopamine metabolism | #144 |
| taurine content | #144 |
| delayed myelination | #144 |
| selective brain | #144 |
| brain gaba | #144 |
| allosteric agonists | #144 |
| ornithine carbamoyltransferase | #144 |
| inferior olivary nucleus | #145 |
| brain tissue | #145 |
| hyperglycemic rats | #145 |
| cerebral microdialysis | #145 |
| receptormediated responses | #146 |
| relation degree | #146 |
| brain peripheral tissues | #146 |
| glucose load | #146 |
| brain hypothermia | #146 |
| comparable degree | #147 |
| rapid filtration | #147 |
| lateral vestibular | #147 |
| increase presence | #147 |
| energy failure | #148 |
| lactate brain | #148 |
| animals brain | #148 |
| western cells rats | #149 |
| acetyllcarnitine | #149 |
| neurosteroids | #149 |
| ohe | #149 |
| diazepam binding inhibitor | #149 |
| cirrhosis hepatic | #149 |
| coa acetyl | #149 |
| glutamate neurons | #149 |
| consumption ethanol | #150 |
| failure studies | #150 |
| metabolic impairments | #150 |
| probenecid rats | #150 |
| zo2 | #151 |
| fatigue scores | #151 |
| animals astrocytes | #151 |
| progesterone metabolites | #151 |
| female friedreich | #151 |
| patient tissue | #151 |
| protein tyrosine nitration | #151 |
| selective neuronal death | #152 |
| patients hepatic encephalopathy | #152 |
| beta actin | #152 |
| increased synthesis | #153 |
| inhibition binding | #153 |
| concentrations amino | #153 |
| testis brain | #153 |
| tight junction proteins | #154 |
| impaired brain | #154 |
| transporter protein | #154 |
| alcoholism brain | #154 |
| 15 1788 | #155 |
| increased cerebral | #155 |
| brain cerebrospinal | #156 |
| experimental male rats | #156 |
| ammonia ligase | #156 |
| neuroactive | #157 |
| protein acute | #157 |
| radioenzymatic | #157 |
| affinity uptake | #157 |
| 1788 | #157 |
| ethanol day | #158 |
| dimethadione | #158 |
| korsakoff syndrome | #158 |
| glt1 expression | #159 |
| prominent increase | #159 |
| water brain | #159 |
| nitrosative | #159 |
| increased 5 | #159 |
| gfap expression | #159 |
| groups responses | #160 |
| astrocytosis | #160 |
| brain dysfunction | #160 |
| 3methoxytyramine | #160 |
| glutamate ampa | #160 |
| expression hepatic | #161 |
| reaction ammonia | #161 |
| gfap mrna | #161 |
| diphosphatase | #161 |
| neuropathologically | #161 |
| mercaptans | #162 |
| perivenous | #162 |
| increased stimulation | #162 |
| homogenates | #162 |
| synaptosomal uptake | #162 |
| vicious cycle | #163 |
| neurological evaluation | #163 |
| rats nitric | #163 |
| affinity transport | #163 |
| manganese concentrations | #164 |
| mice acetaminophen | #164 |
| glutamine production | #164 |
| transketolase | #164 |
| increased degradation | #164 |
| victor | #165 |
| human alcoholics | #165 |
| bergmann glial cells | #166 |
| glast | #166 |
| regions levels | #166 |
| brain energy metabolism | #166 |
| extracellular concentrations | #166 |
| male manganese | #167 |
| increased csf | #167 |
| aids aidsrelated complex | #167 |
| increased cerebrospinal | #167 |
| benzodiazepine | #167 |
| severe signs | #167 |
| neurotransmitter | #167 |
| dansyl chloride | #167 |
| surgical models | #168 |
| neurotoxic compounds | #168 |
| deficiency liver | #168 |
| precise role | #169 |
| malateaspartate shuttle | #169 |
| monophosphatase | #170 |
| strains spectrometry | #170 |
| acetaminophen acetylcysteine | #171 |
| increase pge2 | #171 |
| medial geniculate nucleus | #171 |
| elevated activities | #171 |
| complications liver | #171 |
| expression alpha1 | #172 |
| transport brain | #172 |
| ketoglutarate | #172 |
| terms relationship | #172 |
| apap administration | #172 |
| early increases | #172 |
| rats protective | #173 |
| complex pyruvate | #174 |
| protein gfap | #174 |
| brain energy | #175 |
| dehydroascorbic | #175 |
| taurine concentrations | #175 |
| binding calcium | #175 |
| synergistic actions | #175 |
| stereotyped behavior | #175 |
| chain amino | #175 |
| gfap immunoreactivity | #176 |
| guanidino compounds | #177 |
| eaat4 | #178 |
| neurological dysfunction | #178 |
| neurological complications | #178 |
| patients plasma levels | #179 |
| fine motor function | #179 |
| brain monoamine | #180 |
| serotonin 5hydroxytryptamine | #180 |
| symptoms including | #180 |
| rats csf | #180 |
| autoradiography binding | #181 |
| 3hflunitrazepam | #181 |
| experimental hepatic | #181 |
| brain concentration | #181 |
| accumulation brain | #182 |
| dheas dhea | #182 |
| biochemical consequences | #182 |
| dehydroepiandrosterone sulphate | #182 |
| competitive brain | #183 |
| neuropsychiatric | #183 |
| patients mhe | #183 |
| nutritional consequences | #184 |
| nnos mrna | #184 |
| animals antimetabolites | #184 |
| glast glt1 | #185 |
| amphetamine apomorphine | #185 |
| neurological disorder | #185 |
| fluorescence analysis | #185 |
| branchedchain amino acids | #185 |
| mm kcl | #186 |
| controls regions | #187 |
| spraguedawley serotonin | #187 |
| expression occludin | #187 |
| stress pathogenesis | #187 |
| sequellae | #187 |
| dehydrogenase complex | #188 |
| pcr ratio | #188 |
| dawley serotonin | #188 |
| otc | #188 |
| cb154 | #188 |
| compared sham | #188 |
| alcar | #188 |
| rat cerebellum | #189 |
| highaffinity uptake | #189 |
| vasogenic brain edema | #189 |
| agonist properties | #190 |
| aminobutyric | #190 |
| dopamine turnover | #191 |
| aged ammonia | #192 |
| pregnanolone | #192 |
| specific ligand | #192 |
| studies alterations | #193 |
| patient material | #194 |
| pavlov | #194 |
| righting reflex | #194 |
| gilles tourettes syndrome | #194 |
| of3h | #195 |
| gamma aminobutyric | #195 |
| limited therapeutic | #195 |
| patients immunohistochemistry | #195 |
| intracellular receptors | #196 |
| mice acute | #197 |
| tissue patients | #197 |
| expression tight | #197 |
| concomitant loss | #198 |
| manganese compounds | #198 |
| guanidino | #198 |
| unaltered | #198 |
| astrocyte function | #198 |
| mrna protein expression | #198 |
| thalamus hippocampus | #199 |
| noradrenaline transporter | #200 |
| experimental chronic | #200 |
| etiology patients | #200 |
| substitutive | #200 |
| 35 degrees | #200 |
| mitochondria neurons | #200 |
| glutamatergic synaptic | #200 |
| synthetase expression | #201 |
| brainstem structures | #201 |
| csf concentrations | #201 |
| highest density | #201 |
| cerebral glucose utilization | #202 |
| severity liver disease | #202 |
| translation clinic | #202 |
| equal | #202 |
| activation brain | #202 |
| vitro receptor | #203 |
| activities increased | #203 |
| therapeutic interventions | #203 |
| benzodiazepine binding | #204 |
| chronic alcohol abuse | #204 |
| cns dysfunction | #205 |
| ketone oxidoreductases | #205 |
| poor nutrition | #206 |
| grc | #206 |
| trials low risk | #206 |
| manganism | #206 |
| cuznsod | #206 |
| ldh1 | #207 |
| ldh5 | #207 |
| central noradrenergic | #207 |
| immunohistochemistry messenger receptors | #209 |
| neuropathological studies | #209 |
| astrocytic response | #209 |
| laboratory rat | #209 |
| bergmann | #210 |
| overt hepatic | #210 |
| concomitant increase | #210 |
| ethanol increased | #210 |
| uptake pattern | #210 |
| millimolar concentrations | #211 |
| cns gaba | #212 |
| histopathological studies | #212 |
| brain structures | #212 |
| isoquinolines male | #212 |
| laspartate | #212 |
| patients liver dysfunction | #212 |
| cerebellum striatum | #213 |
| gabaa receptor agonist | #214 |
| patients died | #214 |
| plasma ammonia | #214 |
| address issue | #214 |
| role pathogenesis | #215 |
| 3h8 | #215 |
| failure mice | #216 |
| key factor | #216 |
| glutamine cycle | #216 |
| nitrite nitrate levels | #216 |
| animals liver | #216 |
| noradrenergic function | #217 |
| bbb breakdown | #217 |
| glutamine synthetase activity | #217 |
| cultured rat astrocytes | #218 |
| thiamine vitamin | #219 |
| 3hro | #219 |
| taurine animals | #219 |
| inbred strains spectrometry | #220 |
| excitatory neurotransmitters | #221 |
| glutamate exposure | #221 |
| agonal | #221 |
| new therapeutic opportunities | #221 |
| level severity | #222 |
| 3 post | #222 |
| terry | #223 |
| deficient animals | #224 |
| death mechanisms | #224 |
| cyclase sgc | #225 |
| vulnerable period | #226 |
| 2 quality | #226 |
| gaba receptor | #227 |
| hepatic microcirculation | #228 |
| exposure inhalation | #228 |
| gaba cns | #228 |
| il1beta mrna | #228 |
| animals effects | #229 |
| acute chronic exposure | #229 |
| excitatory transmitter | #229 |
| cortical synaptosomes | #229 |
| opca | #230 |
| shunt | #230 |
| muscarinic cholinergic | #230 |
| cholestatic rats | #230 |
| mk801 treatment | #230 |
| previous report | #231 |
| hippocrates | #231 |
| glutamate excitotoxicity | #231 |
| receptor ligands | #231 |
| extracellular glutamate | #232 |
| rats weeks | #233 |
| spraguedawley reference values | #234 |
| increased intracranial | #234 |
| glutamate transport | #234 |
| increasing evidence | #234 |
| phosphate esters | #235 |
| brain deposition | #235 |
| cau | #235 |
| pair fed | #236 |
| liver injury mice | #236 |
| resonance study | #236 |
| 3hglutamate | #237 |
| serotonin tryptophan | #237 |
| pdh complex | #238 |
| glial proliferation | #238 |
| lc3 lipidation | #238 |
| encephalopathy mhe | #239 |
| animals rats | #239 |
| multiple systematic reviews | #240 |
| concentrations elevated | #240 |
| reduced glutathione levels | #240 |
| end‐stage liver disease | #240 |
| binding brain | #240 |
| levels glutamate | #240 |
| caudate putamen | #241 |
| nacl kcl | #241 |
| minimal hepatic | #241 |
| psychoactive medications | #241 |
| presynaptic neuron | #241 |
| 13cacetate | #242 |
| brain samples | #242 |
| cycle disorders | #242 |
| neurobehavioral | #243 |
| glur2 | #243 |
| treatment central | #243 |
| sgc | #243 |
| alf patients | #244 |
| neuronal membrane | #244 |
| cerebral cortex hippocampus | #244 |
| manganese concentration | #244 |
| neuronal localization | #244 |
| normal processes | #244 |
| hypothalamus hypothalamus | #245 |
| aged monoamine | #245 |
| glutamine concentration | #246 |
| tritium animals | #246 |
| neurologic assessment | #246 |
| bloodbrain barrier breakdown | #246 |
| unchanged | #246 |
| acids animals | #246 |
| synaptosomal preparations | #247 |
| soluble guanylate | #247 |
| plasma brain | #247 |
| nonpregnant rats | #247 |
| minimal hepatic encephalopathy | #248 |
| neuroactive steroids | #248 |
| 5 hydroxyindoleacetic | #248 |
| hippocampal sclerosis | #248 |
| histaminergic | #248 |
| betaep | #249 |
| allosteric coupling | #249 |
| deficient rats | #249 |
| increased expression | #250 |
| synaptic transmission | #250 |
| glutamate transporter glt1 | #250 |
| findings activation | #251 |
| reactive nitrogen intermediates | #251 |
| glutamate gaba | #251 |
| fatigue chronic | #252 |
| gaba uptake | #252 |
| animals aspartic | #253 |
| reduced cerebral | #253 |
| symptoms brain | #253 |
| focal loss | #254 |
| rats taurine | #255 |
| brain caudate | #256 |
| watersoluble vitamins | #256 |
| rat cerebellar | #256 |
| brain disorder | #257 |
| therapeutic measures | #257 |
| alterations expression | #257 |
| soluble guanylate cyclase | #257 |
| 4513 | #257 |
| norepinephrine turnover | #257 |
| mhe | #258 |
| pallidum | #258 |
| animals ataxia | #258 |
| – brain | #259 |
| transporters amino | #259 |
| rats time factors | #259 |
| receptor autoradiography | #259 |
| ed1 | #259 |
| choline acetyltransferase | #259 |
| phenylalanine levels | #260 |
| agents rats | #260 |
| precipitating factors | #260 |
| glutamine synthetase | #260 |
| liver liver failure | #261 |
| gene expression alterations | #261 |
| liver skeletal muscle | #262 |
| binding ligands | #262 |
| endogenous ligands | #262 |
| treatment neurological disorders | #262 |
| acetyl carnitine | #263 |
| neurological impairment | #263 |
| liver testis | #264 |
| muscle rigidity | #264 |
| alcoholic male | #264 |
| spf | #264 |
| concentrations brain | #264 |
| gamma tumor | #264 |
| cisterna | #265 |
| rats compared | #265 |
| gabaergic neurotransmission | #265 |
| calleja | #265 |
| cerebellar pathology | #266 |
| male c57bl6 mice | #267 |
| reactive gliosis | #267 |
| dopamine noradrenaline | #267 |
| dopamine spiperone | #267 |
| isoquinolines | #268 |
| protein gene expression | #268 |
| cell volume regulation | #268 |
| electrically stimulated | #268 |
| contributory | #269 |
| expression nitric | #270 |
| sleep abnormalities | #271 |
| hepatic | #271 |
| female hepatic | #271 |
| hydroxyindoleacetic acid | #272 |
| displaceable | #272 |
| octanoic acid | #272 |
| microdialysates | #272 |
| brain human | #272 |
| pharmacological manipulation | #272 |
| brains | #274 |
| neurotransmitter systems | #274 |
| greenwood | #276 |
| expression brain | #277 |
| normal conditions | #277 |
| quin | #277 |
| neuronal cell death | #278 |
| glutamate uptake | #279 |
| neurotoxic action | #280 |
| national association | #280 |
| gamma liver | #280 |
| tryptamine | #280 |
| microassay | #281 |
| 14c2 | #281 |
| striatum cerebral cortex | #281 |
| metal toxicity | #281 |
| guanylate cyclase | #282 |
| gaba levels | #282 |
| intracranial hypertension | #282 |
| glur3 | #283 |
| maoa | #283 |
| behavioural impairment | #284 |
| 3mt | #284 |
| severe neurological | #284 |
| cortical astrocytes | #284 |
| concentrations dopamine | #285 |
| ht release | #285 |
| barrier breakdown | #285 |
| nitrated proteins | #285 |
| ucds | #285 |
| acute hepatic failure | #287 |
| glomerular filtrate | #287 |
| deficiency disorders | #288 |
| acid astrocytes | #289 |
| excitatory amino acids | #289 |
| apap hepatotoxicity | #290 |
| reduction oxidative stress | #290 |
| adult values | #290 |
| azoxymethane | #291 |
| human liver disease | #292 |
| ligands male | #292 |
| brain cerebellum | #292 |
| mice cerebral | #292 |
| patients fatigue | #292 |
| effects hypothermia | #293 |
| reduced capacity | #293 |
| glutamine | #293 |
| failure rats | #293 |
| concentrations zinc | #293 |
| autoradiographic studies | #293 |
| brain regional | #293 |
| blood – | #294 |
| odn | #294 |
| altered expression | #294 |
| induced swelling | #294 |
| substantial increases | #295 |
| synthase expression | #296 |
| betaactin | #297 |
| rats increased | #297 |
| overt hepatic encephalopathy | #300 |
| rats western cells | #300 |
| brain choline | #304 |
| actin mrna | #304 |
| dawley receptors opioid | #304 |
| groups sham | #304 |
| rifamycins rifaximin | #305 |
| gamma aminobutyric acid | #306 |
| cytotoxic mechanism | #306 |
| lnoarg | #306 |
| damaged liver | #306 |
| severe alterations | #306 |
| powerful antioxidant | #307 |
| 3hsch | #307 |
| selection model | #307 |
| glutamate | #307 |
| cerebral function | #308 |
| bioaccumulation | #308 |
| dihydrolipoamide | #308 |
| molecular biological techniques | #310 |
| tight junction protein | #310 |
| serotonin metabolism | #311 |
| agonists gaba | #312 |
| gaba taurine | #312 |
| brain genes | #312 |
| 4864 | #312 |
| treatment rats | #313 |
| rats messenger | #313 |
| male osmolar | #314 |
| secondary biliary cirrhosis | #315 |
| brain serotonin | #316 |
| chloride animals | #316 |
| receptors glutamate | #316 |
| adjacent sections | #318 |
| mice mutant | #318 |
| nitrogen metabolism | #318 |
| quantitative autoradiography | #319 |
| basal ganglia patients | #319 |
| mitochondrial proliferation | #319 |
| humans manganese | #319 |
| cultured hippocampal neurons | #320 |
| rats brain | #320 |
| cell death mechanisms | #320 |
| tailpipe | #321 |
| dehydrogenase activity | #321 |
| 235triphenyltetrazolium chloride | #322 |
| eaat3 | #322 |
| isethionate | #323 |
| aqp4 expression | #324 |
| thalamus | #325 |
| acid 5 | #325 |
| complications outcome | #327 |
| nervous function | #327 |
| decreased brain | #327 |
| neurochemical studies | #327 |
| 5 hiaa | #328 |
| olivopontocerebellar | #328 |
| pathol | #329 |
| uptake increased | #329 |
| cerebellar astrocytes | #330 |
| flumazenil | #330 |
| sites human | #331 |
| β endorphin | #331 |
| proinflammatory cytokines | #333 |
| aaas | #333 |
| locomotor | #333 |
| uptake brain | #333 |
| experimental rat | #334 |
| 13cglucose | #335 |
| hydroxyindoleacetic | #335 |
| neurotransmitter uptake | #335 |
| increased binding | #335 |
| brain accumulation | #336 |
| 8 rats | #336 |
| nitrotyrosine | #337 |
| inhalation exposure | #338 |
| cortex brain | #339 |
| responsible | #339 |
| positive synergistic | #340 |
| transport defect | #340 |
| pdh activity | #341 |
| human hepatic | #341 |
| biological plausibility | #341 |
| cerebral cortical | #342 |
| mutant rats | #342 |
| reyes syndrome | #343 |
| brain 5 | #344 |
| altered mental status | #344 |
| benzodiazepine site | #344 |
| placebo improvement | #345 |
| dehydrogenase humans | #345 |
| activation nmda | #346 |
| dansyl | #346 |
| vulnerable | #347 |
| intraventricularly | #347 |
| acid gaba | #347 |
| control values | #347 |
| marked decreases | #349 |
| bdl rats | #349 |
| pigs groups | #350 |
| increased immunoreactivity | #350 |
| glutamate levels | #350 |
| nonalcoholics | #351 |
| patients dying | #351 |
| alanine amino | #351 |
| consequent increase | #352 |
| cortex cerebellum | #352 |
| manganese | #353 |
| western brain | #354 |
| consumption rats | #354 |
| proinflammatory cytokine release | #354 |
| apapinduced liver injury | #354 |
| series studies | #354 |
| expression increased | #355 |
| duct ligated | #356 |
| complex male | #356 |
| brain excitability | #356 |
| thiamine supplementation | #356 |
| deterioration | #357 |
| receptor sites | #357 |
| 5hiaa | #358 |
| wellestablished model | #358 |
| postmortem brain tissue | #358 |
| onset brain | #359 |
| convulsions | #359 |
| proposed role | #359 |
| increase extracellular | #361 |
| mammalian brain | #361 |
| glutamate homeostasis | #361 |
| autoradiography brain | #362 |
| metabolic events | #363 |
| neuroinflammatory | #363 |
| histamine h1 | #363 |
| reduced plasma | #363 |
| rats cns | #364 |
| 9998 | #365 |
| expression pglycoprotein | #365 |
| acids branched | #366 |
| white matter structures | #366 |
| posttranslational rats rats | #367 |
| neuroglia | #367 |
| folic acid antagonists | #368 |
| methoxytyramine | #369 |
| cerebral oedema | #370 |
| 56 mm | #370 |
| sulfate dheas | #370 |
| sites binding | #371 |
| nacetylcysteine nac | #371 |
| metabolic impairment | #372 |
| perineuronal | #372 |
| glutamate synthesis | #372 |
| affinities | #373 |
| chemical forms | #373 |
| acid rats | #373 |
| encountered | #373 |
| induction cox2 | #373 |
| astrocytes microglia | #375 |
| 3hmk801 | #375 |
| accompanied | #375 |
| ca1 subfield | #376 |
| highaffinity | #376 |
| anaplerotic | #376 |
| nh3 nh4 | #377 |
| antioxidant nacetylcysteine | #377 |
| acetyltransferase chat | #378 |
| cirrhosis alcoholic | #378 |
| ngnitro | #378 |
| novo synthesis | #379 |
| basal ganglia thalamus | #380 |
| cell swelling | #380 |
| positive allosteric | #380 |
| acute chronic | #382 |
| pons | #382 |
| epileptic patients | #382 |
| pregnenolone | #383 |
| overwhelming evidence | #383 |
| densities | #385 |
| exposure brain | #386 |
| transporter glut1 | #386 |
| dihydrolipoamide dehydrogenase | #386 |
| phenylalanine tyrosine | #388 |
| hyperglycemic conditions | #390 |
| acetylcholine synthesis | #390 |
| effects administration | #390 |
| focal cerebral ischemia | #390 |
| cerebral edema | #390 |
| pbz | #390 |
| pet assessment | #392 |
| mice enos | #393 |
| glycine transporter | #394 |
| thioacetamide induced | #394 |
| phthalaldehyde | #394 |
| phenylacetate | #395 |
| scatchard plot | #395 |
| model acute | #396 |
| failure induced | #396 |
| positive allosteric modulator | #397 |
| carnitine levels | #397 |
| omega 3 | #398 |
| pathophysiological mechanism | #399 |
| bbb permeability | #399 |
| methylhistamines | #399 |
| acetyl coa | #400 |
| vestibular nucleus | #400 |
| korsakoff | #400 |
| patients platelets | #400 |
| insulin metabolism | #401 |
| frontal | #401 |
| inferior olive | #402 |
| falls patients | #402 |
| radioligands | #403 |
| rats purpose | #405 |
| liver gut | #407 |
| concerted effort | #407 |
| neuropathologic | #408 |
| marker enzymes | #408 |
| methionine sulfoximine | #408 |
| releasable | #410 |
| adult activities | #412 |
| dopaminergic neurones | #414 |
| shunt surgery | #415 |
| forebrain cholinergic | #416 |
| patients ataxia | #416 |
| ketamine anesthesia | #417 |
| gabaa gammaaminobutyric acid | #418 |
| pk11195 | #419 |
| intellectual function | #419 |
| fibrillary | #421 |
| alcoholic liver | #421 |
| serotonin content | #422 |
| regions brain | #423 |
| asparagine | #423 |
| sham operation | #423 |
| housekeeping gene | #423 |
| rats animal | #423 |
| diazepam binding | #424 |
| hypothermia | #424 |
| salinetreated controls | #425 |
| tissues brain | #425 |
| direct evidence | #426 |
| aidsrelated complex | #426 |
| binding parameters | #426 |
| exsanguination | #427 |
| rats mutant | #428 |
| hepatocyte necrosis | #430 |
| protein utilization | #431 |
| glutamine levels | #431 |
| sacrificed | #432 |
| onset severe | #434 |
| dawley tissue | #434 |
| peripheral benzodiazepine | #434 |
| hippocampus frontal cortex | #434 |
| rats experimental | #435 |
| cytotoxic edema | #437 |
| patients pbc | #437 |
| benzoate | #438 |
| 12 control subjects | #438 |
| addition evidence | #439 |
| ligand selectivity | #440 |
| isoquinoline | #440 |
| attenuates | #441 |
| central process | #441 |
| acids brain | #442 |
| neurological syndrome | #442 |
| brain glucose | #443 |
| patients encephalopathy | #443 |
| arginine transport | #443 |
| 13c enrichment | #443 |
| brain microglia | #443 |
| glyt1 | #444 |
| cultured astrocytes | #444 |
| cultured cerebellar | #445 |
| operated | #445 |
| compounds rats | #446 |
| butterworth | #446 |
| brain water content | #447 |
| liver skeletal | #450 |
| topographic distribution | #450 |
| pyruvate dehydrogenase | #450 |
| agematched controls | #450 |
| acute mice mice | #451 |
| brain tissue patients | #451 |
| effects liver | #451 |
| t1weighted mri | #453 |
| severe liver | #454 |
| immunohistochemistry liver | #455 |
| aged amino | #455 |
| central pontine myelinolysis | #455 |
| s100beta | #455 |
| parachlorophenylalanine | #456 |
| brain swelling | #456 |
| h1 receptor | #456 |
| body evidence | #456 |
| vitro binding assay | #457 |
| aspartic | #457 |
| impaired liver function | #457 |
| brain monoamines | #458 |
| effects brain | #460 |
| brain alterations | #460 |
| neurobiology | #460 |
| increased release | #461 |
| neuropathology | #462 |
| substantial body | #463 |
| equivocal | #463 |
| 5ht levels | #463 |
| neurological | #465 |
| dentate nuclei | #466 |
| hepatic glutathione | #466 |
| neurobehavioural | #467 |
| studies reveal | #468 |
| central cholinergic | #469 |
| glutamic acid | #469 |
| reye | #470 |
| amino acid levels | #471 |
| monoamine metabolism | #471 |
| urea production | #472 |
| alcoholic liver disease | #473 |
| patients hippocampal | #473 |
| putamen patients | #474 |
| glutamate transporters | #475 |
| gaba glycine | #475 |
| ox42 | #475 |
| liver dysfunction | #475 |
| inherited defects | #476 |
| thiamin | #477 |
| alcohol brain | #477 |
| thiamine pyrophosphate | #479 |
| release proinflammatory cytokines | #479 |
| acid humans | #480 |
| amino acid transporters | #480 |
| parkinsons diseases | #481 |
| images brain | #482 |
| inferior colliculus | #482 |
| acute male | #482 |
| brain csf | #484 |
| chronic alcoholics | #484 |
| nitric oxide synthase | #487 |
| triphosphate amino | #488 |
| concentrations increased | #488 |
| manganese levels | #488 |
| acids rats | #490 |
| multinuclear nmr spectroscopy | #491 |
| urea ammonia | #491 |
| increased production | #492 |
| glial fibrillary | #492 |
| jadad | #492 |
| role brain | #492 |
| ischemic cortex | #493 |
| pet ligand | #494 |
| emitted radiation | #495 |
| pyruvates | #495 |
| aspartate glutamate | #495 |
| ammonium ion | #495 |
| outer mitochondrial membrane | #495 |
| schaffer collaterals | #496 |
| hexanones | #496 |
| rat hippocampal | #496 |
| ataxic | #499 |
| neurons nitric | #499 |
| brain diseases | #501 |
| beneficial | #502 |
| 3hd | #505 |
| brain synaptosomes | #505 |
| 5 hydroxytryptophan | #507 |
| ketoacid | #508 |
| acid metabolites | #509 |
| fatal complication | #510 |
| gene therapy treatment | #510 |
| medulla oblongata | #511 |
| histamine h1 receptors | #511 |
| increased icp | #511 |
| discrete brain regions | #511 |
| exposure rats | #515 |
| acids amino | #516 |
| major feature | #517 |
| abnormal metabolism | #517 |
| humans neurons | #518 |
| chain acyl | #518 |
| concentrations 5 | #521 |
| neurochemistry | #523 |
| ltrp | #523 |
| inflammation mediators | #525 |
| toxic agents | #526 |
| rat hippocampal slices | #530 |
| brain female | #530 |
| aom | #531 |
| dawley receptors | #533 |
| receptor complex | #533 |
| agents dopamine | #533 |
| neurotoxins | #534 |
| focal cerebral | #534 |
| muscle loss | #534 |
| ligation bdl | #534 |
| 100 µg | #534 |
| combined actions | #535 |
| cerebellum cerebral | #536 |
| bdz | #537 |
| divalent metals | #538 |
| selective | #539 |
| severe liver disease | #539 |
| alcoholic cirrhosis | #539 |
| carroll | #539 |
| tipss | #540 |
| tyrosine nitration | #541 |
| hydroxymethylbilane | #541 |
| moderate drinking | #542 |
| brain astrocytes | #542 |
| moderate increase | #543 |
| portasystemic | #544 |
| aspartate | #544 |
| pyruvate oxidation | #544 |
| organic osmolytes | #545 |
| liver enzyme | #545 |
| chronic liver | #545 |
| energy metabolism | #546 |
| model hepatic | #547 |
| dissected | #548 |
| unanesthetized rats | #548 |
| cumene | #548 |
| nitrosative stress | #548 |
| unconjugated bilirubin | #549 |
| alpha1 alpha2 | #549 |
| thalamic lesions | #550 |
| taurine levels | #551 |
| brain region | #551 |
| fatigue patients | #553 |
| genes brain | #553 |
| brain cytokines | #554 |
| glutamatergic neurotransmission | #554 |
| water ammonia | #555 |
| increased uptake | #555 |
| nmda receptor antagonist | #556 |
| disease liver | #557 |
| rats bile | #558 |
| failure liver | #558 |
| levels hepatic | #563 |
| gabaergic gaba | #563 |
| microdialysate | #563 |
| cortex female humans | #564 |
| hydroxytryptophan | #564 |
| microglial response | #566 |
| serum bilirubin levels | #567 |
| mhe patients | #567 |
| malnutrition patients | #567 |
| established role | #568 |
| ischemia liver | #568 |
| autoradiographic | #569 |
| lhistidine | #569 |
| transient increase | #569 |
| neurotransmitter glutamate | #571 |
| neurologic signs | #573 |
| pathway brain | #574 |
| gaba | #574 |
| decarboxylase gad | #576 |
| outcome liver | #577 |
| octopamine | #577 |
| expression mrnas | #578 |
| apap induced | #578 |
| il1beta expression | #578 |
| liver pathology | #580 |
| oxobutanoate | #580 |
| biogenic monoamines | #581 |
| pyridinium compounds | #582 |
| increases blood | #582 |
| octanoic | #582 |
| histological lesions | #583 |
| brain metabolism | #583 |
| 5hydroxytryptophan | #584 |
| neurobehavioral effects | #588 |
| monoamine oxidases | #589 |
| bloodbrain barrier | #589 |
| edema formation | #589 |
| human spinal | #590 |
| activity brain | #591 |
| 13c nuclear | #592 |
| toxic levels | #593 |
| accompanying | #593 |
| catalytic sites | #594 |
| pathophysiological mechanisms | #594 |
| endogenous opioid | #594 |
| t1weighted imaging | #597 |
| highenergy phosphates | #598 |
| aminobutyric acid gaba | #599 |
| extracellular fluid | #600 |
| leigh disease | #601 |
| neuroglial | #601 |
| neuronal nitric | #601 |
| include | #601 |
| 3hcholine | #602 |
| taurine | #602 |
| largest increases | #604 |
| male nitric | #606 |
| methyltyrosines | #606 |
| glutamine humans | #607 |
| vermis | #608 |
| extracellular compartment | #608 |
| cirrhosis | #609 |
| acetyl | #609 |
| molecular studies | #609 |
| cortical slices | #610 |
| male metabolism | #610 |
| ammonia concentration | #612 |
| ventricular enlargement | #612 |
| friedreich ataxia | #612 |
| animals autoradiography | #614 |
| spraguedawley receptors | #615 |
| neurovascular unit | #615 |
| selective accumulation | #616 |
| microglial | #616 |
| axonopathy | #616 |
| tricarboxylic | #618 |
| artery ligation | #618 |
| c57bl6 mice | #618 |
| normothermic | #619 |
| increased expression genes | #620 |
| mammillary | #620 |
| acidic protein | #621 |
| controls addition | #624 |
| junction proteins | #624 |
| new approaches | #625 |
| oxidase mao | #625 |
| hippocampal slices | #625 |
| amino acid concentrations | #626 |
| semi quantitative | #626 |
| edema brain | #627 |
| experimental animal model | #628 |
| nimesulide | #628 |
| hepatic levels | #628 |
| clf | #629 |
| dbi | #629 |
| free radical formation | #630 |
| blood borne | #631 |
| neurobehavior | #631 |
| dehydroepiandrosterone sulfate dheas | #633 |
| ataxia | #634 |
| urea synthesis | #635 |
| allosteric interactions | #635 |
| dopamine striatum | #635 |
| contributory role | #635 |
| encephalopathies | #636 |
| neurological damage | #637 |
| neuroinflammation | #638 |
| harper | #638 |
| levels observed | #638 |
| astrocyte cultures | #638 |
| cerebellum | #639 |
| conduction velocities | #640 |
| deleterious effects | #640 |
| rats glucose | #641 |
| acid hippocampus | #643 |
| receptor densities | #644 |
| excitatory inhibitory | #645 |
| neuronal excitability | #645 |
| early role | #646 |
| nntetraacetic acid | #647 |
| frontal temporal | #647 |
| chronic exposure | #647 |
| desoxycorticosterone | #652 |
| matsumoto | #652 |
| branched chain | #653 |
| excitatory amino | #653 |
| cytokines tnf | #654 |
| tricarbonyl | #655 |
| gabaa gaba | #656 |
| mental state | #657 |
| 1400w | #657 |
| acid transporter | #659 |
| enos gene | #659 |
| dawley sodium | #661 |
| potential toxic effects | #662 |
| cerebral cortex | #663 |
| uptake release | #664 |
| 3hspiperone | #665 |
| metabolic basis | #665 |
| fibrillary acidic | #666 |
| cycle enzymes | #668 |
| heterogeneous distribution | #669 |
| cogent | #670 |
| inhibitory properties | #673 |
| minocycline treatment | #673 |
| potassium concentration | #675 |
| metabolism rats | #675 |
| 7ni | #678 |
| 7nitroindazole | #679 |
| evoked release | #682 |
| neuropathological | #683 |
| reduction expression | #683 |
| millimolar | #684 |
| ornithine | #684 |
| regional specificity | #684 |
| excitatory | #684 |
| ammonia treatment | #684 |
| gammaaminobutyric acid | #685 |
| frontal cortex hippocampus | #686 |
| spraguedawley | #688 |
| microg m3 | #688 |
| cerebral atrophy | #688 |
| protein tspo | #691 |
| brain regions | #695 |
| fulminant | #695 |
| ca1 pyramidal cells | #695 |
| hepatic damage | #695 |
| acetylcysteine animals | #697 |
| daily administration | #697 |
| synthase nnos | #698 |
| extrapyramidal | #698 |
| enzyme complex | #699 |
| brain disorders | #700 |
| bcaas | #700 |
| immunolabeling | #701 |
| blood‐brain barrier | #701 |
| ammonia production | #703 |
| normoglycemic | #703 |
| autophagy markers | #704 |
| rats dawley receptors | #705 |
| quinolinic | #706 |
| ethanol ingestion | #706 |
| acetylcysteine nac | #709 |
| cornerstone | #711 |
| glut1 expression | #714 |
| cortex rats | #715 |
| reductions | #719 |
| bmax values | #723 |
| phenylbutyrate | #723 |
| surgical samples | #724 |
| 6 day | #724 |
| nutritional status patients | #725 |
| acute hepatic | #726 |
| ketoglutaric | #729 |
| contribute | #730 |
| serotoninergic | #730 |
| expression isoforms | #736 |
| intensive study | #737 |
| piribedil | #740 |
| fluorimetric detection | #741 |
| mm nacl | #742 |
| ligation liver | #744 |
| dopaminergic function | #745 |
| biochemical alterations | #746 |
| cerebellar granule | #746 |
| methylglucose | #747 |
| tight junction | #748 |
| male microdialysis | #749 |
| glucose oxidation | #749 |
| choline acetyltransferase chat | #752 |
| cytochrome oxidase activity | #753 |
| scatchard analysis | #754 |
| alterations | #754 |
| illness terminology | #756 |
| portasystemic shunt | #757 |
| glutamate glu | #757 |
| delta receptors opioid | #758 |
| alcoholism animals | #760 |
| ergic | #761 |
| varying degrees | #762 |
| substantial evidence | #763 |
| ammonium chloride | #763 |
| opioid delta receptors | #764 |
| tryptamines | #764 |
| neutron activation analysis | #765 |
| levels 5 | #768 |
| normal liver function | #769 |
| excitotoxic | #769 |
| gdh | #769 |
| barrier permeability | #770 |
| control genes | #773 |
| newborn astrocytes | #774 |
| peripheral organs | #775 |
| cellular energy metabolism | #776 |
| ethanol consumption | #777 |
| increased blood | #778 |
| brain gene | #780 |
| hepatic dysfunction | #783 |
| species reactive | #783 |
| receptor function | #784 |
| cortex thalamus | #785 |
| methods principal findings | #785 |
| mnsod | #785 |
| messenger rats | #786 |
| glut1 | #786 |
| nakatpase | #787 |
| globus pallidus | #787 |
| early alterations | #789 |
| brain function | #790 |
| spraguedawley receptors messenger | #791 |
| major route | #791 |
| probenecid | #791 |
| 2 fold | #792 |
| glyceraldehyde3 phosphate | #792 |
| specific ligands | #793 |
| hypothermia treatment | #793 |
| rat cerebral | #795 |
| selective effects | #796 |
| typical cases | #796 |
| plasma clearance | #797 |
| ethanol solution | #797 |
| neuronal integrity | #799 |
| severity liver | #799 |
| nitroarginine | #801 |
| pertinence | #805 |
| hiaa | #806 |
| nh4cl | #807 |
| neurotoxic effects | #807 |
| ultimately | #807 |
| pyruvate metabolism | #808 |
| mrna protein | #809 |
| chat | #811 |
| acute brain injury | #812 |
| predilection | #812 |
| role astrocytes | #812 |
| enos mice | #815 |
| coma | #816 |
| update | #816 |
| glycolytic activity | #819 |
| cerebellar granule cells | #820 |
| nmethyldaspartate | #822 |
| eaat1 | #823 |
| pbc patients | #823 |
| iii groups | #824 |
| complete disappearance | #825 |
| pathogenesis treatment | #825 |
| edema | #826 |
| age matched | #826 |
| alzheimer type | #828 |
| atomic absorption spectrometry | #828 |
| synthesis rates | #829 |
| nitrite nitrate | #829 |
| glial | #830 |
| water homeostasis | #831 |
| neurons astrocytes | #831 |
| alcoholics | #832 |
| diseases alcoholic | #832 |
| eaat2 | #833 |
| monoamine | #834 |
| decreases | #835 |
| manifested | #836 |
| pathophysiological | #837 |
| operated rats | #837 |
| amino3 | #838 |
| explain | #838 |
| animal cell | #839 |
| oligonucleotide primers | #839 |
| treatment improvement | #841 |
| metabolic disorder | #842 |
| expression ho1 | #843 |
| cell loss | #845 |
| isotopomer | #846 |
| hypothermia patients | #846 |
| cfos cjun | #848 |
| pharmacokinetic analyses | #849 |
| oblongata | #849 |
| chronic alcohol consumption | #851 |
| gaba receptors | #852 |
| nmda receptor | #853 |
| receptor mediated | #853 |
| matched age | #854 |
| daily injections | #854 |
| consequence | #856 |
| glutamatergic | #856 |
| compromised | #857 |
| bbb integrity | #858 |
| aromatic amino acids | #861 |
| griess | #861 |
| hepatic disease | #862 |
| order role | #862 |
| alcoholic | #862 |
| continues | #863 |
| antioxidant action | #863 |
| inflammatory mechanisms | #866 |
| thalamic nuclei | #866 |
| cerebellar ataxia | #867 |
| early induction | #867 |
| normalizes | #869 |
| manifest | #870 |
| chronic liver disease | #871 |
| oxide rats | #872 |
| fpc | #874 |
| succimer | #877 |
| low risk bias | #880 |
| nmda receptor antagonists | #881 |
| excitatory amino acid | #882 |
| greater susceptibility | #882 |
| barrier bbb | #882 |
| cisterna magna | #882 |
| stimulated release | #887 |
| dehydrogenase | #890 |
| western cells | #890 |
| comatose | #890 |
| shamoperated animals | #891 |
| multinuclear | #891 |
| cultured hippocampal | #892 |
| nutritional intervention | #893 |
| interfere | #893 |
| mutant mouse | #894 |
| lipoamide | #897 |
| neuropsychiatric symptoms | #898 |
| exp | #899 |
| acetaminophen apap | #900 |
| dizocilpine maleate | #901 |
| sulfoximine | #901 |
| common death | #901 |
| cirrhosis pbc | #902 |
| lowering | #904 |
| neurons rna | #904 |
| quinolinic acid | #905 |
| experimental animal | #905 |
| autopsy brain | #907 |
| pcs | #907 |
| brain activities | #908 |
| acid animals | #912 |
| factor tumor | #912 |
| selective ligands | #913 |
| pathophysiology | #913 |
| colliculus | #913 |
| placebo intervention | #919 |
| publication acidosis | #919 |
| microdialysis study | #920 |
| cerebellar degeneration | #920 |
| liver homogenates | #922 |
| rat cortical | #922 |
| delta receptors | #924 |
| survival mice | #926 |
| urea cycle | #929 |
| striatum hippocampus | #930 |
| nacetylcysteine | #931 |
| pugh | #931 |
| microglial activation | #932 |
| findings evidence | #932 |
| hydroxy2di | #933 |
| activities enzymes | #936 |
| developing rat brain | #942 |
| tartrates | #942 |
| reaction water | #942 |
| hepatic diseases | #942 |
| mammalian cns | #943 |
| agents oxidative | #943 |
| rats exposed | #943 |
| injured liver | #943 |
| study liver | #943 |
| marked | #945 |
| rapid removal | #945 |
| pca | #948 |
| maladies | #949 |
| cirrhosis magnetic | #950 |
| 25mm | #951 |
| concentrations observed | #954 |
| spontaneous release | #957 |
| altered | #962 |
| spraguedawley receptors rats | #963 |
| detailed review | #964 |
| putamen | #967 |
| assay rats | #967 |
| humans hypothermia | #969 |
| translocator protein | #969 |
| moderate hypothermia | #970 |
| chronic liver diseases | #971 |
| cerebral glucose | #971 |
| acid transport | #971 |
| increased glycolysis | #971 |
| intermediary metabolism | #971 |
| nm range | #973 |
| autoradiographic study | #974 |
| aspartic acid | #979 |
| kidney heart | #979 |
| post translational modifications | #980 |
| neurological disease | #983 |
| occludin | #984 |
| oxygenase1 ho1 | #988 |
| pdh | #990 |
| effective measures | #990 |
| 9 mice mice | #990 |
| aquaporin4 | #991 |
| cirrhosis experimental | #991 |
| rats ethanol | #992 |
| brain oedema | #992 |
| spared | #993 |
| increased plasma | #993 |
| propylaminotetralin | #998 |
| damage mechanisms | #999 |
| role oxidative stress | #1006 |
| adaptive mechanisms | #1006 |
| soluble guanylyl | #1008 |
| uptake kinetics | #1008 |
| flunitrazepam | #1008 |
| cerebro | #1009 |
| rifaximin | #1009 |
| metabolic consequences | #1010 |
| rat brain | #1012 |
| progressing | #1013 |
| neurotoxic | #1013 |
| presymptomatic | #1015 |
| modulatory | #1015 |
| fulminant hepatic | #1016 |
| electrified | #1016 |
| publication amino acids | #1017 |
| ligands receptors | #1019 |
| abundant evidence | #1020 |
| animal models | #1020 |
| unsuspected | #1020 |
| 1h | #1023 |
| acids bcaa | #1023 |
| pallidus humans | #1024 |
| antioxidant anti | #1029 |
| astrocyte | #1030 |
| metabolism inborn | #1031 |
| tele | #1032 |
| microsomes | #1032 |
| etanercept treatment | #1034 |
| 7 hours | #1036 |
| muscle expression | #1038 |
| catalepsy | #1039 |
| interleukin1beta | #1041 |
| nutritional assessment | #1043 |
| monoamine oxidase | #1045 |
| pharmacology | #1048 |
| aqp4 | #1050 |
| acid decarboxylase | #1050 |
| gabaergic | #1050 |
| caudate nucleus | #1053 |
| major factor | #1053 |
| endogenous | #1055 |
| aquaporin 4 | #1056 |
| specific antagonist | #1057 |
| hepatolenticular | #1057 |
| synthetase | #1058 |
| involved pathogenesis | #1058 |
| frontoparietal cortex | #1060 |
| adaptive mechanism | #1060 |
| oxygenase1 | #1064 |
| gabaa receptors | #1066 |
| progression liver | #1067 |
| 5ht neurons | #1067 |
| sodium acetate | #1072 |
| efficacy treatment | #1075 |
| rat hepatocytes | #1075 |
| reflex | #1077 |
| membrane preparations | #1077 |
| inflammation infection | #1078 |
| glucose blotting | #1080 |
| accompanies | #1081 |
| gilles | #1083 |
| enzyme activities | #1083 |
| 34dihydroxyphenylacetic acid | #1085 |
| nonneuronal | #1086 |
| content increased | #1090 |
| lactate concentrations | #1092 |
| complex carbohydrates | #1092 |
| major players | #1095 |
| muscle brain | #1097 |
| radioligand assay | #1098 |
| awaiting | #1099 |
| intense staining | #1099 |
| rat primary | #1101 |
| baptaam | #1102 |
| normal physiological conditions | #1106 |
| cell culture studies | #1107 |
| tpp | #1107 |
| junction protein | #1108 |
| medial septum | #1109 |
| 5 mm | #1111 |
| hyperintensity | #1111 |
| assay receptors | #1113 |
| human brain tissue | #1116 |
| patients alzheimers disease | #1117 |
| inflammation role | #1117 |
| cirrhotics | #1118 |
| severe malnutrition | #1122 |
| atrophy brain | #1122 |
| ischemic core | #1127 |
| sprague | #1128 |
| cirrhosis male | #1129 |
| findings role | #1129 |
| astrocytes | #1130 |
| transient elevation | #1131 |
| amino acids | #1134 |
| tetrabenazine | #1135 |
| weight brain | #1137 |
| age controls | #1138 |
| diagonal band | #1139 |
| haloperidol humans | #1142 |
| oxide synthase | #1143 |
| receptors histamine | #1145 |
| hepatobiliary | #1146 |
| pyruvate | #1148 |
| nonepileptic | #1153 |
| worsens | #1153 |
| lactic acidosis | #1153 |
| dehydroepiandrosterone sulfate | #1154 |
| control tissue | #1157 |
| altered brain | #1162 |
| biogenic amines | #1163 |
| cresyl | #1166 |
| portosystemic | #1167 |
| h1 | #1168 |
| benzilate | #1171 |
| combustion products | #1172 |
| emax | #1173 |
| enzymologic | #1174 |
| lactate | #1177 |
| etanercept | #1179 |
| rats subjected | #1180 |
| parkinsonian symptoms | #1181 |
| peripheral tissues | #1182 |
| glutamate dehydrogenase | #1182 |
| nerve conduction | #1183 |
| rats receptors | #1185 |
| nnos | #1185 |
| urine levels | #1186 |
| principally | #1189 |
| mechanisms involved | #1191 |
| synaptic cleft | #1192 |
| cardinal features | #1192 |
| hyperintensities | #1193 |
| delta opioid | #1196 |
| causal factor | #1197 |
| rapid onset | #1198 |
| gabaa receptor | #1199 |
| transcriptase polymerase | #1201 |
| venous blood | #1204 |
| dopamine uptake | #1205 |
| dawley | #1205 |
| death cells | #1207 |
| acetyl cysteine | #1207 |
| hepatolenticular degeneration | #1209 |
| development brain | #1211 |
| increasing body | #1214 |
| direct effects | #1216 |
| stereotypy | #1218 |
| binding inhibitor | #1220 |
| radiometric | #1220 |
| brains mice | #1220 |
| pig model | #1221 |
| 5htp | #1222 |
| nmethyld | #1223 |
| fold increase | #1224 |
| neuropsychological impairment | #1226 |
| skeletal rats rats | #1226 |
| mitochondrial swelling | #1228 |
| wilson disease | #1229 |
| transjugular | #1229 |
| deprenyl | #1229 |
| 100 iu | #1232 |
| severity assessment | #1234 |
| circadian rhythmicity | #1234 |
| cultured rat | #1234 |
| hippocampus vitro | #1236 |
| spraguedawley receptors opioid | #1239 |
| hyperexcitability | #1239 |
| nakatpase activity | #1239 |
| congenitally | #1241 |
| glyceraldehyde3 | #1242 |
| hypermetabolism | #1242 |
| brain axis | #1246 |
| partial recovery | #1251 |
| elucidation | #1252 |
| kinetics male | #1253 |
| receptors neurotransmitter | #1254 |
| sprague dawley | #1255 |
| convincing evidence | #1258 |
| methyl aspartate | #1259 |
| gabaa | #1260 |
| 5hydroxyindoleacetic acid | #1261 |
| albumen | #1261 |
| hippocampus striatum | #1262 |
| acetylcysteine | #1262 |
| clinical entities | #1262 |
| myoinositol | #1264 |
| overactivation | #1270 |
| 1h 13c | #1271 |
| astroglial | #1271 |
| olfactory bulbs | #1273 |
| maleate | #1276 |
| rats expression | #1276 |
| congenital | #1281 |
| milligram | #1281 |
| apoenzyme | #1281 |
| vicious | #1281 |
| variable degree | #1282 |
| glutamate decarboxylase | #1287 |
| patients tle | #1288 |
| loss expression | #1288 |
| induced inhibition | #1289 |
| brain inflammation | #1290 |
| acid male | #1291 |
| acid cycle | #1291 |
| metabolite | #1291 |
| cortex kidney | #1292 |
| quisqualate | #1294 |
| ischemia cerebral | #1295 |
| radioreceptor | #1296 |
| rifamycins | #1296 |
| dawley animals | #1297 |
| deficient | #1297 |
| protective | #1297 |
| zinc concentrations | #1300 |
| permeability blood | #1301 |
| synaptosomes | #1302 |
| potential therapeutic approach | #1305 |
| frontoparietal | #1306 |
| opioid delta | #1308 |
| 7 males | #1308 |
| neuronal dysfunction | #1310 |
| caveolin1 | #1310 |
| liver | #1314 |
| 5mm | #1314 |
| heme oxygenase1 | #1316 |
| greater magnitude | #1317 |
| adrenals | #1318 |
| 35°c | #1319 |
| threefold | #1320 |
| receptors methyl | #1321 |
| invariably | #1324 |
| neurotransmission | #1325 |
| nanomolar | #1328 |
| dopamine serotonin | #1328 |
| appearance | #1329 |
| guanylyl | #1329 |
| major complication | #1334 |
| animal electrophoresis | #1334 |
| signaling mechanisms | #1335 |
| acetyltransferase | #1337 |
| phosphate dehydrogenase | #1344 |
| cerebellum hippocampus | #1344 |
| astrocytes cells | #1346 |
| cgmp pathway | #1349 |
| heavy drinkers | #1350 |
| transporter proteins | #1352 |
| brain effects | #1358 |
| dopamine female | #1361 |
| neuronal | #1361 |
| female globus | #1364 |
| interleukin1 receptors | #1364 |
| shunt tips | #1368 |
| male rats rats | #1369 |
| hypoglycaemic | #1375 |
| small decrease | #1378 |
| fur | #1380 |
| electrolyte balance | #1381 |
| aromatic amino | #1383 |
| bile duct ligation | #1386 |
| synergism | #1387 |
| chelation therapy | #1387 |
| nitrated | #1388 |
| gaba agonists | #1389 |
| ca2independent | #1392 |
| preliminary studies | #1394 |
| neurological sequelae | #1395 |
| transamination | #1396 |
| occipital cortex | #1401 |
| intrauterine growth | #1402 |
| immediateearly genes | #1403 |
| guanylate | #1409 |
| pallidus | #1409 |
| larginine | #1412 |
| selectively | #1416 |
| cerebral | #1417 |
| patients findings | #1425 |
| paper details | #1426 |
| normo | #1427 |
| mutant strains | #1429 |
| acute brain | #1433 |
| motor nerve | #1441 |
| paralleled | #1444 |
| shamoperated | #1445 |
| childpugh score | #1450 |
| common approaches | #1450 |
| risk falls | #1451 |
| mitochondrial membranes | #1451 |
| peripheral | #1452 |
| longer wavelength | #1453 |
| hypoglycaemia | #1455 |
| intraventricular injections | #1456 |
| effective prevention | #1456 |
| benzodiazepinones | #1459 |
| clonazepam | #1460 |
| modulatory effects | #1462 |
| hydroxydopamines | #1465 |
| studies brain | #1471 |
| quinuclidinyl | #1472 |
| swelling | #1477 |
| brain tissues | #1479 |
| patients liver disease | #1481 |
| saturable | #1482 |
| 13c | #1485 |
| 23390 | #1485 |
| deficiency | #1486 |
| excitatory neurotransmission | #1488 |
| characteristic | #1488 |
| gfap | #1491 |
| dopamine agents | #1499 |
| messenger rats rats | #1504 |
| neuroprotective role | #1505 |
| histological studies | #1509 |
| bilirubin levels | #1509 |
| primary concern | #1509 |
| increases | #1512 |
| volume regulation | #1512 |
| cortex striatum | #1513 |
| primary biliary cirrhosis | #1514 |
| receptor subunits | #1515 |
| herniation | #1516 |
| liver disease | #1519 |
| rat cerebral cortex | #1519 |
| 1h magnetic | #1523 |
| integrity | #1525 |
| glutamic acid decarboxylase | #1525 |
| tyrosine residues | #1527 |
| branched | #1530 |
| tk | #1532 |
| temporal profile | #1539 |
| increased capacity | #1541 |
| transport animals | #1546 |
| brain homogenates | #1547 |
| acetylcarnitine | #1548 |
| apomorphine | #1548 |
| cholinergic | #1549 |
| vitamins minerals | #1550 |
| tricarboxylic acid | #1551 |
| wistar receptors rats | #1552 |
| lactulose | #1554 |
| regional differences | #1557 |
| pathological hallmark | #1557 |
| neurochemical | #1559 |
| lactate levels | #1561 |
| cirrhosis liver | #1564 |
| reflexes | #1566 |
| pathological mechanisms | #1567 |
| extracellular | #1568 |
| neurotransmitters | #1572 |
| poor diet | #1575 |
| major forms | #1579 |
| brain cerebral | #1580 |
| light energy | #1584 |
| biliary cirrhosis | #1584 |
| scad | #1584 |
| epilepsy tle | #1585 |
| tryptophan | #1585 |
| brain cell | #1586 |
| patients review | #1589 |
| ependymal cells | #1591 |
| ngnitrolarginine methyl ester | #1592 |
| new findings | #1594 |
| lesser extent | #1595 |
| pyruvate carboxylase | #1596 |
| aspartate nmda | #1598 |
| llysine | #1600 |
| pbc | #1601 |
| rat hippocampus | #1602 |
| mri signal | #1605 |
| specific therapies | #1606 |
| brain slices | #1606 |
| tdp | #1615 |
| ouabain | #1615 |
| travelled | #1618 |
| unanesthetized | #1623 |
| anastomosis | #1626 |
| acute mice | #1627 |
| neuroglia neurons | #1629 |
| deficient diet | #1631 |
| failure mechanisms | #1633 |
| receptor human | #1635 |
| prevents | #1637 |
| zinc copper | #1640 |
| cerebellar | #1641 |
| tritium | #1642 |
| dorsal raphe nucleus | #1646 |
| regulation animals | #1647 |
| male membrane glycoproteins | #1648 |
| died | #1650 |
| animals cerebral | #1651 |
| experimental treatment | #1651 |
| brain endothelial | #1652 |
| neuromodulatory | #1653 |
| synthase nitric | #1653 |
| amino acid transport | #1654 |
| glutamate receptors | #1657 |
| distribution animals | #1657 |
| fourfold | #1658 |
| extracellular space | #1660 |
| excitotoxicity | #1661 |
| rapid accumulation | #1664 |
| bbb disruption | #1664 |
| striking similarities | #1667 |
| gapdh | #1667 |
| supporting cells | #1669 |
| autoradiography | #1673 |
| previous findings | #1674 |
| synthetase activity | #1675 |
| messenger | #1677 |
| veratrum | #1688 |
| brain area | #1691 |
| dehydrogenase deficiency | #1694 |
| diseases metabolic | #1696 |
| glycogen metabolism | #1701 |
| brainstem | #1704 |
| postulated | #1708 |
| midbrain | #1708 |
| thp | #1710 |
| accumulate | #1716 |
| fulminant hepatic failure | #1723 |
| ibotenic | #1723 |
| dizocilpine | #1724 |
| inborn | #1724 |
| polyclonal antibody | #1725 |
| benzodiazepines | #1726 |
| phenomenon | #1726 |
| il1beta | #1733 |
| alternative mechanism | #1734 |
| carnitine | #1735 |
| animals arginine | #1735 |
| noninvasive techniques | #1737 |
| cumene hydroperoxide | #1737 |
| disorders nervous | #1739 |
| decarboxylase | #1750 |
| normalization | #1756 |
| liver disease patients | #1757 |
| alternative hypothesis | #1757 |
| magna | #1759 |
| consequent | #1760 |
| tricarboxylic acid cycle | #1761 |
| shunts | #1762 |
| c57bl6 | #1762 |
| spiperone | #1763 |
| metabolism glucose | #1769 |
| allosteric | #1770 |
| intrahepatic portosystemic | #1770 |
| critical appraisal | #1773 |
| betaamyloid | #1781 |
| granule neurons | #1785 |
| acetaminophen induced | #1788 |
| muscarinic | #1789 |
| cell damage | #1790 |
| rats spraguedawley receptors | #1791 |
| brain damage | #1791 |
| body temperature | #1794 |
| normothermia | #1794 |
| adult rat brain | #1794 |
| glucose utilization | #1797 |
| common complication | #1799 |
| nmr study | #1802 |
| ampa receptors | #1806 |
| superfusion | #1810 |
| preliminary investigation | #1812 |
| primary metabolism | #1813 |
| nutritional supplements | #1815 |
| coa dehydrogenase | #1815 |
| major organs | #1815 |
| endorphin | #1817 |
| pyruvic | #1822 |
| oxazepam | #1822 |
| rat | #1829 |
| hypertension intracranial | #1832 |
| dorsal raphe | #1833 |
| hippocampal ca1 | #1834 |
| hepatic failure | #1835 |
| vmax values | #1836 |
| major roles | #1837 |
| bdl | #1839 |
| mild | #1840 |
| reuptake | #1843 |
| neurological deterioration | #1844 |
| compared controls | #1845 |
| granule cells | #1846 |
| metalloproteinase9 | #1847 |
| γaminobutyric acid | #1849 |
| toxins | #1850 |
| regulatory processes | #1854 |
| capillary gas chromatography | #1856 |
| ammonium compounds | #1857 |
| chronic alcohol | #1857 |
| monoaminergic | #1862 |
| cirrhotic rats | #1863 |
| body water | #1865 |
| liver transplantation patients | #1865 |
| caudate | #1868 |
| cholinergic neurons | #1872 |
| stroke outcome | #1876 |
| lactate production | #1877 |
| immunoreactivities | #1877 |
| platelets patients | #1882 |
| neurotoxicity syndromes | #1886 |
| glutamate release | #1886 |
| disorder treatment | #1886 |
| beta endorphin | #1892 |
| acute | #1900 |
| locomotor activity | #1902 |
| hepatoprotective | #1903 |
| common feature | #1904 |
| induced liver | #1906 |
| atp adp | #1913 |
| induced rats | #1917 |
| cirrhosis biliary | #1919 |
| penicillamine | #1920 |
| stereotyped | #1920 |
| colorimetric assay | #1921 |
| patients cirrhosis | #1923 |
| rodent models | #1923 |
| grossly | #1925 |
| dipeptides | #1930 |
| behavioral abnormalities | #1932 |
| precipitated | #1934 |
| tspo | #1935 |
| nitration | #1937 |
| areas brain | #1941 |
| patients aids | #1944 |
| neurocognitive impairment | #1945 |
| major metabolite | #1952 |
| major site | #1957 |
| synthase | #1958 |
| dpat | #1961 |
| concomitant | #1962 |
| cerebral metabolism | #1965 |
| normal dogs | #1965 |
| acid transporters | #1966 |
| acid synthesis | #1966 |
| spectroscopy male | #1968 |
| manganese superoxide dismutase | #1970 |
| nmethyldaspartate receptors | #1977 |
| globus | #1977 |
| druginduced liver injury | #1977 |
| 5hydroxytryptamine | #1977 |
| mice compared | #1981 |
| 28 weeks | #1981 |
| degeneration humans | #1986 |
| potassium exchanging | #1987 |
| erk1 | #1990 |
| duct ligation | #1991 |
| neurologic symptoms | #1991 |
| cognitive dysfunction | #1991 |
| idazoxan | #1993 |
| ideal model | #1994 |
| oxotremorine | #1994 |
| 5 ht | #1996 |
| recirculating | #1997 |
| primary biliary | #2000 |
| radioligand | #2001 |
| 2fold increase | #2006 |
| mk801 | #2007 |
| ampa receptor | #2015 |
| heterogeneously | #2017 |
| cerebellar cortex | #2019 |
| overactivity | #2020 |
| injury mice | #2022 |
| arterio | #2023 |
| pet imaging | #2028 |
| glucose brain | #2034 |
| aminoacids | #2036 |
| neurologic complications | #2036 |
| microdialysis | #2036 |
| sham rats | #2036 |
| sham | #2040 |
| osmolytes | #2041 |
| peroneal nerve | #2041 |
| resonance nmr | #2043 |
| exchanging atpase | #2043 |
| cerebri | #2046 |
| cyclase | #2046 |
| pathogenetic mechanisms | #2047 |
| passive diffusion | #2050 |
| suggested | #2053 |
| groups iii | #2063 |
| tracings | #2064 |
| decreased activity | #2064 |
| 10 12 | #2068 |
| dawley rats | #2069 |
| convulsants | #2071 |
| stage liver | #2072 |
| vivo brain | #2074 |
| elucidated | #2077 |
| tumor necrosis factoralpha | #2079 |
| penumbra | #2080 |
| biochemical parameters | #2082 |
| deficit | #2084 |
| acetates | #2087 |
| transjugular intrahepatic | #2089 |
| trace amounts | #2090 |
| international society | #2094 |
| autopsy | #2098 |
| ensuing | #2103 |
| zo1 | #2106 |
| solely | #2108 |
| atrophies | #2109 |
| p0018 | #2111 |
| nitric oxide synthesis | #2117 |
| portal pressure | #2117 |
| chp | #2121 |
| parallel | #2121 |
| synthase type | #2125 |
| neurological manifestations | #2141 |
| ligase | #2142 |
| synergistically | #2143 |
| exception | #2143 |
| brain barrier | #2148 |
| subsequent degradation | #2149 |
| indicative | #2150 |
| rats spraguedawley | #2158 |
| bmax | #2158 |
| time onset | #2158 |
| intracranial pressure | #2167 |
| amnestic | #2169 |
| male rat | #2170 |
| muscimol | #2173 |
| acute effects | #2178 |
| human patients | #2179 |
| neural inhibition | #2180 |
| gaa | #2180 |
| reactive nitrogen | #2187 |
| subchronic | #2189 |
| apap | #2194 |
| blood csf | #2194 |
| increasing recognition | #2200 |
| cox2 | #2203 |
| overt | #2205 |
| parkinsonism | #2209 |
| methysergide | #2212 |
| pressure icp | #2217 |
| homovanillic acid | #2217 |
| vitamin supplements | #2220 |
| hypothermic | #2223 |
| nitroarginine methyl | #2223 |
| brain cells | #2225 |
| function brain | #2230 |
| antiparkinson | #2232 |
| liver enzymes | #2238 |
| minocycline | #2242 |
| pss | #2244 |
| chelators | #2245 |
| neurological disorders | #2248 |
| humans liver | #2249 |
| diminution | #2262 |
| blood brain | #2265 |
| liver circulation | #2265 |
| symporters | #2265 |
| doubt | #2267 |
| nutritional deficiencies | #2268 |
| messenger systems | #2271 |
| gliosis | #2279 |
| behavior rats | #2280 |
| additional factors | #2297 |
| synaptic vesicles | #2297 |
| rats liver | #2299 |
| phosphate | #2300 |
| eeg activity | #2302 |
| acrylamides | #2303 |
| patients minimal | #2304 |
| isoxazolepropionic | #2307 |
| immunoreactive neurons | #2308 |
| superoxide dismutase | #2314 |
| tle | #2315 |
| memantine | #2320 |
| multiorgan failure | #2322 |
| cortex hippocampus | #2325 |
| brain expression | #2326 |
| cultured cerebral | #2327 |
| primary cultures | #2328 |
| systemic inflammatory response | #2328 |
| male nerve | #2330 |
| blindly | #2333 |
| hrqol patients | #2334 |
| housekeeping | #2336 |
| relative increase | #2338 |
| acidosis | #2338 |
| convincing | #2340 |
| scatchard | #2349 |
| lactates | #2359 |
| ligands | #2360 |
| binding assays | #2360 |
| olivary | #2362 |
| benzoic | #2364 |
| inbred strains | #2366 |
| patients increased | #2373 |
| endstage liver disease | #2376 |
| voluntary | #2377 |
| synaptic dysfunction | #2377 |
| competitive inhibitor | #2380 |
| clinical condition | #2391 |
| deficiencies | #2392 |
| mental fatigue | #2392 |
| potential adverse effects | #2393 |
| brains patients | #2401 |
| exchanging | #2401 |
| neurotoxin | #2406 |
| homovanillic | #2416 |
| lnmma | #2430 |
| induced brain | #2432 |
| protein mrna | #2433 |
| transporter 2 | #2443 |
| calcium binding | #2449 |
| cerebral metabolic | #2467 |
| extracellular levels | #2471 |
| 01 mm | #2473 |
| histamine receptor | #2483 |
| fluorescence detection | #2489 |
| peripheral inflammation | #2490 |
| adult male rats | #2491 |
| bbb | #2498 |
| receptors ampa | #2502 |
| synaptic function | #2508 |
| pathogenic role | #2509 |
| count cell | #2510 |
| effects alcohol | #2511 |
| animal model | #2513 |
| pyridinium | #2513 |
| activation microglia | #2514 |
| noxious stimuli | #2518 |
| hypotonia | #2524 |
| vmax | #2529 |
| 5ht | #2530 |
| physical conditioning | #2532 |
| dopac | #2534 |
| nuclear magnetic | #2534 |
| metabolic acidosis | #2541 |
| expression endothelial | #2563 |
| alcohol induced | #2566 |
| male matrix | #2571 |
| fmol | #2572 |
| understanding pathophysiology | #2573 |
| humans ligands | #2573 |
| receptor density | #2577 |
| alpha1 | #2577 |
| ataxias | #2577 |
| vessel walls | #2581 |
| postmortem brain | #2588 |
| microglia neurons | #2591 |
| mao | #2594 |
| multiple mechanisms | #2597 |
| acetylcholinesterase | #2598 |
| cerebrospinal | #2601 |
| groups subjects | #2608 |
| il1β il6 | #2619 |
| 10 microm | #2621 |
| possibility | #2621 |
| cognitive motor | #2623 |
| 15–30 | #2625 |
| greater extent | #2626 |
| methylaspartate | #2630 |
| normalisation | #2632 |
| nitrosation | #2635 |
| biochemical evidence | #2639 |
| circulating concentrations | #2640 |
| deteriorating | #2640 |
| day treatment | #2647 |
| activity rats | #2661 |
| transcriptase | #2663 |
| thalamic | #2663 |
| nitric | #2665 |
| katpase | #2665 |
| chc | #2665 |
| binding competitive | #2668 |
| glutathione levels | #2669 |
| olfactory bulb | #2669 |
| osmolar | #2683 |
| patients alcoholic | #2684 |
| guanylyl cyclase | #2685 |
| glial cell | #2686 |
| serotonin 5 | #2689 |
| effects ethanol | #2695 |
| indwelling | #2704 |
| nerve terminals | #2705 |
| rats control | #2705 |
| laboratory findings | #2710 |
| groups animals | #2715 |
| lactic | #2723 |
| situ nickend | #2733 |
| publication animals behavior | #2737 |
| frontal lobe | #2742 |
| hemodiafiltration | #2755 |
| suggests | #2760 |
| glutaminase | #2764 |
| functional integrity | #2767 |
| regions | #2769 |
| 6hydroxydopamine | #2771 |
| neurons animals | #2774 |
| kindred | #2775 |
| leucine | #2779 |
| turnover rate | #2779 |
| 24h | #2786 |
| glutamate receptor | #2789 |
| systemic circulation | #2789 |
| animal rats | #2790 |
| rhythmicity | #2798 |
| amino acid | #2798 |
| severity patients | #2806 |
| osmolar concentration | #2813 |
| inbred strains mice | #2814 |
| pontine | #2817 |
| exposed | #2821 |
| mechanisms | #2824 |
| hydroxy5 | #2826 |
| microglial cells | #2827 |
| p38mapk | #2831 |
| gastrointestinal agents | #2833 |
| neurological deficit | #2834 |
| regulation enzymologic | #2834 |
| minneapolis | #2835 |
| blood brain barrier | #2841 |
| brain calcium | #2847 |
| marked decrease | #2867 |
| bilirubin | #2876 |
| twofold increase | #2877 |
| alcoholic fatty | #2882 |
| amino | #2882 |
| nerve cells | #2883 |
| alanine | #2885 |
| synaptic | #2888 |
| diabetic animals | #2890 |
| ca2dependent | #2893 |
| pet study | #2897 |
| mmt | #2898 |
| trafficking | #2901 |
| kainate | #2903 |
| rigidity | #2905 |
| slices | #2905 |
| standpoint | #2906 |
| ameliorating | #2910 |
| confirming | #2918 |
| clinical syndrome | #2931 |
| cell volume | #2936 |
| dying | #2938 |
| normal control | #2938 |
| normal animals | #2939 |
| subfield | #2943 |
| translocator | #2943 |
| 12 weeks treatment | #2944 |
| receptors opioid | #2962 |
| impaired | #2964 |
| 11c | #2965 |
| assist devices | #2970 |
| astrocytes cell | #2971 |
| brain uptake | #2974 |
| unaffected | #2982 |
| inflammation liver | #2982 |
| excitatory synapses | #3000 |
| pyruvic acid | #3000 |
| intermediary | #3008 |
| normal values | #3015 |
| aquaporin | #3036 |
| uptake | #3039 |
| kainic | #3043 |
| barrier brain | #3047 |
| cox2 expression | #3051 |
| incubation medium | #3051 |
| ca1 pyramidal | #3053 |
| biliary obstruction | #3054 |
| weighted magnetic | #3069 |
| concert | #3073 |
| tmp | #3076 |
| metabolite concentrations | #3078 |
| portosystemic shunt | #3078 |
| harmful effects | #3082 |
| attenuation | #3083 |
| selegiline | #3086 |
| activated microglia | #3088 |
| reserpine | #3093 |
| liver injury | #3095 |
| cd1 | #3099 |
| catecholaminergic | #3109 |
| atp levels | #3111 |
| adult rats | #3113 |
| renal vein | #3115 |
| valine | #3133 |
| short halflife | #3136 |
| toxic effects | #3137 |
| relative roles | #3149 |
| decreased | #3156 |
| myo inositol | #3161 |
| higher doses | #3168 |
| animals binding | #3169 |
| dhea | #3171 |
| nmda | #3172 |
| loss | #3180 |
| carboxamide | #3189 |
| failure | #3192 |
| endorphins | #3192 |
| relation | #3194 |
| abruptly | #3195 |
| radical scavengers | #3198 |
| bcaa | #3199 |
| inhalation | #3199 |
| mental retardation | #3201 |
| enzymologic genes | #3209 |
| clinical presentations | #3210 |
| ketanserin | #3214 |
| liver function | #3214 |
| heavy drinking | #3218 |
| coenzymes | #3220 |
| noradrenaline | #3224 |
| imidodiphosphate | #3226 |
| active transport | #3232 |
| portal | #3235 |
| shortchain fatty acids | #3238 |
| gad | #3238 |
| acidic | #3243 |
| synaptic membranes | #3244 |
| pyrophosphate | #3248 |
| induced hepatic | #3252 |
| treated rats | #3256 |
| nitrogen species | #3267 |
| systemic | #3276 |
| oxidative metabolism | #3281 |
| respects | #3285 |
| induced seizures | #3287 |
| synaptosomal | #3291 |
| drug repositioning | #3296 |
| behavioral symptoms | #3300 |
| water electrolyte | #3306 |
| kcl | #3307 |
| cell death | #3311 |
| metabolic alterations | #3324 |
| anterolateral | #3326 |
| reverse | #3327 |
| metabolized | #3331 |
| nanomolar concentrations | #3335 |
| sedatives | #3342 |
| general circulation | #3344 |
| nac | #3347 |
| dab | #3352 |
| rats received | #3359 |
| regionally | #3359 |
| benzoates | #3360 |
| membrane transport | #3361 |
| dosedependent fashion | #3364 |
| aspartate receptors | #3366 |
| rats inbred | #3368 |
| subsequent studies | #3371 |
| phenylalanine | #3384 |
| opioid | #3388 |
| cerebral ischemia | #3388 |
| inbred strains receptors | #3389 |
| cortex | #3391 |
| robust evidence | #3394 |
| hydroxytryptamine | #3402 |
| tyrphostins | #3403 |
| galactosamine | #3404 |
| brain disease | #3407 |
| brain lesions | #3412 |
| disturbances | #3421 |
| falls | #3421 |
| progressive increase | #3423 |
| histamine | #3423 |
| ldopa | #3426 |
| quaternary ammonium | #3427 |
| morphologic | #3428 |
| transaminases | #3432 |
| gln | #3436 |
| decreased levels | #3437 |
| modulation | #3439 |
| levels liver | #3443 |
| indole3 | #3446 |
| superior colliculus | #3451 |
| epilepsy temporal | #3453 |
| toxic | #3455 |
| strains mice | #3456 |
| biogenic | #3458 |
| accumulates | #3462 |
| timecourse | #3467 |
| phosphocreatine | #3473 |
| rats rats | #3474 |
| indomethacin | #3480 |
| striatum | #3482 |
| developing rat | #3485 |
| upregulation | #3491 |
| glycine | #3492 |
| brain stem | #3495 |
| subcortical structures | #3497 |
| liver male | #3497 |
| electrochemical detection | #3499 |
| new evidence | #3499 |
| basal ganglia | #3500 |
| lobe epilepsy | #3503 |
| rat models | #3503 |
| previous observations | #3507 |
| aids patients | #3511 |
| huntington | #3515 |
| dehydroepiandrosterone | #3537 |
| aging brain | #3542 |
| rats treatment | #3545 |
| neurons oxidative | #3545 |
| kidney liver | #3555 |
| tyramine | #3558 |
| fold | #3563 |
| cytokines disease | #3576 |
| nerve degeneration | #3584 |
| portal vein | #3600 |
| tissue distribution | #3600 |
| inferior vena cava | #3600 |
| brain structure | #3613 |
| antioxidant properties | #3627 |
| truncated 250 | #3627 |
| pathology | #3635 |
| cofactor | #3636 |
| prolonged exposure | #3636 |
| hypertonic saline | #3638 |
| disease states | #3648 |
| implication | #3650 |
| increased activity | #3655 |
| hydroxydopamine | #3657 |
| ache | #3664 |
| precipitating | #3664 |
| fatty liver | #3666 |
| investigator | #3675 |
| circadian rhythms | #3680 |
| scavengers | #3682 |
| lobe | #3694 |
| splanchnic | #3699 |
| regional variation | #3700 |
| arginine | #3718 |
| proinflammatory cytokine | #3722 |
| new model | #3723 |
| medial | #3735 |
| thioacetamide | #3741 |
| cassette transporters | #3742 |
| treated animals | #3746 |
| induced neurotoxicity | #3751 |
| stress rats | #3755 |
| normal mice | #3758 |
| consensus statement | #3765 |
| dopamine d1 | #3773 |
| 4 wk | #3786 |
| 1968 | #3791 |
| parietal lobe | #3793 |
| acetylcholinesterase ache | #3799 |
| dietary protein | #3801 |
| mitochondrion | #3807 |
| finding | #3814 |
| major | #3815 |
| control animals | #3825 |
| diazepam | #3825 |
| neural cell | #3825 |
| resemble | #3833 |
| western blot analyses | #3838 |
| systemically | #3846 |
| inborn errors | #3846 |
| prefrontal | #3857 |
| effects chronic | #3872 |
| nmr spectroscopy | #3879 |
| malabsorption | #3896 |
| type nitric | #3897 |
| dopamine d1 receptors | #3899 |
| dopa | #3907 |
| enhanced production | #3909 |
| metabolic pathway | #3911 |
| elucidate | #3914 |
| levels measured | #3915 |
| new therapeutic approaches | #3919 |
| nitric oxide production | #3919 |
| tone | #3924 |
| pindolol | #3929 |
| peripheral neuropathy | #3937 |
| ascorbate | #3942 |
| medulla | #3949 |
| reabsorption | #3949 |
| csf | #3949 |
| wet weight | #3951 |
| tourette | #3975 |
| neuropsychiatric disorders | #3978 |
| purkinje cells | #3983 |
| antiinflammatory | #3987 |
| fatigue | #3992 |
| complication | #3992 |
| tca cycle | #4003 |
| pseudotumor | #4006 |
| brain activation | #4009 |
| day 5 | #4011 |
| treatment prevention | #4021 |
| transporter | #4026 |
| elevated blood | #4053 |
| nmda receptors | #4053 |
| bz | #4054 |
| strains receptors | #4069 |
| neurotoxicity | #4070 |
| fischer | #4082 |
| cultured neurons | #4097 |
| remove | #4101 |
| gastrointestinal bleeding | #4103 |
| involve | #4104 |
| nonalcoholic | #4111 |
| intracranial | #4134 |
| coa | #4138 |
| visible spectrum | #4140 |
| induced mitochondrial | #4149 |
| exacerbate | #4165 |
| lower affinity | #4172 |
| motor activity | #4178 |
| future clinical trials | #4178 |
| reverse transcriptase | #4185 |
| nitroso | #4190 |
| nuclear magnetic resonance | #4193 |
| oxide production | #4198 |
| ampa | #4204 |
| endothelial nitric | #4205 |
| liver cirrhosis | #4232 |
| steadystate levels | #4244 |
| knockout receptors | #4249 |
| enkephalins | #4276 |
| tips | #4318 |
| isoenzymes | #4321 |
| pathogenetic | #4326 |
| contention | #4326 |
| 3h | #4342 |
| oxidase inhibitors | #4346 |
| female frontal | #4355 |
| alcohol abuse | #4357 |
| matched | #4358 |
| chelator | #4359 |
| vitro model | #4364 |
| groups rats | #4365 |
| chorea | #4373 |
| acids | #4373 |
| geniculate | #4374 |
| prevention | #4375 |
| ratelimiting enzyme | #4382 |
| neocortical | #4398 |
| rtpcr | #4402 |
| mrna expression | #4418 |
| enos | #4425 |
| hepatic artery | #4425 |
| immunohistochemical analysis | #4428 |
| peripherally | #4430 |
| postnatally | #4433 |
| 10 micrograms | #4438 |
| specific activities | #4449 |
| carbon isotopes | #4449 |
| acid amino | #4455 |
| inos | #4460 |
| tetrahydrobiopterin | #4480 |
| diencephalon | #4481 |
| citric | #4487 |
| agents steroidal | #4499 |
| isoleucine | #4507 |
| chemical drug | #4509 |
| incompletely | #4517 |
| hippocampal neurons | #4518 |
| endogenously | #4521 |
| potent inhibitor | #4528 |
| pglycoprotein | #4535 |
| tissue concentrations | #4552 |
| model chronic | #4561 |
| gssg | #4562 |
| animal studies | #4562 |
| mitochondrial dysfunction | #4575 |
| substantia nigra | #4577 |
| neurological function | #4585 |
| explanation | #4600 |
| acetaminophen | #4606 |
| transaminase | #4608 |
| 250 | #4627 |
| small increase | #4629 |
| liver diseases | #4637 |
| mrna | #4639 |
| narcotic | #4643 |
| models neurological | #4666 |
| enzymes | #4671 |
| myo | #4677 |
| dopamine | #4679 |
| choline | #4683 |
| nitrites | #4684 |
| worsening | #4685 |
| tremor | #4694 |
| relate | #4701 |
| ho1 | #4704 |
| diphosphate | #4705 |
| neuronal survival | #4712 |
| develops | #4714 |
| realtime quantitative pcr | #4719 |
| techniques male | #4729 |
| key enzymes | #4730 |
| debilitating | #4732 |
| skeletal muscle | #4736 |
| amines | #4737 |
| receptors tumor | #4740 |
| motor coordination | #4745 |
| neurovascular | #4749 |
| patients liver cirrhosis | #4749 |
| triphosphate | #4752 |
| receptors | #4761 |
| apoptotic cell death | #4774 |
| patients liver | #4775 |
| neuroprotective agents | #4778 |
| mn2 | #4792 |
| male rats | #4793 |
| ulnar | #4795 |
| opioid peptides | #4821 |
| ganglia | #4828 |
| failing | #4835 |
| membrane cells | #4837 |
| liver regeneration | #4853 |
| regional cerebral | #4875 |
| constellation | #4875 |
| nonselective | #4891 |
| opioid receptors | #4901 |
| modulator | #4905 |
| tyrosine | #4906 |
| transporters | #4906 |
| 001 | #4915 |
| animals antioxidants | #4919 |
| injections intraperitoneal | #4921 |
| neurons rats | #4927 |
| glucose humans | #4936 |
| epilepsy humans | #4940 |
| degree | #4943 |
| kainic acid | #4963 |
| evident | #4988 |
| rapid progression | #4996 |
| viral hepatitis | #4998 |
| indazoles | #5000 |
| methyl2 | #5002 |
| clinical conditions | #5004 |
| 25 mm | #5009 |
| ammonium | #5017 |
| acid metabolism | #5018 |
| neurological diseases | #5024 |
| raphe | #5043 |
| consequences | #5048 |
| immunostaining | #5051 |
| weighted mri | #5053 |
| offspring | #5054 |
| tight | #5055 |
| alcoholism | #5063 |
| cyclooxygenase2 | #5066 |
| malnutrition | #5080 |
| metabolism | #5084 |
| suggesting | #5106 |
| endoperoxide | #5129 |
| clinical criteria | #5130 |
| acid | #5133 |
| nitric oxide | #5140 |
| disorder | #5143 |
| sarcopenia | #5163 |
| anticonvulsant | #5164 |
| glial cells | #5213 |
| temporal lobe | #5226 |
| leads | #5232 |
| animals | #5236 |
| portal hypertension | #5238 |
| child pugh | #5266 |
| sustained | #5277 |
| severe | #5277 |
| normal rats | #5278 |
| cerebrum | #5280 |
| organ dysfunction | #5288 |
| cerebrospinal fluid | #5299 |
| animal brain | #5308 |
| restores | #5312 |
| reversal | #5325 |
| methylarginine | #5330 |
| intoxication | #5344 |
| major impact | #5349 |
| 4 groups | #5350 |
| animal humans | #5364 |
| biomarkers brain | #5401 |
| gastroenterology | #5403 |
| experimental model | #5414 |
| superoxide production | #5416 |
| publication animals | #5417 |
| presynaptic | #5426 |
| induced acute | #5434 |
| regional brain | #5435 |
| gastrointestinal diseases | #5444 |
| intracellular levels | #5450 |
| postsynaptic | #5452 |
| concentrations | #5459 |
| food deprivation | #5463 |
| blotting western | #5466 |
| focal | #5466 |
| thioredoxins | #5505 |
| halflife | #5506 |
| aquaporins | #5515 |
| involving | #5517 |
| cns | #5517 |
| effects exposure | #5523 |
| nash | #5525 |
| controls | #5541 |
| catecholamines | #5549 |
| isolated rat | #5552 |
| affinity | #5553 |
| tca | #5564 |
| glucose metabolism | #5569 |
| lack | #5572 |
| higher density | #5575 |
| sleep disturbances | #5580 |
| hyperbilirubinemia | #5586 |
| glucose transport | #5607 |
| n11 | #5608 |
| summarizes | #5611 |
| platelets | #5615 |
| endotoxemia | #5639 |
| major complications | #5645 |
| free radicals | #5647 |
| postnatal development | #5651 |
| magnetic resonance images | #5652 |
| cachexia | #5666 |
| acute ischemic | #5672 |
| drinkers | #5693 |
| antimetabolites | #5699 |
| tnf | #5709 |
| 73 patients | #5711 |
| transport systems | #5712 |
| receptor binding | #5730 |
| 24 hours | #5741 |
| icp | #5768 |
| evidence base | #5790 |
| precipitate | #5790 |
| dehydrogenases | #5796 |
| nonalcoholic steatohepatitis | #5796 |
| p005 | #5800 |
| brain animals | #5810 |
| depolarization | #5812 |
| aspartate receptor | #5824 |
| serotonin | #5840 |
| substances | #5848 |
| prefrontal cortex | #5859 |
| extravasation | #5862 |
| steroidal | #5865 |
| neuroprotective | #5883 |
| levels elevated | #5885 |
| ketone | #5892 |
| western blot analysis | #5897 |
| appropriately | #5900 |
| mounting evidence | #5926 |
| enkephalin | #5928 |
| potentiate | #5945 |
| detoxification | #5949 |
| acrylamide | #5950 |
| disaccharides | #5950 |
| acid antagonists | #5952 |
| 100 microm | #5954 |
| background objectives | #5954 |
| bulb | #5976 |
| muscle mass | #5993 |
| metabolites | #5993 |
| coenzyme | #5994 |
| etiologies | #5997 |
| anterior cingulate cortex | #6016 |
| antagonist | #6019 |
| butyric | #6023 |
| reversible | #6029 |
| aged rats | #6030 |
| sodium potassium | #6068 |
| additional evidence | #6080 |
| transporter 1 | #6103 |
| methyl4 | #6109 |
| zona | #6114 |
| chemistry | #6120 |
| occurs | #6122 |
| barrier | #6138 |
| trh | #6148 |
| postmortem | #6152 |
| cirrhosis patients | #6152 |
| cortical regions | #6162 |
| hippocampus | #6166 |
| hydroperoxide | #6169 |
| deoxyglucose | #6171 |
| risk bias | #6188 |
| inbred | #6199 |
| esters | #6202 |
| proteins rats | #6221 |
| reduction oxidative | #6231 |
| nervous cns | #6235 |
| disruptions | #6250 |
| vascular endothelium | #6265 |
| anti inflammatory | #6284 |
| mitochondrial function | #6287 |
| hematoxylin | #6290 |
| lactate dehydrogenase | #6298 |
| chain | #6315 |
| carboxylase | #6322 |
| alpha2 | #6323 |
| protein expression | #6343 |
| induced increases | #6360 |
| 20 cases | #6371 |
| rna messenger | #6388 |
| dha | #6392 |
| cbf | #6404 |
| gamma | #6412 |
| remained | #6413 |
| chelating agents | #6422 |
| olfactory | #6441 |
| prosencephalon | #6456 |
| snap | #6464 |
| rats animals | #6469 |
| roi | #6470 |
| antagonists | #6475 |
| peripheral nerve | #6478 |
| histidine | #6482 |
| acyltransferases | #6490 |
| patients chronic | #6498 |
| mesencephalon | #6508 |
| notion | #6511 |
| disease brain | #6514 |
| bromocriptine | #6531 |
| ingestion | #6548 |
| ligation | #6552 |
| dopaminergic | #6553 |
| humans kinetics | #6566 |
| control mice | #6572 |
| longterm treatment | #6575 |
| nomenclature | #6576 |
| disease aged | #6579 |
| physiological function | #6586 |
| humans mitochondria | #6594 |
| oxidase | #6596 |
| microg | #6596 |
| led | #6597 |
| accumulation | #6599 |
| fluid csf | #6600 |
| mmol | #6609 |
| animal dose | #6610 |
| glycolytic | #6625 |
| publication analysis | #6642 |
| inducible nitric | #6643 |
| resonance spectroscopy | #6660 |
| lowers | #6665 |
| glu | #6665 |
| animals bile | #6671 |
| slowing | #6682 |
| p001 | #6684 |
| patients placebo | #6688 |
| proceedings | #6700 |
| interferongamma | #6742 |
| differential effects | #6755 |
| poisoning | #6767 |
| granule | #6768 |
| dystonia | #6769 |
| psychometric | #6774 |
| lad | #6783 |
| rats wistar receptors | #6791 |
| biological transport | #6801 |
| transport proteins | #6806 |
| specific regions | #6806 |
| cortices | #6825 |
| nitrates | #6833 |
| inflammatory processes | #6849 |
| n5 | #6849 |
| protects | #6857 |
| receptors dopamine | #6859 |
| tomography emission | #6887 |
| acetaldehyde | #6894 |
| enter | #6908 |
| patients brain | #6909 |
| sleep disorders | #6915 |
| mitochondrial membrane | #6916 |
| nutritional | #6921 |
| hypothalamus | #6930 |
| humans intracranial | #6937 |
| nutrition | #6972 |
| rendered | #6975 |
| cerebral blood flow | #6981 |
| low affinity | #6986 |
| acid levels | #7005 |
| eosin | #7011 |
| vitamins | #7012 |
| ascites | #7020 |
| adenosine triphosphate | #7030 |
| patients alzheimer | #7040 |
| compensatory | #7089 |
| free radical | #7092 |
| rois | #7098 |
| common form | #7109 |
| general agreement | #7117 |
| expression | #7125 |
| prothrombin | #7133 |
| mice treated | #7139 |
| synthases | #7140 |
| 13c nmr | #7146 |
| methyl | #7151 |
| hippocampus male | #7165 |
| methyl ester | #7177 |
| tartrate | #7178 |
| levels blood | #7198 |
| central nervous cns | #7202 |
| protective agents | #7214 |
| catecholamine | #7216 |
| undertaken | #7226 |
| probiotics | #7244 |
| humans inflammation | #7253 |
| systemic inflammation | #7280 |
| antiinflammatory agents | #7284 |
| neurodegeneration | #7290 |
| male sprague | #7307 |
| bile duct | #7311 |
| additional studies | #7322 |
| animal doseresponse relationship | #7334 |
| nh4 | #7336 |
| glucose transporter | #7337 |
| cyclooxygenase 2 | #7344 |
| life hrqol | #7350 |
| administration | #7353 |
| preliminary evidence | #7358 |
| symptomatic | #7371 |
| neuroprotection | #7374 |
| histamine release | #7378 |
| regional | #7382 |
| urea | #7386 |
| hippocampal | #7389 |
| insult | #7392 |
| pyridines | #7404 |
| intravenous infusion | #7420 |
| competitive | #7424 |
| animal | #7433 |
| excitability | #7442 |
| molecular mechanisms | #7448 |
| restored | #7464 |
| spectrophotometric | #7474 |
| osmotic | #7475 |
| biochemical studies | #7481 |
| ht | #7485 |
| excreted | #7507 |
| urease | #7536 |
| organ specificity | #7540 |
| lipid peroxidation | #7550 |
| pathological conditions | #7553 |
| dismutase | #7553 |
| brain ischemia | #7557 |
| implicating | #7564 |
| onset | #7570 |
| cytoprotection | #7580 |
| neuropathic pain | #7583 |
| imaging magnetic | #7585 |
| chromatography mass | #7603 |
| microglia | #7605 |
| matrix metalloproteinase | #7621 |
| mental status | #7630 |
| blood platelets | #7640 |
| characterized | #7659 |
| neuroprotective effects | #7659 |
| deleterious | #7665 |
| neurologic examination | #7672 |
| cortical neurons | #7687 |
| diminished | #7696 |
| specific binding | #7700 |
| guanidines | #7737 |
| perturbations | #7769 |
| alpha tnf | #7777 |
| oxide | #7779 |
| immunoreactivity | #7801 |
| oedema | #7810 |
| il6 levels | #7833 |
| tissue proteins | #7854 |
| tnf α | #7864 |
| animals blotting | #7882 |
| albumins | #7888 |
| m3 | #7897 |
| ca1 | #7899 |
| brain development | #7915 |
| parietal cortex | #7915 |
| freely | #7932 |
| cells brain | #7932 |
| lname | #7950 |
| aspartate aminotransferases | #7961 |
| assayed | #7986 |
| metabolic | #7989 |
| aetiology | #8016 |
| mouse brain | #8023 |
| alzheimer | #8025 |
| liver transplantation | #8033 |
| ka | #8038 |
| constitutes | #8040 |
| computerized | #8040 |
| organometallic compounds | #8052 |
| established | #8056 |
| brain humans | #8073 |
| cerebrovascular circulation | #8079 |
| chelation | #8081 |
| inferior | #8097 |
| reproduces | #8103 |
| modulate | #8143 |
| confirm | #8153 |
| produces | #8156 |
| large variety | #8164 |
| intraperitoneally | #8167 |
| immunohistochemistry male | #8184 |
| maintained | #8185 |
| benzazepines | #8192 |
| organs | #8193 |
| fluorescence intensity | #8201 |
| reduced | #8207 |
| neurologic | #8214 |
| dopamine receptor | #8253 |
| abnormally | #8260 |
| norepinephrine | #8288 |
| inflammatory agents | #8301 |
| neuronal damage | #8302 |
| antioxidant | #8310 |
| condition | #8326 |
| dependent | #8332 |
| therapeutic implications | #8336 |
| epileptic | #8359 |
| chromatography pressure | #8383 |
| turn | #8404 |
| gray matter | #8407 |
| reflect | #8410 |
| and or | #8413 |
| wistar receptors | #8433 |
| receptor expression | #8442 |
| chain reaction | #8446 |
| hyponatremia | #8454 |
| plasma levels | #8470 |
| hyperglycemia | #8472 |
| citalopram | #8472 |
| stereotaxic | #8495 |
| systemic inflammatory | #8499 |
| polymerase chain | #8501 |
| purkinje | #8517 |
| immunocytochemical | #8519 |
| brain imaging | #8538 |
| chloride | #8546 |
| copper | #8549 |
| intracellular ca2 | #8583 |
| restoration | #8595 |
| hepatotoxicity | #8598 |
| ischemia | #8616 |
| activates | #8631 |
| hippocampus humans | #8641 |
| oxide nitric | #8664 |
| levodopa | #8665 |
| n10 | #8672 |
| inflammatory cytokines | #8690 |
| male middle aged | #8715 |
| organometallic | #8716 |
| pyramidal cells | #8724 |
| retardation | #8736 |
| oxidative | #8742 |
| gsh | #8742 |
| 37°c | #8758 |
| emission computed | #8767 |
| parietal | #8790 |
| potassium chloride | #8814 |
| hplc | #8824 |
| nmr | #8871 |
| superoxide | #8875 |
| tonic | #8879 |
| sulfates | #8892 |
| devoid | #8898 |
| egf receptor | #8905 |
| lactic acid | #8906 |
| minimal | #8910 |
| caveolin | #8912 |
| oxo | #8932 |
| biochemical | #8935 |
| consciousness | #8985 |
| reflected | #9011 |
| intravenous injection | #9019 |
| alanine transaminase | #9038 |
| encephalitis | #9077 |
| emission tomography | #9083 |
| methylmercury | #9099 |
| aminotransferases | #9108 |
| acetate | #9111 |
| syndromes | #9112 |
| brain cognition | #9130 |
| aimed | #9163 |
| awake | #9175 |
| 62 patients | #9176 |
| likewise | #9181 |
| treated mice | #9194 |
| normal | #9207 |
| dysfunction | #9218 |
| corpus striatum | #9247 |
| key factors | #9254 |
| elevated | #9263 |
| deprived | #9285 |
| neuropathy | #9344 |
| cerebrospinal fluid csf | #9364 |
| cerebral blood | #9391 |
| pressure liquid | #9396 |
| deoxy | #9420 |
| immunoblotting | #9445 |
| complications patients | #9489 |
| citric acid | #9505 |
| intrahepatic | #9572 |
| oxidative stress | #9585 |
| irreversible | #9607 |
| naloxone | #9609 |
| absence | #9615 |
| synthase inos | #9615 |
| occipital | #9621 |
| neurons | #9627 |
| seizures | #9631 |
| terminals | #9647 |
| nerve tissue | #9655 |
| postoperative day | #9682 |
| compensate | #9687 |
| micromol | #9692 |
| imaging studies | #9718 |
| ameliorated | #9722 |
| bw | #9727 |
| protective effects | #9749 |
| 2 mm | #9756 |
| 064 | #9783 |
| neuro | #9788 |
| tumor necrosis | #9791 |
| middle cerebral | #9809 |
| chelating | #9823 |
| dependently | #9825 |
| patch clamp | #9830 |
| succinate | #9834 |
| diseases liver | #9842 |
| prevented | #9863 |
| severely | #9864 |
| contributes | #9880 |
| receptor agonist | #9912 |
| microm | #9930 |
| necrosis factor | #9933 |
| quantitative | #9943 |
| tight junctions | #9963 |
| liver cells | #9987 |
| neurobiological | #10000 |
| binding cassette | #10002 |
| central nervous | #10003 |
| conflicting | #10023 |
| kinetic parameters | #10033 |
| cycle | #10052 |
| mediated | #10072 |
| cortical | #10128 |
| cava | #10136 |
| dopamine receptors | #10169 |
| liver damage | #10178 |
| negative impact | #10202 |
| minerals | #10211 |
| stores | #10215 |
| ros production | #10235 |
| attenuated | #10240 |
| expression activity | #10242 |
| cgmp | #10262 |
| glutathione gsh | #10266 |
| transport complex | #10286 |
| plasma concentrations | #10292 |
| plasma patients | #10296 |
| urinary excretion | #10301 |
| adversely | #10328 |
| vitamin deficiency | #10328 |
| forebrain | #10337 |
| cassette | #10370 |
| permeable | #10373 |
| specific activity | #10384 |
| steatohepatitis | #10395 |
| electroencephalogram | #10395 |
| areas | #10419 |
| subacute | #10435 |
| biliary | #10436 |
| protein levels | #10453 |
| liver transplant | #10455 |
| hrqol | #10455 |
| nigra | #10479 |
| cerebral artery | #10481 |
| positron emission tomography | #10525 |
| biosynthesis | #10531 |
| substantia | #10550 |
| nervous | #10616 |
| transmitter | #10626 |
| twofold | #10627 |
| management patients | #10657 |
| lipopolysaccharide | #10674 |
| alzheimers disease | #10694 |
| dose dependent | #10699 |
| normal range | #10730 |
| nutritional status | #10752 |
| protein level | #10752 |
| quaternary | #10765 |
| glutathione | #10772 |
| glucose | #10806 |
| water content | #10826 |
| monophosphate | #10827 |
| liver mice | #10852 |
| vena | #10853 |
| nervous diseases | #10861 |
| microgram | #10880 |
| performance liquid | #10883 |
| entity | #10889 |
| eventually | #10941 |
| intraventricular | #10958 |
| occur | #10968 |
| saline | #10968 |
| dietary proteins | #10978 |
| breakdown | #10983 |
| earlier studies | #10997 |
| etiology | #10998 |
| doses | #11003 |
| accumbens | #11004 |
| impair | #11006 |
| rats inbred strains | #11023 |
| radioimmunoassay | #11026 |
| behavior animal | #11026 |
| atrophy | #11041 |
| tnfalpha | #11044 |
| atp binding | #11055 |
| western | #11061 |
| tests male | #11061 |
| peroxidation | #11077 |
| riboflavin | #11140 |
| positron emission | #11153 |
| potentiated | #11172 |
| preparations | #11184 |
| precursor | #11188 |
| adult male | #11195 |
| broad spectrum | #11196 |
| superoxides | #11202 |
| nick | #11227 |
| steroids | #11232 |
| animals anti | #11234 |
| acyl | #11314 |
| enzyme activity | #11342 |
| drug induced | #11347 |
| early identification | #11376 |
| neuropathic | #11380 |
| necrotic | #11392 |
| neurodegenerative disease | #11395 |
| centrally | #11415 |
| depletion | #11434 |
| major component | #11447 |
| clinical signs | #11463 |
| 3 weeks | #11495 |
| receptor antagonist | #11502 |
| animals disease | #11503 |
| complications | #11504 |
| alteration | #11581 |
| il1β | #11649 |
| trp | #11651 |
| prostaglandins | #11656 |
| survival cells | #11657 |
| kd | #11671 |
| dogs | #11676 |
| gut | #11676 |
| alcohol | #11740 |
| wilson | #11741 |
| dentate | #11769 |
| disappearance | #11773 |
| receptor antagonists | #11774 |
| ibuprofen | #11820 |
| neuron | #11824 |
| radiopharmaceuticals | #11825 |
| appears | #11872 |
| pigs | #11917 |
| inherited | #11924 |
| organ size | #11944 |
| mild cognitive impairment | #11954 |
| pyramidal | #12051 |
| corpus callosum | #12054 |
| gasoline | #12095 |
| aged alzheimer | #12101 |
| circulating levels | #12111 |
| carrier proteins | #12112 |
| reactive | #12134 |
| severity | #12227 |
| receptor activation | #12230 |
| blotting | #12274 |
| huntington disease | #12346 |
| infusions | #12347 |
| electrophysiological | #12375 |
| elevation | #12412 |
| aphasia | #12425 |
| emerging evidence | #12434 |
| atpase | #12447 |
| subclinical | #12476 |
| nh3 | #12499 |
| aminotransferase | #12509 |
| peripheral nervous | #12515 |
| absorbed | #12546 |
| cyclooxygenase | #12569 |
| exerts | #12573 |
| scavenger | #12589 |
| bile ducts | #12634 |
| c57bl 6 | #12683 |
| publisher | #12687 |
| chlorides | #12701 |
| reversed | #12782 |
| subcellular fractions | #12790 |
| inositol | #12832 |
| neuronal death | #12840 |
| measured | #12864 |
| intraperitoneal | #12878 |
| disorders | #12899 |
| cultured cells | #12900 |
| tnf alpha | #12912 |
| mediate | #12984 |
| mars | #13100 |
| slowly | #13118 |
| vesicular | #13121 |
| lesser | #13134 |
| pretreatment | #13141 |
| cerebral infarction | #13141 |
| therapeutic strategies | #13143 |
| basal | #13155 |
| 005 | #13194 |
| positron | #13197 |
| tomography pet | #13207 |
| circadian | #13222 |
| md | #13224 |
| caused | #13226 |
| hypotheses | #13238 |
| infused | #13242 |
| ischemic | #13289 |
| subjected | #13291 |
| methionine | #13299 |
| disrupted | #13336 |
| animals biomarkers | #13337 |
| normal controls | #13360 |
| anticonvulsants | #13440 |
| downregulation | #13444 |
| neurodegenerative | #13467 |
| reduction | #13499 |
| 23 patients | #13506 |
| chronic | #13511 |
| histocytochemistry | #13552 |
| psychomotor | #13555 |
| tissue | #13620 |
| sodium | #13631 |
| interleukin1 | #13734 |
| alpha | #13754 |
| cerebrovascular | #13767 |
| agonist | #13768 |
| partially | #13885 |
| oxidant | #13907 |
| postural | #13923 |
| mainstay | #13926 |
| sulfate | #13971 |
| nerve | #14045 |
| necrosis | #14050 |
| improvement | #14081 |
| gray | #14104 |
| hypothesize | #14117 |
| μmol | #14145 |
| skeletal | #14152 |
| exposure | #14214 |
| alcohol drinking | #14214 |
| electroencephalography | #14223 |
| sulfhydryl | #14242 |
| glia | #14250 |
| deficient mice | #14274 |
| blot analysis | #14352 |
| cytokine production | #14379 |
| multifactorial | #14398 |
| p002 | #14416 |
| damage | #14417 |
| enzyme inhibitors | #14422 |
| normalized | #14430 |
| dinoprostone | #14442 |
| permanent | #14471 |
| limbic | #14474 |
| cingulate | #14502 |
| healthrelated quality | #14573 |
| release | #14673 |
| 11 patients | #14695 |
| pge2 | #14705 |
| male | #14712 |
| ethanol | #14751 |
| chronic disease | #14773 |
| alzheimer disease | #14778 |
| cell count | #14785 |
| learning memory | #14831 |
| triphosphate animals | #14839 |
| vivo studies | #14851 |
| understood | #14879 |
| uric | #14905 |
| nmol | #14931 |
| agonists | #14948 |
| subcortical | #14957 |
| imbalance | #14958 |
| weighted | #15064 |
| manifestations | #15066 |
| lactation | #15115 |
| psychiatric | #15192 |
| creatine | #15221 |
| fluid | #15257 |
| cytokines | #15272 |
| triphosphatases | #15273 |
| intake | #15351 |
| protein tyrosine | #15367 |
| tissues | #15409 |
| localized | #15466 |
| ester | #15533 |
| synapses | #15538 |
| intellectual | #15568 |
| 042 | #15583 |
| evoked potentials | #15595 |
| prophylaxis | #15602 |
| clamp | #15646 |
| drinking | #15676 |
| sclerosis | #15727 |
| cholestasis | #15758 |
| nafld | #15783 |
| adenosine | #15804 |
| signs | #15804 |
| hypothesis | #15809 |
| trace | #15853 |
| chromatography | #15875 |
| exert | #15905 |
| appeared | #15927 |
| degeneration | #15939 |
| subcutaneously | #15941 |
| vivo vitro | #16006 |
| magnetic resonance | #16007 |
| reflects | #16036 |
| killed | #16092 |
| released | #16133 |
| parkinsons disease | #16161 |
| plays | #16220 |
| randomized controlled | #16247 |
| therapeutic | #16276 |
| 0001 | #16290 |
| hepatectomy | #16303 |
| muscle skeletal | #16331 |
| 1 week | #16336 |
| dorsal | #16343 |
| symptoms | #16440 |
| cytosolic | #16446 |
| aspect | #16495 |
| hepatitis chronic | #16549 |
| 5 | #16588 |
| transport | #16615 |
| abnormalities | #16625 |
| nucleus accumbens | #16636 |
| induction | #16656 |
| inadequate | #16667 |
| involves | #16686 |
| hepatocyte | #16740 |
| psychometrics | #16793 |
| decreasing | #16803 |
| cd40 | #16918 |
| random allocation | #16959 |
| pet | #17001 |
| mechanism | #17020 |
| spontaneous | #17046 |
| folic | #17100 |
| 10 patients | #17114 |
| organ | #17129 |
| 05 | #17137 |
| administered | #17168 |
| impairment | #17220 |
| transported | #17290 |
| reduces | #17300 |
| prominent | #17312 |
| publication aged aged | #17315 |
| tnfα | #17356 |
| diagnose | #17452 |
| humans | #17580 |
| parkinson | #17599 |
| mitochondrial | #17645 |
| incubation | #17654 |
| evoked | #17725 |
| modulates | #17799 |
| stimulatory | #17860 |
| commonly | #17870 |
| spectroscopy | #18016 |
| alter | #18029 |
| removed | #18045 |
| pharmacological | #18082 |
| 21 patients | #18092 |
| enzyme | #18126 |
| cognition disorders | #18188 |
| adult brain | #18254 |
| hepatocytes | #18338 |
| prevent | #18353 |
| blood samples | #18374 |
| moderately | #18395 |
| putative | #18427 |
| partly | #18450 |
| suffer | #18502 |
| stimulate | #18563 |
| animals biological | #18741 |
| neurodegenerative diseases | #18774 |
| depressed | #18788 |
| metalloproteinase | #18921 |
| vein | #19240 |
| ascorbic | #19380 |
| plasma | #19440 |
| 7 | #19485 |
| blot | #19526 |
| correlated | #19582 |
| membrane potentials | #19625 |
| serves | #19635 |
| depleted | #19648 |
| neuropsychological tests | #19672 |
| traumatic brain injury | #19727 |
| mm | #19825 |
| animals calcium | #19827 |
| soluble | #20005 |
| acetic | #20054 |
| frequently | #20106 |
| tumor necrosis factor | #20133 |
| serine | #20180 |
| dosedependent manner | #20198 |
| vitro techniques | #20371 |
| controversial | #20390 |
| motor | #20407 |
| radical | #20464 |
| ventral | #20527 |
| micrograms | #20674 |
| circulation | #20783 |
| raised | #20843 |
| inducible | #20861 |
| hypothalamic | #20873 |
| oxidation reduction | #20882 |
| counts | #20909 |
| brain mapping | #21000 |
| reactive oxygen | #21049 |
| 16 patients | #21061 |
| underlying mechanisms | #21109 |
| weeks | #21219 |
| labeled | #21292 |
| rodent | #21335 |
| method female | #21700 |
| maximal | #21940 |
| species ros | #22112 |
| vivo | #22128 |
| blood | #22216 |
| response relationship | #22303 |
| inflammation | #22526 |
| 073 | #22553 |
| induced cell | #22589 |
| 13 patients | #22656 |
| activation | #23016 |
| sufficient | #23212 |
| male membrane | #23275 |
| imaging mri | #23302 |
| gastrointestinal | #23302 |
| inflammatory | #23317 |
| intravenously | #23392 |
| infusions intravenous | #23567 |
| releasing | #23665 |
| magnetic resonance imaging | #23801 |
| intracellular | #24009 |
| cellular | #24252 |
| reducing | #24301 |
| c57bl | #24413 |
| correlate | #24434 |
| displayed | #24599 |
| unable | #24707 |
| 096 | #24715 |
| assess | #24780 |
| 12 patients | #24814 |
| activity | #25360 |
| body | #25376 |
| acquired | #25673 |
| modify | #25866 |
| limiting | #25928 |
| inhibit | #26079 |
| inbred c57bl | #26079 |
| modulated | #26122 |
| remain | #26178 |
| immunohistochemical | #26211 |
| cognitive | #26948 |
| represents | #26971 |
| management | #27196 |
| reflecting | #27352 |
| mental | #27490 |
| improves | #27652 |
| preventing | #27673 |
| behavioral | #27813 |
| hydrogen ion | #28292 |
| concluded | #28335 |
| proven | #28570 |
| aims | #28575 |
| evaluate | #28931 |
| proteins mice | #28975 |
| ion concentration | #29194 |
| magnetic | #29339 |
| mechanisms underlying | #29900 |
| subcellular | #29913 |
| mice inbred | #30075 |
| stained | #30210 |
| quantitatively | #30454 |
| arterial | #30516 |
| abnormal | #30579 |
| corrected | #30667 |
| humans hydrogen | #30710 |
| demonstrated | #30993 |
| sensitive | #31344 |
| resonance | #31346 |
| induces | #31608 |
| cultured | #31958 |
| enzyme activation | #32060 |
| markedly | #32813 |
| animals apoptosis | #33677 |
| remains | #34554 |
| unclear | #34875 |
| subsequent | #35401 |
| hypothesized | #36243 |
| treated | #36316 |
| inhibited | #36986 |
| linked | #37013 |
| inbred c57bl mice | #39261 |
| induce | #39552 |
| aged | #56385 |
Open the FULL List in Excel | |
Key People For Hepatic Encephalopathy
Top KOLs in the world
Select a search phrase hepatic encephalopathy , hepatic encephalopathy patients , hepatic encephalopathy humans , hepatic encephalopathy 95 , hepatic encephalopathy rats
Roger F Butterworth∗:Expert Impact
Concepts for whichRoger F Butterworth∗has direct influence:Hepatic encephalopathy, Acute liver failure, Liver failure, Thiamine deficiency, Cirrhotic patients, Brain edema, Portacaval anastomosis, Mild hypothermia.
Roger F Butterworth∗:KOL impact
Concepts related to the work of other authors for whichfor which Roger F Butterworth∗ has influence:Hepatic encephalopathy, Acute liver failure, Thiamine deficiency, Liver cirrhosis, Oxidative stress, Brain edema, Cirrhotic patients.
Tools
Is this your profile? Claim your profile Copy URL Embed Link to your profile |